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1. Introduction
1.1 The immune system
Animals are constantly exposed to a vast range of  infectious agents able to enter their bodies at different sites causing various diseases. Thus, a well coordinated, adequate and specific reaction 
of  the immune system is a prerequisite to be able to cope with such possibly life-endangering threats. 
In mammals, the immune system can grossly be classified into an innate and adaptive branch. All 
immune cells develop from pluripotent hematopoietic stem cells (HSC) produced in the fetal liver or 
the bone marrow (BM) after birth, further differentiating into common myeloid or common lymphoid 
progenitor cells (CMP, CLP). Amongst others CMPs give rise to granulocytes and macrophages, 
important players of  the innate immune response. CLPs on the other hand can further differentiate 
into B and T or natural killer cells, of  which the latter are considered to be part of  innate immunity. 
B and T cells belong to the adaptive arm of  the immune system resuming essential functions there. 
The innate immune response represents the first rapid, yet relatively unspecific line of  defence against 
pathogens with macrophages and neutrophils, both phagocytic cells as key players. The adaptive 
immune response on the other hand, often also designated as acquired immunity, features high antigen 
specificities, self-non-self  discrimination and immunological longterm memory to pathogens, though 
at the expense of  time as it takes four to seven days before first effects become noticable. The adaptive 
immune reaction can further be subdivided into humoral and cell-mediated immunity. The decision 
which path needs to be taken is mainly determined by the cytokine profile prevailing at that time. Cell-
mediated immunity involves the activation of  phagocytes as well as cytotoxic T cells and is risen against 
intracellular pathogens, virally infected cells, as well as against abnormal cells of  the body. Humoral 
immune response is based on the effect mediated by antibodies specific for the prevailing antigen, 
secreted by antigen-activated B cells. Innate and adaptive immune responses are permanently being 
executed involving repeated expansion and deletion cycles of  antigen-specific cell populations. Thus, 
thorough control mechanisms are needed to prevent dangerous developments such as autoimmunity, 
cellular transformation or overreactions eventually resulting in allergies (Janeway et al., 2012).
1.2 Lymphocyte development
1.2.1 Early B cell development in the bone marrow
The BM provides a highly appropriate microenvironment for early B cell development with non-
lymphoid stromal cells furnishing essential survival, proliferation and differentiation factors (Janeway 
et al., 2012). Early B cell development implies several sequential differentiation steps in the end 
aiming at producing immature B cells expressing a functional, non-self-reactive B cell receptor (BCR). 
Commitment to the B cell lineage is driven by the controlled interplay of  the interleukin 7 (IL-7) 
cytokine receptor, the transcription factors Ikaros, E2A (including its products E12 and E47), PU.1, 
Paired Box 5 (Pax5) and early B cell factor 1 (EBF1) (Ramirez et al., 2010). Thereby, EBF1 seems to 
be the master regulator in promoting B cell differentiation (Northrup and Allman, 2008). The BCR 
is made up of  two identical immunoglobulin heavy (IgH) and light chains (IgL), associated with two 
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invariant accessory proteins, one Igα and one Ig�. Both heavy and light chains are composed of  
variable and constant (C) regions, with variable regions (VH and VL) providing antigen binding and 
specificity. Igα and Ig� on the other hand take over intracellular signalling after receptor binding as 
they represent the only noteworthy cytoplasmic domains of  the BCR. To ensure the recognition of  
all possible antigens, a highly diverse repertoire of  antigen specificities must be obtained during B cell 
development. To achieve this, the VH region is encoded in numerous, different copies of  three DNA 
segments, called the variable (VH), diversity (DH) and joining (JH) segments. The same is true for the 
light chains except that there are only two variable and joining (VL and JL) and no D gene segments. 
The random selection and recombination of  one gene segment of  each type with each other to 
form the variable region is called somatic V(D)J recombination and accounts by sheer combinatorial 
diversity already for a substantial part of  the great diversity of  the BCR (Janeway et al., 2012; Jung et al., 
2006; Edry and Melamed, 2004). After successful V(D)J recombination, immature B cells expressing 
a functional BCR are subsequently tested for the reactivity of  their receptor. If  strongly self-reactive 
BCRs - hence possible elicitors of  autoimmunity - are detected within the BM, either clonal deletion 
ensures that cell development is stopped at this stage via apoptosis of  these cells or receptor editing is 
induced, trying to change the current “self-specificity” of  the BCR by further rearrangements (Edry 
and Melamed, 2004). B cells that recognise self-antigens can also become anergic, a state which comes 
along with short half-life as well as the downregulation of  IgM and the BCR signalling pathway hence 
inhibiting further activation (Goodnow et al., 1988). In the end, each B cell carries a unique, non self-
reactive antigen receptor of  a single specificity. Hence, B cell development results in the generation of  
millions of  different B cell receptors displaying different antigen specificities. 
1.2.2 Late B cell development in the spleen
1.2.2.1 Splenic architecture
The spleen (SP) is the largest secondary lymphoid organ (SLO) harbouring about one-fourth of  
the body’s lymphocytes. It is comprised of  two compartments known as red and white pulp, which 
differ in their function and morphology. The red pulp constantly filters blood thereby removing old 
and damaged erythrocytes as well as foreign material, whereas the white pulp is in charge of  the 
initiation of  immune responses. Most of  the splenic lymphocytes can be found in the white pulp, 
next to macrophages and dendritic cells (DC). It can be subdivided into three sub-compartments: the 
periarteriolar lymphoid sheath (PALS) harbouring mainly T cells, the follicles containing primarily 
follicular (Fo) B as well as follicular dendritic cells (FDCs) and the marginal zone (MZ). The latter 
has extensive vasculature and comprises MZ B cells, stromal cells and marginal zone macrophages 
(MZMs), which are interspersed within the MZ. Lining the marginal sinus are furthermore marginal 
metallophilic macrophages (MMMs). The different types of  macrophages can be distinguished from 
one another by surface expression of  MOMA-1 (MMMs) or the C-type lectin SIGN-R1 and the 
macrophage receptor with collagenous structure (MARCO) (MZMs). Together with the marginal 
sinus the MZ builds the border between the red and the white pulp (Mebius and Kraal, 2005; Cesta,     
2006). Lymphocytes are thought to leave the follicle via the marginal zone bridging channels (MZBCs), 
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which are extensions of  the white pulp through the MZ into the red pulp. It is also the place where 
antigen-activated B cells become plasmablasts (Balaszs et al., 2002) and from where they directly gain 
access to the red pulp (for detail see chapter 1.3.1.2). In these regions T cells are adjacent to the MZ               
(Mebius and Kraal, 2005). A detailed scheme of the splenic microarchitecture is depicted in figure 1.            
1.2.2.2 Development from an immature B cell population to mature B cells
Most immature B cells exit the BM to migrate to the spleen, where they finish their maturation (Fig. 2). 
These cells are called “transitional” B cells as they are “in transit” from one organ to another. Although 
immature B cells can also at least to a certain degree continue their maturation in the BM (Fig. 2)  
(Allman and Pillai, 2008; Cariappa et al., 2007b; Lindsley et al., 2007), MZ B cells only develop in the 
splenic environment (Tan et al., 2009; Pillai and Cariappa, 2009). B cell maturation in the periphery              
involves three stages of  transitional B cell populations (T1-3), from which follicular or MZ B cells can 
develop. Transitional B cells are characterised 
by the expression of  AA4.1+, CD24+, higher 
IgM and lower CD22 and B220 levels than 
mature B cells (Chung et al., 2003; �eramilli and        
Knight, 2011). BCR expression is essential for     
the survival of  the transitional B cell population 
(Lam et al., 1997; Kraus et al., 2004; Tze et al., 
2005), but from the T2 stage on, in addition         
to tonic BCR signalling, signals from the B cell 
activating factor (BAFF) receptor are needed 
for B cell survival	(Batten et al., 2000; Cancro, 
2009; Chung et al., 2003; Gross et al., 2001; 
Schiemann et al., 2001). Transitional B cells can    
either develop into splenic Fo B or MZ B cells 
and an interplay of  multiple different signalling 
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Figure 2: Peripheral B cell maturation from the bone 
marrow (taken from Allman and Pillai, 2008). Current 
model for peripheral B cell maturation from the bone 
marrow. T1-3 (transitional B cell stages), NF (newly formed, 
immature B cells), FOLI-II (follicular B cells), MZ (marginal 
zone B cells), MZP (marginal zone B cell precursors).
Figure 1: Schematic view of the microarchitecture 
of the spleen (from Pillai and Cariappa, 2009). 
Blood arrives at the spleen through the afferent 
splenic artery, which branches into central arterioles 
sheathed by the white-pulp. It reaches the marginal 
sinus from where it flows to the red pulp through the 
marginal zone (MZ) or to the white pulp through the 
conduit network. From the red pulp the blood runs 
into venous sinuses, which collect into the efferent 
splenic vein. The white pulp of the spleen consists of a 
T cell zone, also called periarteriolar lymphoid sheath 
(PALS), B cell follicles mainly harboring follicular (Fo) 
B cells, marginal metallophilic macrophages (MMM) 
lining the marginal sinus and the marginal zone 
(MZ) with its marginal zone macrophages (MZM) 
and marginal zone B cells. Marginal zone bridging 
channels (MZBCs) are extensions of the white pulp 
through the MZ into the red pulp.
Bone marrow Periphery
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pathways as well as factors involved in B cell migration and retention are assumed to influence this 
decision. Concerning signalling pathways, the BCR with its co-receptor CD19 were a long time among 
the most prominent factors believed to impact on the Fo B versus MZ B cell decision, with strong 
BCR signalling involving the Bruton’s tyrosine kinase (Btk) favouring the formation of  Fo B cells 
(Hardy et al., 1983; Hikida et al., 2003; Wen et al., 2003; Pillai and Cariappa, 2009) and a weak one the     
development of  MZ B cells precursors (MZBPs) and ultimately MZ B cells (Samardzic et al., 2002;    
Cariappa et al., 2001; Pillai et al., 2005). �et, recently we could show that Notch2 signalling is essential          
and the key pathway in regulating MZ B versus Fo B cell development (discussed in detail in chapter 
1.4.3), as constitutive Notch2 signalling could rescue MZ B cell development in CD19-deficient mice, 
which had been shown to be devoid of  MZ B cells (Hampel et al., 2011; Martin and Kearney, 2000).        
Apart from that, the nuclear factor “kappa-light-chain-enhancer” of  activated B cells (NF�B) signalling 
pathway is also implicated in Fo B and MZ B cell differentiation. BAFF, which can be found at high 
concentrations in the lymphoid follicles (Hase et al., 2004; Suzuki et al., 2010) and which mainly 
induces non-canonical NF�B signalling is primarily needed by T2 and Fo B cells (Pillai and Cariappa,   
2009). The MZ B cell fate on the other hand seems mainly triggered via the canonical NF�B pathway                 
(Sasaki et al., 2006), as mice lacking p50, I�Ba or p65 - all members of  the canonical NF�B pathway 
- show defects in MZ B cell development (Cariappa et al., 2000). However, Weih and colleagues could      
show that in addition the non-canonical NF�B pathway also impacts on MZ B cell development 
(Weih et al., 2001). In addition, deficiencies in the phosphatase SHIP (Helgason et al., 1998), or the             
phosphatidylinositide-3-kinases delta isoform (PI3Kδ) (Okkenhaug et al., 2002), have been shown to 
result in reduced MZ B cell numbers (Clayton et al., 2002; Jou et al., 2002), whereas mice deficient for the 
phosphatase and tensin homologue (PTEN), a negative regulator of  PI3K signalling, display increased 
MZ B cell numbers (Suzuki et al., 2003). These data suggest that PI3K signalling positively regulates            
MZ B cell development. Besides the just described signalling pathways various factors mediating B cell 
migration, retention and positioning are crucial for MZ B cell development, as it is still believed that 
transitional B cells need to migrate into the MZ environment to be able to fully mature to MZ B cells 
(Pillai and Cariappa, 2009). During peripheral maturation chemokine receptor CXCR5-expressing T1       
B cells (IgMhigh IgD- CD21- CD23-) enter the splenic white pulp via the marginal sinus, where they 
migrate into the splenic follicles in response to a CXCL13 gradient created by FDCs (Lo et al., 2003).    
There they further differentiate into T2 (IgMhigh IgD+ CD21+ CD23+) and T3 (IgMlow IgD+ CD21+ 
CD23+) transitional B cells, which are now able to recirculate (Chung et al., 2003; Allman et al., 2001b;         
Pillai and Cariappa, 2009). The sphingosine-1-phosphate receptors 1 and 3 (S1PR1/3) are already         
highly expressed on MZ B cell precursors and participate in MZ B cell homing to as well as retention 
in the sphingosine-1-phosphate (S1P) rich MZ. They are essential for overcoming the just described 
attraction to the follicle by CXCL13. Next to its indispensable role in MZ B cell commitment, Notch2 
signalling could potentially also be implicated in supplying MZ B cells and their precursors with MZ 
localisation signals (Saito et al., 2003; Cinamon et al., 2008; Cinamon et al., 2004; Simonetti et al., 
2013). Other players that engage in MZ B cell migration and localisation are for example the Wiskott-
Aldrich syndrome protein (WASP), a cytoskeletal protein, which if  missing causes a disruption of  the 
actin polymerisation in MZ B cells so that they are no longer able to migrate in response to the S1P 
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gradient (Thrasher, 2002; Westerberg et al., 2008) or SWAP-70, a RhoGTPase-interacting and F-actin-
binding protein, which regulates MZ B cell adhesion (Chopin et al., 2010). MZ B cells are furthermore         
positioned to the MZ by the interaction of  the two integrins lymphocyte function-associated antigen 1 
(LFA1) and α4�1 on their surface with the intracellular adhesion molecule 1 (ICAM1) and the vascular 
cell adhesion molecule 1 (VCAM1), respectively (Lu and Cyster, 2002). And last but not least, MZ B 
cells may also receive further MZ retention signals from MARCO+ macrophages (Karlsson et al., 2003) 
that are localised in the MZ. However, besides all this knowledge, until today it is not completely clear 
if  there is a specific B cell stage from which MZ B and Fo B cells branch from each other or where MZ 
B cell precursors reside within the spleen. There are interesting studies showing that MZ B cells can 
also develop from mature Fo B cells in rats (Dammers et al., 1999) implicating that MZ B cells could 
potentially also arise from later transitional stages or even mature Fo B cells. Apart from that, the role 
of  T3 transitional B cells in B cell development is still not completely clear, although it is currently 
under discussion if  these cells represent anergic B cells (Teague et al., 2007; Liubchenko et al., 2012).        
So, in summary, an integrated model out of  differentiation and migration factors cooperating at the 
same time rather than in a chronological order mediate this important cell fate decision. 
1.2.2.3 Mature B cell populations
Fo B cells represent the majority of  mature B cells (~75 %) mainly homing to B cell follicles in the 
spleen and lymph nodes (LN). They continually recirculate via the (blood) circulation through the BM 
and peripheral lymphoid organs. They typically are IgDhigh IgMlow CD23+ and CD21Int. Follicular B cell 
zones are always adjacent to T cell areas, allowing a rapid interaction of  antigen-activated Fo B and T 
cells if  necessary. Therefore, Fo B cells are well suited for and hence key players of  T cell-dependent 
(TD) immune responses where B and T cells need to interact (details in 1.3.1.3). With ~5 %, MZ B 
cells are less abundant and in contrast to Fo B cells sessile within the spleen (Srivastava et al., 2005).    
They express high levels of  IgM, CD21, CD1d, CD25, CD9, CD80, CD86 and integrins as well as low 
levels of  IgD and CD23 (Pillai et al., 2005). They reside in the MZ which is constantly exposed to large 
amounts of  blood exiting the circulation via the marginal sinus. There they are perfectly positioned 
to fullfill their main and very important function, namely to rapidly trap and react to blood-borne 
pathogens (for detail see 1.3.1.2) (Zandvoort and Timens, 2002). To fullfill this important role a large 
fraction of  MZ B cells carry polyreactive BCRs and express high levels of  toll-like receptors (TLR) 
for a quick recognition of  conserved microbial molecular patterns (Bendelac et al., 2001; Martin and      
Kearney, 2002; Treml et al., 2007; Gururajan et al., 2007). In addition, they are described to have a        
pre-activated phenotype (Gunn and Brewer, 2006; Oliver et al., 1999b), the capacity to self-renew 
(Tarakhovsky, 1997) and to survive the whole life-span of  the host (Hao and Rajewsky, 2001; Pillai 
et al., 2005; Martin and Kearney, 2002), although it is currently under discussion if  their pool is 
constantly being refilled via their self-renewing capacity or by precursors (Pillai et al., 2005). Next to       
Fo B and MZ B cells, which represent B-2 cells, another naïve mature B cell population exists in the 
periphery, referred to as B-1 cells. B-1 B cells, which can further be sub-divided into B-1a and B-1b B 
cells, are believed to arise early in life and are thought to be mainly derived from fetal liver stem cells 
(Allman and Pillai, 2008; Dorshkind and Montecino-Rodriguez, 2007). B-1 B cells represent the main 
Introduction
6
B cell population in the peritoneal and pleural cavities (Allman and Pillai, 2008) and are CD19high, 
B220low, IgMhigh, CD43+. Furthermore they express the myeloid marker CD11b, yet they lack CD23. 
The two subpopulations B-1a and B-1b can be differentiated by means of  their CD5 expression. 
While B-1a cells are positiv for CD5, B-1b cells are not (Dorshkind and Montecino-Rodriguez, 2007). 
B-1 cells have like MZ B cells the potential to self-renew (Tarakhovsky, 1997) and both cell types often 
cooperate with each other in T cell-independent (TI) immune responses (Martin et al., 2001). B-1a     
and MZ B cells are major sources of  natural, mostly IgM+, polyreactive antibodies arising without 
the stimulation by environmental antigens, providing instantaneous protection against for example 
microbial antigens. These antibodies play a crucial part in protecting the organism in the early phase 
of  infection (Holodick et al., 2014; Casali and Schettino, 1996; Cerutti et al., 2013). Hence, B-1 and               
MZ B cells are two cell populations playing a pivotal role during the transition from innate to adaptive 
immune response (more details about this in 1.3.1.2). 
 
1.3 B cell activation and plasma cell development
1.3.1 T cell-dependent and T cell-independent immune reactions
B cells and their ability to differentiate into plasma cells (PCs) producing antigen-specific antibodies, 
which in turn are able to identify and neutralise invading bacteria or viruses are a crucial mechanism of  
the humoral arm of  adaptive immunity. Depending on the type of  antigen, where antigen encounter 
takes place and which B cell subset and accessory cells are involved, the outcome of  the immune 
reaction differs. B cell activation is generally divided into two different routes: T cell-dependent and 
T cell-independent immune response. Figure 3 illustrates schematically the different ways of  immune 
reactions described in this chapter.
Figure 3: Cross section of the splenic white 
pulp illustrating the different ways of 
immune reactions (from Oracki et al., 2010). 
Antigens entering via the blood circulation 
activate Fo B and/or MZ B cells, causing 
their migration towards the T cell area and a 
subsequent burst of proliferation. MZ B cells - 
now plasmablasts - then exit the white pulp via 
the bridging channels and further differentiate 
into short-lived plasma cells in extra-follicular 
foci. Fo B cells carrying a BCR with high antigen-
affinity continue migrating towards the red 
pulp, where they also form extra-follicular foci. 
Fo B cells with a low-affinity BCR re-enter the 
follicle and form germinal centers (GC), where 
they undergo further affinity maturation. PALS 
(periarteriolar lymphoid sheath), PC (plasma 
cell), TFH cell (T follicular helper T cell).
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1.3.1.1 Antigen capturing and presentation
Mature, naïve B cells whose antigen receptor is able to bind an antigen are activated, start to proliferate 
(clonal expansion) and finally differentiate to plasma cells secreting antigen-specific antibodies 
(Janeway et al., 2012). B cells bind antigens, when these are tethered to the surface of  specialised 
antigen-presenting cells (APC). �et, in contrast to T cells, B cells recognise antigens only in their 
unprocessed native state (Bergtold et al., 2005; Huang et al., 2005). This means that APCs must either              
be able to stably immobilise and display antigen on their surface for a longer time or internalise them 
into non-degrading intracellular compartments for subsequent presentation. The most important 
cell populations implicated in antigen capturing and presentation are macrophages, granulocytes 
(especially neutrophils), DCs and FDCs. They are constantly monitoring the blood and lymphatic 
fluids for foreign antigens. Most of  these antigens are either directly trapped and ingested within 
SLOs such as the spleen, lymph nodes, Peyer’s patches or are captured in the circulation, ingested 
and then transported to SLOs, where they are presented to B cells (Batista and Harwood, 2009). 
Macrophages express different receptors enabling them to present unprocessed antigen: MAC1 
(macrophage receptor 1), the FcγRIIB (low-affinity receptor for IgG) and SIGN-R1 for example have 
been shown to be implicated in the internalisation and/or retention of  antigen on the cell surface 
(Phan et al., 2007; Bergtold et al., 2005; Koppel et al., 2005). The same receptors (SIGN-R1 and     
FcγRIIB receptor) have been shown to be expressed by DCs (Batista and Harwood, 2009). Due to 
technical limitations, antigen presentation to B cells has predominantly been studied in lymph nodes. 
However, as the spleen exhibits a similar core organisation, mechanisms might resemble each other 
in both tissues. In lymph nodes, a CD169+ macrophage population resides within the follicle just 
beneath the subcapsular sinus, with processes extending into lymphatic vessels. In this way, antigens 
can be captured out of  the lymphatics and subsequently presented and transferred to Fo B cells. It 
is conceivable that CD169+ macrophages have a similar role in the spleen (Batista and Harwood, 
2009; Cyster, 2010). Furthermore, DCs of  the lymph nodes have been shown to localise outside the 
follicle near high endothelial venules, where they can present antigen to passing, circulating Fo B cells 
entering the lymph nodes (Qi et al., 2006). In the spleen, mainly MZ macrophages and circulating            
CD11c+ DCs interact with MZ B cells, thereby transferring captured antigen (Balazs et al., 2002; Chen     
et al., 2005; Kang et al., 2006). MZ B cells whose BCR is able to bind the antigen can now initiate              
TI antibody responses and in addition transport the antigens into the follicle, where they are further 
transferred to FDCs (Chorny et al., 2012; Cinamon et al., 2008). FDCs are subsequently able to keep              
these antigens on their surface for longer periods to ensure an efficient encounter of  the presented 
antigen with a cognate Fo B cell (Suzuki et al., 2009). However, also non-cognate MZ B cells can           
bind antigens on APCs and due to a constant up- and downregulation of  the S1PR1, MZ B cells are 
continuously shuttling between the MZ and the follicle (Arnon et al., 2013), thereby permanently 
transferred antigens onto FDCs. Thus, the probability that the antigen is recognised by a cognate Fo 
B cell is strongly increased. This antigen transfer between MZ B cells and FDCs however is dependent 
on complement receptors, which are highly expressed on both cell types (Batista and Harwood, 2009). 
Antigen-activated splenic neutrophils, which localise in peri-MZ regions, can also interact with MZ 
B cells and thereby trigger antibody production as well as class switch recombination (CSR) and 
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somatic hypermutation (SHM) involving BAFF and a proliferation-inducing ligand (APRIL) (Puga et  
al., 2012). Last but not least, within lymph nodes small soluble antigens are believed to be able to gain                 
access to Fo B cells and FDCs by directly entering the follicle via small pores within the subcapsular 
sinus without the help of  any antigen-presenting cell (Pape et al., 2007). Fo B cells subsequently are         
able to capture antigens directly and in turn present them. However, whether a similar mechanism 
exists in the spleen is not known so far. 
1.3.1.2 T cell-independent immune response
The TI immune response links innate and adaptive immunity and bridges the temporal gap until the 
production of  high-affinity antibodies is initated by Fo B cells (Martin et al., 2001). Therefore, it is the     
first and more rapid, hence still rather unspecific, reaction of  the adaptive immune system in reponse 
to infectious agents. It is in large parts accomplished by “innate-like” B-1 and MZ B cells, without the 
help of  T cells and is therefore known as T cell-independent immune response (Martin et al., 2001;    
MacLennan et al., 2003; Zandvoort and Timens, 2002; Hsu et al., 2006; Haas et al., 2005; Alugupalli 
et al., 2004). In contrast to TD immune reactions (see next chapter), it does not involve affinity              
maturation of  the BCR and has a minor role in creating long-lived memory B cells. TI antigens are 
further split into TI type 1 and TI type 2 antigens. The typical example for a TI-1 antigen is the cell 
wall component lipopolysaccharide (LPS) of  gram-negative bacteria. TI-1 antigens are mitogens that 
bind to TLRs and BCRs irrespective of  their antigen specificity, thus activating B cells in a polyclonal 
fashion, thereby inducing proliferation and subsequent differentiation to antibody-secreting plasma 
cells (Bekeredjian-Ding and Jego, 2009; Peng, 2005; Minguet et al., 2008). Type 2 antigens are highly      
repetitious molecules such as polysaccharides from the cell wall of  encapsulated bacteria, viral capsids 
or polymeric proteins, thereby leading to an extensive cross-linking of  antigen-specific BCRs, delivering 
a persistent signal via Btk (Mond et al., 1995). Artifical TI-2 antigens are typically haptens coupled to            
ficoll, dextran or acrylamide (Oracki et al., 2010; Elgert, 2009). Activation by these type of antigens            
triggers the maintenance or upregulation of  CXCR4 as well as the downregulation of  S1PR1, CXCR5, 
CCR7 and probably also integrin adhesiveness on B cells (Cinamon et al., 2004; Hargreaves et al., 
2001; Lu and Cyster, 2002) enabling them to move to the outer PALS, where they become B cell blasts 
and undergo clonal expansion, steps involving proliferation and the increase in size. A proportion 
of  this proliferating population will start to secrete antigen-specific antibodies and is then defined 
as plasmablasts. During all this time, these cells continue to migrate towards the bridging channels 
following a gradient of  the CXCR4 ligand CXCL12 (highly concentrated in the red pulp) to gain access 
to the red pulp, where they cluster into extra-follicular foci (Wehrli et al., 2001; Hargreaves et al., 2001).        
Within these foci cells further differentiate into mature plasma cells, which have stopped proliferating 
and mostly secrete low-affinity IgM and IgG3 (Martin et al., 2001; Ellyard et al., 2005). CD11c        high DCs, 
macrophages or stromal cells secrete the tumor necrosis factor (TNF) receptor ligands BAFF and 
APRIL, which are essential for the survival and continuous differentiation of  plasmablasts and plasma 
cells (Balazs et al., 2002; Garcia, V et al., 1999a; Garcia, V et al., 1999b). However, these extra-follicular 
foci soon disperse and thus barely contribute to the long-lasting plasma cell pool (Smith et al., 1996). 
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1.3.1.3 T cell-dependent immune response
TD antigens consist of  whole cells, viruses, parasites or soluble proteins and do not induce antibody 
production without T cell help (Stein, 1992). Key players in TD immune responses are Fo B cells,          
although they have also been shown to respond to TI antigens and to enhance TI immune responses 
(Swanson et al., 2010). Fo B cells are constantly recirculating through SLOs, where they screen for            
antigens on the surface of  APCs. Those cells that are able to bind antigens with their antigen-specific 
BCR, ingest, process and present them on major histocompatibility complex (MHC) class II proteins 
on their surface (Avalos and Ploegh, 2014; Lanzavecchia, 1990; Carrasco and Batista, 2007). This           
initial antigen induced activation further leads to an upregulation of the ICOS ligand, a co-stimulatory            
molecule for T cells and the chemokine receptor CCR7 (Pereira et al., 2010; Mak et al., 2003; Tafuri et 
al., 2001). The latter draws Fo B cells to and makes them align along the B-T cell boundary within the 
splenic follicle (Reif et al., 2002). Simultaneously, naïve CD4      + T cells located within the T cell zone are 
primed by parts of  the same antigen presented by APCs, making them so called armed CD4+ helper 
T (TH) cells. An upregulation of  the chemokine receptor CXCR5 is directing them in the direction 
of  the B cell follicle (Haynes et al., 2007). This orchestrated movement of B and T cells, specific             
for the same antigen towards each other from different positions greatly enhances the likelihood of  
their encounter and thus the induction of  an adequate immune response (Oracki et al., 2010). The 
MHC II:peptide complex on the B cell surface can now be recognised by the antigen-specific T cell 
receptor (TCR) on armed CD4+ helper T cells, thereby forming the so called immunological synapse 
(Duchez et al., 2011). This interaction entails the further production of surface-bound and secreted          
cues, enabling TH cells and B cells to activate each other, in the end triggering B cell proliferation 
and subsequent plasma cell differentiation (Janeway et al., 2012). The most common and important 
activating molecules expressed by activated T cells are the CD40 ligand (CD40L), a member of  the 
TNF receptor (TNFR) family, which is membrane-bound and binds to the CD40 receptor on B cells 
(van and Banchereau, 2000; Basso et al., 2004) as well as the secreted cytokine IL-4 (Nelms et al.,           
1999). At the B-T cell boundary, both B and T cells will proliferate for several days. Subsequently,                
dependent on the strength of BCR-antigen interaction, Fo B cells can now either enter a germinal                
center (GC) or form extra-follicular foci (Paus et al., 2006; MacLennan et al., 2003). Fo B cells with a             
high-affinity BCR will continue proliferating and develop into plasmablasts while migrating towards 
the red pulp via the bridging channels, where they will form extra-follicular foci. After some days 
proliferation ceases and the plasmablasts become short-lived plasma cells (MacLennan et al., 2003).    
Those cells with a low-affinity binding re-enter the follicle to initiate the GC reaction, which is a 
hallmark of  TD immune responses. GCs arise within follicles of  SLOs and consist of  proliferating 
B cells, forming a sort of  secluded appropriate microenvironment in which they can undergo further 
proliferation, Ig class switch recombination as well as affinity maturation via somatic hypermutation 
to ultimately produce antibody-secreting B cells with greater affinity and specificity for the cognate 
antigen as well as memory B cells (Shlomchik and Weisel, 2012; Honjo et al., 2002). The GC reaction           
has a pivotal role in contributing to the immunological memory, as the majority of  memory B cells 
and long-lived BM plasma cells are germinal center-derived (Shlomchik and Weisel, 2012; Oracki et al., 
2010). In both TD and TI immune responses long-lived plasma cells need to gain access to specialised 
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niches within the BM, providing them with essential survival signals. Otherwise they would undergo 
apoptosis within some days (Radbruch et al., 2006).
1.3.2 Fundamental molecular mechanisms in plasma cell differentiation
Two groups of  transcription factors antagonising and able to repress each other in their function 
regulate plasma cell differentiation. Key players of  the first group, suppressing plasma cell development 
are Pax5 and B cell lymphoma 6 protein (Bcl6), whereas members of  the second group such as B 
lymphocyte-induced maturation protein 1 (Blimp-1), interferon regulatory factor 4 (Irf4) and X-box 
binding protein 1 (Xbp1) drive plasma cell development (Shapiro-Shelef  and Calame, 2005). Pax5 
has a major role in establishing and maintaining B cell identity, and its target genes are associated 
with important B cell functions such as immunoglobulin gene rearrangement and BCR signalling 
(CD19, CD79a and B-cell linker (BLNK)) (Schebesta et al., 2007). At the same time it inhibits gene           
transcription essential for plasma cell development (Oracki et al., 2010; Nutt et al., 2001; Nera and           
Lassila, 2006). Bcl6 has been shown to be necessary for GC formation and its crucial function in this                
context consists in inhibiting further differentiation of  B cells to low-affinity, short-lived plasma cells 
by repressing Blimp-1 (Shaffer et al., 2000; Rel�ic et al., 2000). So, for efficient and productive plasma              
cell development it is not sufficient to upregulate plasma cell-specific genes, but concomitantly the 
B cell gene expression program needs to be downregulated. Blimp-1 fulfills both roles as it represses 
mature B cell genes such as pax5, spiB, CIITA as well as genes of  the GC program such as bcl6 and 
activation-induced cytidine deaminase (aicda) (Lin et al., 2002; Lin et al., 1997; Martins and Calame, 
2008; Sciammas and Davis, 2004; Shaffer et al., 2002). At the same time it induces a gene which is also            
pivotal for plasma cell development and especially for later antibody secretion, namely xbp1, which 
activates genes of  the secretory pathway (Shaffer et al., 2002; Shaffer et al., 2004). Beyond this, Blimp-          
1 leads to the upregulation of  CXCR4, which guides plasmablasts to the red pulp where they can 
further develop to fully mature plasma cells (Sciammas and Davis, 2004). MZ B and B-1 cells express       
higher Blimp-1 levels than Fo B cells, which allows them to develop into plasma cells and hence react 
to pathogens more rapidly (Fairfax et al., 2007). However, although Blimp-1 is indispensable for the           
full differentiation of  plasma cells and their longterm maintenance, it is not needed for its initiation 
(Kallies et al., 2004; Shapiro-Shelef  and Calame, 2005; Kallies et al., 2007). Irf4 is, like Blimp-1, highly      
expressed in plasma cells and necessary for their development. �et, in contrast to Blimp-1, Irf4 is 
quite likely to play a critical part in the initiation phase of  plasma cell development and to preceed 
Blimp-1 expression, as it has been shown to induce Blimp-1, and Irf4-deficient B cells are devoid 
of  the entire Blimp-1-dependent plasma cell program (Klein et al., 2006; Sciammas et al., 2006).        
Transient Irf4 expression is known to induces the GC reaction, whereas sustained and higher Irf4 
concentrations lead to plasma cell differentiation at the expense of  GC formation (Ochiai et al., 2013).    
Another factor possibly implicated in the initiation of  the plasma cell program is the micropthalmia-
associated transcription factor (Mitf), which negatively regulates Irf4, as Mitf  knockout mice exhibit 
spontaneous plasma cell formation, which can be reverted by an Irf4 knockdown (Lin et al., 2004).    
Next to these key players there are various other factors known to be implicated in the regulation 
of  plasma cell differentiation (reviewed in Oracki et al., 2010; Shapiro-Shelef  and Calame, 2005). 
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There are different steps in plasma cell development characterised by varying levels of  specific surface 
markers and changes in transcription factor activity (Fig. 4). �et, mature plasma cells typically have 
low levels of  CD19, B220, MHC class II, CD79, CD5, CD86, CD21, CD22 as well as surface Ig and 
increased levels of  Syndecan-1 (CD138), CD9, CD43 and CD93 (Smith et al., 1996; Lalor et al., 1992;        
Fairfax et al., 2008).
1.4 Notch receptor signalling
1.4.1 The structure and activation of  Notch receptors
The Notch signalling pathway is evolutionary highly conserved and can be found in most multicellular 
organisms as diverse as nematodes and mammals (Radtke et al., 2010). It is named after the Notch          
receptor gene, which was first discovered 1917 by Thomas Hunt Morgan due to an altered, “notched” 
phenotype in the wings of  fruit flies (Morgan, 1917). Later on, a loss of function of the         Drosophila 
Notch gene, which was cloned in the mid eighties, was found to be responsible for that phenotype 
(Kidd et al., 1986; Wharton et al., 1985). Notch signalling plays amongst others an important role in the          
regulation of  cell survival and proliferation, cell fate decisions and cell differentiation in a wide variety 
of  biological systems from embryonic to adult life (Alberi et al., 2013; Fortini et al., 2014; Zanotti and 
Canalis, 2013; Koch et al., 2013; Noah and Shroyer, 2013; Fouillade et al., 2012; Perrimon et al., 2012). 
Mammals possess four different members (Notch1, 2, 3, 4) of  the Notch family of  transmembrane 
receptors and five different ligands of  the Delta-like (Dll) or Jagged family (Dll1, 3, 4, and Jagged1, 2) 
(Fig. 5). Receptors and ligands of  adjacent cells are able to interact with each other, thereby inducing 
the Notch signalling cascade (Bray, 2006). Notch receptors are heterodimers that belong to the group         
of  single-pass type I transmembrane receptors. They consist of  an extracellular domain (NotchEC) 
at the N-terminus containing epidermal growth factor (EGF)-like repeats that mediate ligand 
Figure 4: Expression of surface markers and transcription factors during plasma cell development (taken 
from Oracki et al., 2010). The different stages of plasma cell development can be identified according to the 
expression of some specific surface markers. Depending on the differentiation stage, the levels of the transcription 
factors Pax5, Irf4 and Blimp-1 may change considerably.
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binding, three cysteine rich LIN12-Notch repeats (LNR) that prevent ligand-independent activation 
and the heterodimerisation domain made of  a hydrophobic stretch of  amino acids (Fig. 5) (Kopan  
and Ilagan, 2009). This NotchEC is non-covalently conjoined to the C-terminal part of  the Notch 
receptor consisting of  an extracellular heterodimerisation (HD), a transmembrane (NotchTM) and a 
cytoplasmic intracellular domain (NotchIC) (Blaumueller et al., 1997; Logeat et al., 1998; Kopan and          
Ilagan, 2009). The cytoplasmic, intracellular part NotchIC mediates signal transduction and comprises          
a RAM domain, six ankyrin repeats (ANK) necessary for the binding to the transcription factor CSL/
RBP-J� (CBF in human, Suppressor of Hairless in        Drosophila, Lag1 in C. elegans, RBP-J� in mice), two    
nuclear localisation signals (NLS), a transactivation domain (TAD) as well as a proline-glutamine-
serine-threonine-rich (PEST) domain, which is implicated in protein stability (Fig. 5) (Gordon et al.,     
2008; Radtke et al., 2010). When Notch signalling is triggered by receptor-ligand interaction between         
neighbouring cells (Fig. 6), two proteolytic cleavage steps are induced. At first, metalloproteases of  
the ADAM family, probably ADAM10 or 17, cleave Notch extracellularly, thereby leaving the shedded 
NotchEC to endocytosis by the ligand-expressing cell. The second cleavage step is effected within        
the transmembrane domain, thus liberating the intracellular part of  the Notch receptor (NotchIC) 
and is mediated by the γ-secretase (GS) activity of  a multiprotein complex (Fig. 6). NotchIC can now 
translocate into the nucleus, where it interacts with the DNA binding protein and transcriptional 
repressor CSL/RBP-J�. Subsequently other co-activators are recruited such as mastermind proteins 
(MAML1-3) and the MED8-mediator transcription activation complex thereby abolishing repression 
and inducing the transcription of  Notch target genes (Fig. 6) (Radtke et al., 2010). A great number of         
genes can directly be regulated by Notch (Palomero et al., 2006; Hamidi et al., 2011; Weng et al., 2006)            
amongst which the most prominent target genes are members of  the hairy enhancer of  split (Hes) 
or hairy related genes (Hey). Notch signalling is regulated at multiple levels (reviewed in Bray, 2006;            
Figure 5: Notch receptors and their ligands (adapted from Radtke et al., 2010). Mammals have four Notch 
receptors (Notch1-4) and five different ligands: Jagged1, 2 and Delta-like (Dll) 1, 3 and 4. All ligands typically carry 
an amino-terminal domain called DSL (Delta, Serrate and Lag2), responsible for receptor binding followed by 
epidermal growth factor (EGF)-like repeats. In Jagged1 and 2, a cysteine-rich domain (CR) is located close to the 
plasma membrane (PM) downstream of the EGF-like repeats. The receptors also carry EGF-like repeats in their 
extracellular domains (NotchEC, mediating ligand-binding), followed by three cystein-rich LIN domains - inhibiting 
ligand-independent activation - and the heterodimerisation domain (HD). The cytoplasmic part (NotchIC) consists 
of a RAM domain, six ankryin repeats (ANK), which bind to the transcription factor RBP-Jκ, two nuclear localisation 
signals (NLS), a transactivation domain (TAD, only in Notch1 and 2) and a proline-glutamine-serine-threonine-rich 
(PEST) sequence regulating protein stability.
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Kopan and Ilagan, 2009). Restricting the expression of Notch receptors or their ligands to a specific             
cell-type or in a spatial or temporal manner represents one of  them (Besseyrias et al., 2007; Santos et      
al., 2007; Radtke et al., 2004). Furthermore, ligand-receptor interaction is regulated by posttranslational       
modification. The Fringe glycosyltransferase for example facilitates Notch signalling induced by Delta 
ligands, while simultaneously inhibiting Jagged-mediated signalling by adding N-acetylglucosamine to 
some EGF-like repeats (Haines and Irvine, 2003; Moloney et al., 2000; Besseyrias et al., 2007). Another             
way of  controlling Notch signalling is by regulating its half-live. Once NotchIC is released into the 
nucleus, it is quite rapidly subjected to ubiquitin-dependent proteasomal degradation executed via its 
PEST domain, thereby stopping further transcription of  Notch regulated genes (O’Neil and Look, 
2007; Deimling et al., 2007). Furthermore, Notch signalling can be negatively regulated, for example          
via the MINT (Msx2-interacting nuclear target) repressor protein, which competes with NotchIC 
for the interaction with CSL/RBP-J� (Kuroda et al., 2003). Notch belongs to the rare group of        
genes in diploid organisms that display haploinsufficiency, meaning that one copy of  the gene is not 
enough to generate sufficient gene product. Hence, the organism is quite sensitive to changes in gene 
dosage. Haploinsufficiency of  Notch2 or Jagged1 for example has been shown to lead to Alagille��s 
syndrome (Oda et al., 1997; McDaniell et al., 2006), whereas reduced Notch1 signalling is associated 
with a special type of  aortic disease (Garg et al., 2005). Amplification or overexpression of Notch on          
the other hand is mainly cancerogenic (for detail see 1.4.4) Thus, it seems that not only the type of  
receptor-ligand interaction determines the outcome of  Notch signalling, but also the cellular context 
and the signalling strength.
Figure 6: Notch receptor activation. The interaction of Notch-specific ligands with the extracellular part of 
the Notch receptors on neighbouring cells induces two sequential proteolytic cleavage steps. First, Notch is 
cleaved extracellularly by metalloproteases of the ADAM family, while the γ-secretase (GS) cleaves it within the 
transmembrane domain. The now freed intracellular part of the receptor (NotchIC) can translocate into the nucleus, 
where it displaces the co-repressor complex consisting of SKIP (Ski-interacting protein), MINT (Msx2-interacting 
nuclear target protein) and HDAC1 (histone deacetylase 1) by interacting with the transcription factor RPB-Jκ 
and further recruiting a co-activator complex consisting of MAML (mastermind-like), p300, pCAF (p300-associated 
factor) and SKIP. In this manner the transcription of Notch target genes is induced.  
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1.4.2 Notch signalling in lymphocytes
In lymphocytes, predominantly Notch1 and Notch2 are expressed, where they fullfill non-redundant 
functions. Nevertheless, the implication of  Notch, especially Notch1 in T cell lineage commitment and 
development is the best-characterised function of  these receptors in hematopoiesis. Inactivation of  
Notch1 or RBP-J� in early lymphocyte progenitors of  the BM leads to a block in T cell development and 
at the same time to the emergence of  an ectopic B cell population in the thymus (Han et al., 2002; Radtke     
et al., 1999). Overexpression of Notch1 in these progenitors on the other hand culminates in ectopic T              
cell development in the BM accompanied by a block in B cell development at the pro-/pre-B cell stage 
(Pui et al., 1999). This data clearly demonstrates that Notch1 is necessary and sufficient to induce T             
cell development. Furthermore, Notch1 is continuously required for α� T cells development up to the 
double negative stage 3, whereas it seems dispensable for γδ T cells (Wolfer et al., 2002). Together with      
the signalling via the pre-TCR it is essential for successful �-selection, after which it is downregulated 
(Ciofani et al., 2006; Maillard et al., 2006; Allman et al., 2001a). Early B lymphocytes in the BM express       
both Notch1 and Notch2, whereas Notch2 is the predominant receptor on mature B cells, with highest 
expression levels in MZ B cells and their precursors. Notch2 is expendable for T cell development, yet it is 
cucial for MZ B cell development (Walker et al., 2001; Saito et al., 2003; Witt et al., 2003; Tan et al., 2009).                
Expression of  different levels of  a constitutively active Notch2 receptor in hematopoietic stem cells by 
means of  a retrovirus revealed that high Notch2 levels led to the development of  a strongly proliferating 
T cell population in the BM, while lower Notch2 expression levels blocked B-2 B cell development at the 
large pre-B cell stage and enhanced splenic B-1 B cell differentiation (Witt et al., 2003).   
1.4.3 Notch in MZ B cell development
Notch2 is an indispensable key player in MZ B cell development and this has clearly been confirmed 
by analysing various different mouse models. Mice with B cell-specific ablations of  Notch2 or RPB-J� 
(Saito et al., 2003; Tanigaki et al., 2002) as well as mice with deletions of  Mastermind-like 1 (MAML1) 
(Wu et al., 2007; Oyama et al., 2007), ADAM10 (Gibb et al., 2010) or Delta-like 1 (Hozumi et al.,          
2004) all reveal defects in MZ B cell development, while the generation of  Fo B cells is not affected. 
Constitutively active Notch2 signalling shifts nearly all B cells to the MZ B cell compartment even in the 
absence of  CD19 (Hampel et al., 2011). Furthermore, inactivation of MINT, a suppressor of Notch,            
results in an increase in MZ B cells (Kuroda et al., 2003). The ligand which is crucial for MZ B cell          
differentiation is Dll1, mainly found on endothelial cells of  the splenic red pulp and in the MZ. T2 B 
cells with a strong Notch2 signalling are believed to be guided to the MZ, where the initially rather weak 
binding between Notch2 and Dll1 is strengthened by the two glycosyltransferases lunatic and manic 
fringe inducing them to differentiate into MZBPs (IgMhigh IgDhigh CD21high CD1dhigh CD23+) and hence 
into MZ B cells (Tan et al., 2009; Allman and Calamito, 2009). Furthermore, it seems necessary that      
Dll1 is endocytosed by the ligand-expressing cell after binding, as deficiencies in the E3 ubiquitin ligase 
Mindbomb1 (MIB1) also impair MZ B cell development (Song et al., 2008). Although Notch2 is clearly        
an essential part during MZ B cell differentiation, its interplay with other signalling pathways is probably 
a prerequisite for the generation of  mature, functional MZ B cells correctly located in the MZ. 
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1.4.4 Notch signalling in lymphoma and other malignancies
The oncogenic potential of  mammalian Notch was for the first time discovered in 1991, when in a 
subset of  T cell acute lymphoblastic leukemia (T-ALL) patients a chromosomal translocation - later 
named TAN1 (translocation-associated Notch homologue) - was revealed resulting in an overexpressed 
constitutively active Notch1 receptor (Ellisen et al., 1991). Subsequent studies disclosed that within         
the hematopoietic system, deregulated Notch signalling seems particularly oncogenic for T cells (Pear 
et al., 1996). Weng and colleagues as well as Aster and colleagues could show that 50 % of all human                 
T-ALLs and 55 % of  pediatric primary T-ALL tumors had activating mutations of  the Notch1 gene 
(Weng et al., 2006; Aster et al., 2008). In addition, not only constitutive active Notch1, but also Notch2          
and 3 have been shown to lead to T cell leukemias (Tzoneva and Ferrando, 2012; Pui et al., 1999;        
Bellavia et al., 2000; Rohn et al., 1996). Apart from that, altered Notch signalling has up to now also 
been associated with different B cell malignancies such as mantel cell lymphoma (MCL) (Kridel et al.,   
2012), diffuse large B cell lymphoma (DLBCL) (Lee et al., 2009), splenic marginal zone lymphoma        
(SMZL) (Troen et al., 2008; Kiel et al., 2012; Rossi et al., 2012), Hodgkin lymphoma (Jundt et al., 2002;                  
Jundt et al., 2004) and B cell chronic lymphocytic leukemia (B-CLL) (Hubmann et al., 2002; Gianfelici, 
2012; Rosati et al., 2009) and reviewed in (Rossi et al., 2012; South et al., 2012; Roy et al., 2007; Koch                 
and Radtke, 2007; Bolos et al., 2007; Hopfer et al., 2005). In these B cell malignancies, most types of        
defects in Notch signalling in some way affected the PEST domain of  the receptors itself  or inhibitory 
interaction partners of  Notch, thereby leading to impaired degradation or inhibition and hence to 
sustained or enhanced Notch signalling. However, it is also known that Notch can, depending on the 
cellular context, also act as a tumor suppressor. In the skin, for example, Notch clearly has a tumor 
suppressive role, as various skin cancers are linked to a knockout of  the notch1 gene (Nicolas et al., 
2003) and reviewed in (South et al., 2012). �et in summary, it seems that the interplay between Notch 
and other signalling cascades as well as the cellular context, determine the outcome and effect of  
Notch signalling with regard to cellular differentiation, induction of  apoptosis or rather proliferation 
and hence possibly tumor formation.
1.5 Model systems
In this work the Notch2IC-transgenic mouse line (Hampel et al., 2011) and a mouse strain carrying a 
truncated Notch2 receptor (Besseyrias et al., 2007) were used. The following section will give a brief  
overview of  the generation of  these mice and results that are already published.
1.5.1 The Notch2IC-transgenic mouse strain
1.5.1.1 Generation
To investigate the influence of  constitutive Notch2 signalling on B cell development, activation and 
lymphomagenesis in vivo, the conditional transgenic mouse strain Notch2ICflSTOP was generated in our 
research group. By using the Cre/loxP system a ligand-independent, thus constitutively active expression 
of  the intracellular part of  the Notch2 receptor (Notch2IC) could be achieved. The details of  the 
targeting strategy are described in (Hampel et al., 2011). A schematic illustration is depicted in figure 7. 
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1.5.1.2 Phenotype 
The detailed phenotypical charaterisation of  the Notch2IC-transgenic mouse line has already 
been described (Hampel et al., 2011). In brief, B cell-specific expression was achieved by breeding 
Notch2ICflSTOP mice to CD19-Cre+/- mice. Expression of  the Cre-recombinase controlled by the 
endogenous CD19 promoter led to a deletion efficiency of  17 % in B cells of  the bone marrow and 
of  79 % in splenic B cell populations (Hampel et al., 2011). CD19-    Cre-induced conditional expression 
of  Notch2IC resulted in a slight splenomegaly (1.5-fold), with normal T and B cell numbers in these 
animals. However, the most obvious phenotype was an induction of  a strong differentiation towards 
MZ B cells at the expense of  the Fo B cell population. Notch2IC-expressing MZ B cells thereby 
reflected the phenotype and biological behaviour of  wild type (wt) MZ B cells with respect to their 
localisation in the MZ, expression of  characteristic surface markers and their pre-activated state. For 
simplicity, mice carrying one notch2IC and one CD19-Cre allele will be refered to as Notch2IC//
CD19Cre+/-, whereas mice with two CD19-Cre alleles will be refered to as Notch2IC//CD19Cre+/+.
1.5.2 The Notch2-deficient mouse strain
1.5.2.1 Generation
Another approach to clarify the role of  Notch2 signalling in MZ B cell development and immune 
response was the generation of  a mouse strain enabling a conditional ablation of  Notch2 signalling 
specifically in B cells. To this end, a targeting vector based on the genomic DNA fragment of  the murine 
Figure 7: Targeting strategy for the generation of Notch2IC-transgenic mice. The conditional notch2IC allele 
(notch2ICflSTOP) and an IRES-hCD2 coding sequence as a reporter were both inserted into the murine rosa26-locus. A 
loxP-flanked transcription and translation termination sequence (STOP cassette) was placed upstream of the 
notch2IC coding sequence. (1) Wild type rosa26-locus with its three exons and the XbaI restriction site within the first 
intron, where the transgene was inserted; (2) the rosa26-locus after successful homologous recombination, now 
harbouring the targeting construct (Notch2ICflSTOP); (3) the rosa26-locus after successful homologous recombination 
and deletion of the STOP cassette via Cre-mediated recombination (Notch2IC), leading to the expression of notch2IC 
under the control of the constitutive active CAGGS promoter. The dotted lines represent homologous and Cre-
mediated recombination events. CAGGS (CMV early enhancer/chicken β-actin/rabbit globin promoter); STOP 
(STOP cassette); hCD2 (truncated human CD2); NEO (neomycin-geneticin resistance gene); Cre (Cre recombinase) 
loxP (locus of X-over P1); frt (flippase recognition target sites).
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notch2-locus including exons b to h and the 5`-part of  exon i (according to the nomenclature described 
in Hamada et al., 1999; coding for the transmembrane and intracellular part of  the Notch2 receptor) was 
used. The two endogenous exons d and e (coding for the C-terminal part of  the RAM23 domain and the 
nuclear localisation sequence) were flanked by loxP sites, allowing a Cre-mediated excision of  this functional 
intracellular part of  the Notch2 receptor. Figure 8 shows a schematic illustration of  the targeting strategy. 
1.5.2.2 Phenotype
The B cell-specific ablation of  Notch2 signalling was achieved by breeding Notch2fl/fl mice to 
CD19-Cre+/- mice. Mice carrying two notch2fl transgenes and one CD19-Cre allele will be refered to 
as Notch2fl/fl//CD19Cre+/-. Cre-mediated deletion of  the two exons d and e of  the notch2 gene led 
to the expression of  a truncated Notch2 protein, lacking the functional, intracellular part. B cell-
specific truncation of  the Notch2 receptor resulted in the ablation of  MZ B cell development. As 
notch2 belongs to the genes displaying haploinsufficiency heterozygous Notch2wt/fl//CD19Cre+/- mice 
already exhibited the typical phenotype, characterised by a lack in MZ B cells (see chapter 3.3.4). In 
accordance, in immunohistological analyses no IgM+ MZ B cells could be detected outside of  the 
marginal sinus lined by MOMA-1+ macrophages (see chapter 3.3.4).
Figure 8: Targeting strategy for the generation of B cell-specific Notch2-deficient mice. A targeting vector 
based on a genomic DNA fragment of the murine notch2-locus including exons b to h and the 5’-part of exon i 
(coding for the transmembrane and intracellular part of Notch2) were inserted into the murine wild type notch2-
locus. Within the construct, exons d and e (coding for the C-terminal part of the RAM23 domain and the nuclear 
localisation sequence) were flanked by loxP sites. (1) Wild type notch2-locus with its exons and the SphI restriction 
sites before exon b and within exon i, where the transgene was inserted; (2) the notch2-locus after successful 
homologous recombination, now harbouring the targeting construct (Notch2fl); (3) the notch2-locus after successful 
homologous recombination and deletion of exons d and e via Cre-mediated recombination (Notch2Δ), leading 
to the expression of a truncated, non-functional Notch2 receptor. The dotted lines represent homologous and 
Cre-mediated recombination events. Exons marked in blue belong to the targeting vector, whereas white exons 
belong to the wild type locus. Cre (Cre recombinase), loxP (locus of X-over P1).
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2. Aim
Notch2 signalling is critical for MZ B cell differentiation, and increased Notch activity has been 
implicated in the development of  various types of  lymphomas. To investigate the influence of  a 
constitutively active Notch2 signal or a constitutive Notch2 ablation on B cell development, activation 
and lymphomagenesis in vivo, two transgenic mouse strains were generated in our research group 
expressing either conditionally a constitutively active or a truncated Notch2 receptor dependent on the 
Cre/loxP system. B cell-specific expression of  the intracellular part of  the Notch2 receptor (Notch2IC) 
resulted in an expansion of  MZ B cells, whereas truncation of  the Notch2 receptor resulted in a lack 
of  the MZ B cell population, underlining the central role of  Notch2 in the development of  MZ B 
cells. 
To learn more about the contribution of  Notch2 signalling to the biology of  MZ B cells on a large 
scale, differences and similarities between wild type and Notch2IC-expressing MZ B cells as well as 
between wild type and Notch2-deficient Fo B cells were to be investigated by whole mouse-genome 
gene expression profiling analyses. By this approach we intended to distinguish Notch2-regulated 
genes from those influenced by the cell-type identity or cellular environment.
Compared to control B cells, Notch2IC-expressing cells exhibited enhanced proliferation after LPS 
or α-CD40 stimlation and enhanced Akt, Erk, Jnk signalling. As MZ B cells are known to exhibit an 
activated phenotype and an increased proliferation potential compared to other B cell types, we aimed 
at figuring out whether enhanced proliferation and signalling of  Notch2IC-expressing cells is an MZ 
B cell intrinsic phenotype or further increased by constitutive Notch2IC expression. Furthermore, 
we planned to investigate whether the MZ B cell phenotype and the increased activity of  signalling 
pathways is induced by constitutive Notch2 expression or the MZ environment. 
MZ B cells are key players in T cell-independent immune responses. �et, it is still unknown if  and how 
Notch2 signalling is implicated in this type of  immune reaction. To get deeper insights into the role of  
Notch2 in B cell activation and its regulation during immune responses, the TI immune reaction was 
to be explored in Notch2IC//CD19Cre+/- and Notch2-deficient mice. 
Activating mutations in the Notch signalling pathway have been described in several B cell lymphomas, 
in particular in splenic marginal zone lymphomas. Notch2IC-expressing B cells displayed increased 
activation and c-Myc expression as well as enhanced proliferation in comparison to control B cells. 
Hence, we suspected that these mice might develop MZ B cell lymphomas due to the strong Notch2 
activity and hence expansion of  MZ B cells. To investigate this, cohorts of  Notch2IC//CD19Cre+/- 
and control mice were to be aged and analysed for lymphoma development.
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3. Results
3.1 C omparison of  gene expression profiles of  Notch2IC-
expressing MZ B and Notch2-deficient Fo B cells with 
wild type MZ B and Fo B cells
The spleen comprises two main, mature B cell populations, MZ B and Fo B cells, which are distinct 
in their function, frequency, localisation, the expression of  characteristic surface markers as well as 
in their activation state (for detail see chapter 1). Notch2 signalling plays a pivotal role regarding the 
decision whether Fo B or MZ B cells develop (see 1.4.3). Mice carrying a B cell-specific Notch2 ablation 
have no MZ B cells, whereas other B cell populations are not affected (Saito et al., 2003; Besseyrias     
et al., 2007). On the other hand, constitutive, ligand-independent, B cell-specific expression of the           
intracellular part of  Notch2 (Notch2IC) leads to a strong expansion of  the MZ B cell population 
at the expense of  Fo B cells (Hampel et al., 2011). In addition to MZ B cell differentiation, Notch2            
signalling is presumably also implicated in positioning MZ B cells and their precursors in the MZ and 
it is assumed that MZ B cell precursors need to reside at least a certain time in the MZ to become 
mature MZ B cells (Tan et al., 2009; Simonetti et al., 2013). To learn more about Notch target genes               
in B cells, we aimed to investigate which genes are differentially regulated in Notch2IC-expressing B 
cells in contrast to Notch2-deficient B cells and how closely related they are to their respective wild 
type counterparts. By this approach we also aimed at differentiating between genes controlled by 
Notch2, from genes that are regulated by the cell-type identity and hence possibly by the environment 
surrounding Fo B or MZ B cell populations. 
3.1.1 The experimental setting - Illumina BeadChip micorarrays
As our research group has the Notch2fl/fl//CD19Cre+/-  and Notch2IC//CD19Cre+/- mouse strains 
as well as wild type mice at hands, we were able to generate and assess whole mouse-genome gene 
expression profiles of  Fo B cells from Notch2fl/fl//CD19Cre+/- mice, Notch2IC-expressing MZ B 
cells as well as wild type Fo B and MZ B cells using Illumina BeadChip microarrays. A schematic 
outline of  the experimental workflow of  the conducted microarray hybridisation experiments using 
Illumina BeadChips is depicted in figure 9. In total, splenic B cells of  six Notch2fl/fl//CD19Cre+/- and 
five Notch2IC//CD19Cre+/- mice were sorted for Fo B cells and MZ B cells respectively (Fig. 10). In 
addition splenic B cells of  21 control mice were sorted for both cell populations (Fig. 10). To this end, 
splenic B cells were stained and sorted according to their CD21 and CD23 expression, with MZ B cells 
being CD21high CD23low and Fo B cells CD21low CD23high (Fig. 11). Notch2IC//CD19Cre+/- cells were 
additionally gated on hCD2+ lymphocytes. Sorted cell populations were recovered with an average 
purity of  97 to 98 % of  lymphocyte-gated cells. Figure 11 shows exemplary dot plots displaying 
frequencies of  both B cell populations, gating and purity before and after the sorting procedures. Total 
RNA of  �ust purified cell populations was isolated after sorting. Its quality and quantity was assessed 
and only samples exhibiting an intact ribosomal RNA species of  good quality (Fig. 12A) were used in 
cRNA amplifications.
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Figure 9: Schematic workflow of a whole mouse-genome gene expression profiling assay using Illumina 
BeadChip arrays. Desired B cell populations were sort-purified using fluorescence-activated cell sorting (FACS) 
and total RNA was subsequently extracted. The quality, integrity and quantity of the gained RNA was examined 
utilising a Nanodrop 2000 and an Agilent 2100 Bioanalyzer. Total RNA was then amplified and at the same time 
labeled with biotinylated nucleoside triphosphates (NTP) for later detection. Similar as before the generated so 
called biotinylated copy RNA (cRNA) underwent quality control and quantification. cRNAs were then hybridised 
onto Illumina BeadChip arrays and finally signal detection and subsequent data analyses were performed. 
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Figure 10: Sorted cell populations and 
experimental groups for gene expression 
profiling analyses. MZ B and/or Fo B 
cells were sort-purified from Notch2IC//
CD19Cre+/-, Notch2fl/fl//CD19Cre+/- and 
CD19Cre+/- mice. Subsequently samples 
exhibiting the best quality and highest RNA 
amounts were placed on Illumina BeadChip 
arrays for the comparison of whole mouse-
genome gene expression profiles.
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Figure 11: Exemplary dot plots from 
sorting experiments depicting splenic 
B cell populations before and after the 
FACS sorting procedure. Splenic cells 
from CD19Cre+/- control mice, Notch2IC//
CD19Cre+/- and Notch2fl/fl//CD19Cre+/- 
mice were sorted for MZ B and/or Fo 
B cell populations via CD21 and CD23 
expression. Depicted dot plots are pre-
gated on Thy1.2-, B220+, and in the case of 
Notch2IC-expressing cells, additionally on 
hCD2+ lymphocytes. During sorting either 
CD21high CD23low MZ B cells and/or CD21low 
CD23high Fo B cells were sort-purified. 
Sorting was performed with an average 
purity of 97 to 98 % of lymphocyte- gated 
cells. 
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RNA samples of  six Notch2fl/fl//CD19Cre+/-, five Notch2IC//CD19Cre+/- and 15 control mice were 
sub�ected to two independent cRNA amplification rounds. To minimise technical bias introduced 
by the different amplification batches, which might later on influence the identified differences in 
gene expressions, samples from the four different cell populations were equally distributed between 
both amplification rounds. In the end, the 24 best cRNA samples (based on amplification-yield and 
quantity, Fig. 12B) were placed on the Illumina BeadChip arrays, comprising five samples of  sorted 
Notch2-deficient Fo B cells, five samples of  sorted Notch2IC-expressing MZ B cells as well as seven 
samples of  wild type MZ B cells and Fo B cells respectively. Here again, sample randomisation and 
alternating processing between the experimental groups was applied in order to avoid technical bias 
and hence falsifying subsequent gene expression profiles gained by group comparisons. Scanning of  
the Illumina BeadChip arrays and subsequent quality control (QC) analyses, background removal, 
Variance Stabilising Normalisation (VSN), scatterplots, hierarchical clustering and Principal Component 
Analyses (PCA) as well as statistical analyses were performed by or in cooperation with Dr. Peter 
Weber from the MPI of  Psychiatry. Figure 13 gives an schematic outline of  the analytical workflow 
performed on microarray data. 
Quality controls, which were directly performed after BeadChip scanning yielded overall good 
results. �et two outliers (one CD19Cre+/- MZ B cell sample and one Notch2IC//CD19Cre+/- MZ 
B cell sample) could be detected, which had to be removed from all subsequent analyses (Fig. 14).
For all the remaining samples fulfilling QC criteria a threshold was set (p-detection < 0.05 in at 
Figure 12: Examples of Bioanalyzer 
graphs of total RNA and cRNA samples 
of high integrity and quality. MZ B cells 
from a Notch2IC//CD19Cre+/- mouse were 
sort-purified. Total RNA was subsequently 
isolated and subjected to cRNA amplification. 
RNA quality and integrity was measured on a 
Bioanalyzer before (A) and after amplification 
(B). 5S, 18S and 28S peaks represent the 
subunits of eukaryotic ribosomal RNA.
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Figure 13: Schematic workflow of Illumina BeadChip microarray data analyses (performed by or in 
cooperation with Dr. Peter Weber). Microarray data were initially subjected to platform-specific quality controls. 
Subsequently background removal was performed (threshold: p-detection < 0.05 in at least three samples of 
whole data set), followed by a Variance Stabilising Normalisation (VSN). Via hierarchical clustering and Principal 
Component Analyses (PCA) outliers and sample patterns (batch) were identified. In the end a variance filter 
(variance > 0.05) was applied and remaining probes were subjected to statistical analysis of variance (ANOVA). 
To identify biologically enriched terms Annotation Cluster Analyses were performed on final gene lists using the 
DAVID online platform.
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least three samples in the whole data set) allowing us to separate significant gene expression from 
background noise, leaving us with 20242 variables (genes) above background for further analyses. To 
adjust signal intensities between samples, a Variance Stabilising Normalisation was performed. This 
type of  adjustment normalises data, while concomitantly performing a transformation, resulting in 
approximately constant variances between samples. This homogeneity of  variance (homoscedasticity) 
is a prerequisite for subsequent statistical tests. The combined background removal and VSN 
normalisation in the end resulted in the assimilation of  the different data distribution of  each sample 
to each other. Thereby technical variance is diminished while biological variances are preserved, thus 
making data more comparable. Figure 15 depicts exemplary boxplots showing the distribution of  
raw data (Fig. 15A), data after background removal (Fig. 15B) and data after background removal and 
VSN normalisation (Fig. 15C). The depicted boxplots illustrate how background removal and VSN 
normalisation assimilate the data, leading to almost normal distributions. 
Figure 14: Quality controls revealed two 
outliers among all analysed cRNA samples. 
Intensity plots showing the microarray mean 
intensity of each analysed sample. Thereby 
y-axes represent mean signal intensities of 
each individual sample; x-axes represent each 
of the 24 analysed samples (array index). The 
intensity plot on the left depicts mean signal 
intensities of housekeeping genes on the 
array; the intensity plot on the right mean 
intensities of all expressed genes.
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Figure 15: Box plots showing optimisations of microarray intensity distributions during data processing. 
(A) Depicted box plots represent unprocessed microarray data directly after scanning of Illumina BeadChips. (B) 
Box plots of microarray data after background removal. Data above background: p-detection < 0.05 in at least three 
samples in the whole data set. (C) Box plots of microarray data after background removal and VSN normalisation. 
Black lines within box plots represent the median values. Any data not within the range of the whiskers are plotted 
as individual dots. 
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3.1.2 Gene expression profiles of  Notch2IC-expressing MZ B as well as 
Notch2-deficient Fo B cells exhibit a close relationship to those of  their 
respective wild type counterparts
As additional quality control and to receive a first impression of  similarities and differences between 
gene expression profiles of  Notch2-deficient Fo B cells, Notch2IC-expressing MZ B cells and wild 
type Fo B and MZ B cells, VSN normalised data were subjected to a hierarchical clustering analysis. 
This method aims at building cluster hierarchies based on a dissimilarity metrics, which can then be 
displayed as a dendrogram. Thus, gene expression profiles that show pronounced overall similarity 
will be displayed in greater proximity than samples that are highly different. However, one should 
keep in mind that hierarchical clustering analyses comprise both, technically and biologically induced, 
differences in gene expression. Analysis of  the dendrogram revealed that samples clustered in the 
first place according to their cell-type identity. Regardless of  constitutive Notch2 signalling or an 
ablation of  the Notch2 signal, MZ B cell populations and Fo B cells constituted two big clusters 
(Fig. 16). However, within these two main clusters, cell populations grouped again into two and three 
subgroups, clearly separating Notch2-expressing MZ B cells and Notch2-deficient Fo B cells from 
their respective wild type counterparts. �et, “cluster 2” branched up much earlier into its subcluster 
2.1 and 2.2 than “cluster 1” into its respective subclusters, suggesting that Notch2-deficient Fo B cells 
are presumably more closely related to wild type Fo B cells than MZ B cell populations among each 
other. The third “subcluster 1.2” among Fo B cells is most likely the result of  a mild technical bias 
induced by the two different amplification rounds (for detailed explanation see below). 
Figure 16: Gene expression profiles of Notch2IC-expressing MZ B and Notch2-deficient Fo B cells resemble 
their wild type counterparts. Dendrogram of unsupervised, agglomerative hierarchical clustering analysis of VSN 
normalised Illumina BeadChip microarray data from sort-purified Notch2-deficient Fo B cells (blue) and Notch2IC-
expressing MZ B cells (orange) as well as control MZ B (red) and Fo B cells (green). The degree of relationship 
between the samples is illustrated by the dendrogram, whereas the height of each branch represents the distance 
between the two samples or clusters being connected. Numbers (e.g. 6903024040_D) are Illumina internal sample 
identifiers.
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For a deeper and more detailed analysis of  the aquired data and to differentiate between biological 
and technical effects, Principal Component Analyses (PCA) were performed. PCA is a common 
multivariate technique for finding patterns in data sets comprising high dimensions. The central idea 
of  a PCA is to reduce the dimensionality of  a data set consisting of  a large number of  interrelated 
variables (in our case genes), while retaining as much of  the existing information and variation as 
possible. In the following PCA graphs, each dot depicts the sum of  all expressed genes of  one sort-
purified B cell population and the three axes represent the three main principal components displaying 
the main differences between the analysed B cell populations.
As different cRNA amplification rounds often result in a technical bias eventually masking “real” 
biological effects (Dr. Peter Weber, personal communication; Leek et al., 2010), data was checked for 
such a possible, technically induced bias. Figure 17 clearly shows that in spite of  taking precautions by 
applying sample randomisation, there was still some mild amplification round induced bias detectable. 
Hence, subsequent PCA analyses and lists of  differentially regulated genes were generated by including 
the amplification rounds as a co-variate - so called “eliminated factor” - in regression based statistics.
Further PCA analyses now focusing only on the biological differences between the four different 
sample types (experimental groups) again clearly revealed that Fo B and MZ B cell populations were 
separate from each other (Fig. 18A, B). Greater differences were again detectable between wild type 
and Notch2IC-expressing MZ B cells (Fig. 18A, B) than among the wild type and Notch2-deficient 
Fo B cells (Fig. 18C, D). However, the similarity between the two Fo B cell populations was even more 
pronounced now after removal of  the amplification round-induced bias. 
3.1.3 Differences in B cell-specific gene expression profiles induced by 
constitutive Notch2IC expression or Notch2 deficiency
After PCA analyses, lists comprising differentially regulated genes were generated (Glucore Omics 
Explorer). Data was first filtered by variance (variance > 0.05) and subsequently an analysis of  
variance (ANO��A) with the amplification round as co-variate (eliminated factor) was conducted. For 
comparison of  CD19Cre+/- MZ B and Fo B cells, paired tests were applied as both cell populations 
Figure 17: Different amplification rounds result in a 
mild technical bias. Principal Component Analysis of 
VSN normalised Illumina BeadChip microarray data from 
sort-purified Notch2-deficient Fo B cells and Notch2IC-
expressing MZ B cells as well as control MZ B and Fo 
B cells. Red spheres are samples processed during the 
first amplification round, while green spheres represent 
all samples of the second amplification round. Percents 
represent the percentages of variance explained by 
each of the depicted main principal components one 
to three.
MZ B cells Fo B cells
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had always been isolated from one individual wild type mouse and are thus biologically related to each 
other. For the other comparisons unpaired tests were performed. To control for false positive rates due 
to multiple testing the Benjamini-Hochberg procedure was used for correction of  the p-values, thereby 
obtaining the so called q-values. Final gene lists comprise only data with a q-value < 0.05 (see CD in the 
appendix). For convenience, the top 100 most strongly regulated genes of  these final gene lists were 
included in the appendix (Tables S1 - S4). The following scheme (Fig. 19) shall give a first impression 
of  the varying numbers of  regulated genes among the analysed samples. With only 44 differentially 
regulated genes, wild type Fo B cells are closely related to Notch2-deficient Fo B cells, followed by wild 
Figure 18: Gene expression profiles of the two Fo B cell populations are more closely related then those 
of the two MZ B cell populations. (A-B) Principal Component Analysis of VSN normalised Illumina BeadChip 
microarray data from sort-purified Notch2-deficient Fo B cells and Notch2IC-expressing MZ B cells, as well as control 
MZ B and Fo B cells including the amplification round as co-variate (eliminated factor). (C-D) Principal Component 
Analysis of VSN normalised Illumina BeadChip microarray data comparing sort-purified Notch2-deficient Fo B cells 
with control Fo B cells including the amplification round as co-variate (eliminated factor). Notch2IC-expressing MZ 
B cells (orange); CD19Cre+/- MZ B cells (red); CD19Cre+/- Fo B cells (green); Notch2-deficient Fo B cells (blue). The 
percentages of variance explained by each of the depicted main principal components one to three are given.
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type and Notch2IC-expressing MZ B cells with 298 genes. The greatest difference could be observed 
when comparing two different cell-types with each other. Still, comparing Notch2IC-expressing B 
cells with Notch2-deficient cells yielded the strongest gene regulation with 3567 differentially regulated 
genes. To visualise and to get an overview of  the extracted lists of  differentially regulated genes, so 
called ��olcano plots were generated, in which the statistical significance (q-value) is plotted against 
the fold change. In contrast to multivariate PCA analyses, Volcano plots are univariate analyses based 
on the individual gene expression level. Hence, every single gene is depicted as spot, whereas in PCA 
analyses a spot represents the combinations of  all genes of  one B cell population. Labeled genes 
highlighted by filled, coloured circles within ��olcano plots represent the top 25 most significant and 
most strongly regulated genes of  the respective comparisons. As analyses before, they showed that 
comparisons of  different cell types (Fo Bs versus MZ Bs)  yielded more significantly regulated genes 
(Fig. 20A, B) than comparisons of  similar cell populations (Fig. 20C, D). Interestingly, among the top 
25 regulated genes between control and Notch2-deficient Fo B cell populations, a large proportion was 
only regulated two-fold or less (Fig. 20D), whereas in the other three comparisons more of  the top 25 
regulated genes were regulated more than two-fold (Fig. 20A, B, C). Furthermore, these plots revealed 
that more of  the most strongly regulated genes were upregulated in those cell populations that had 
presumably more Notch2 signalling in the respective comparisons, suggesting that Notch2 might be 
responsible for these upregulations. In detail, when comparing Notch2IC-expressing MZ B cells to 
other B cell populations with less Notch2 signalling, more of  the top regulated genes were upregulated 
in Notch2IC-expressing cells (Fig. 20A, C). A similar effect could be observed for wild type MZ B 
cells versus Fo B cells (Fig. 20B), with MZ B cells being the ones with more Notch2 signalling, and for 
the comparison of  Notch2-deficient B cells with wild type Fo B cells (Fig. 20D), in which wild type 
Fo B cells have more Notch2 signalling. These results demonstrate that a constitutive Notch2 signal 
or an ablation of  Notch2 signalling leads to additional gene regulations beyond those defining the 
cell-type identity, although these differences are smaller when comparing Fo B cell populations among 
each other. However, it still suggests that wild type Fo B cells get at least sporadic Notch2 signalling 
from time to time, possibly explaining some of  the differentially regulated genes between wild type 
and Notch2-deficient Fo B cells. 
To get a first notion in what range obtained fold regulations and statistical significances on our lists of  
regulated gene lists are and to have some reference values to be able to differentiate between “strong” 
and “weak” regulations, obtained gene lists were at first sorted by statistical significance and checked 
for candidate genes already well known to be up- or downregulated in MZ B cells or directly by Notch2 
Figure 19: Number of differentially regulated 
genes between the different B cell populations 
of the analysed mouse strains. VSN normalised 
Illumina BeadChip microarray data from sort-
purified Notch2-deficient Fo B and Notch2IC-
expressing MZ B cells as well as control MZ B 
and Fo B cells was filtered by variance (> 0.05). 
Subsequently, an ANOVA was conducted 
including the amplification round as co-variate 
(eliminated factor). The scheme depicts numbers 
of regulated genes with a q-value < 0.01.
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signalling. The most common and important ones, also known to be somehow implicated in MZ B cell 
development, localisation, and phenotype, were found among regulated genes (Tables 1 - 4). Members 
of  the hairy enhancer of  split (Hes) and hairy related genes (Hey) for example as well as deltex genes 
and the complement receptor type 2 (CR2, CD21) are known to be prominent direct Notch targets 
(Saito et al., 2003; Strobl et al., 2000). According to this, genes such as Hes1 and 5, Hey2 and 3 as well              
as Deltex1, 2 and 4 and CD21 were upregulated in MZ B cells populations and some even more when 
Figure 20: Volcano plots depicting differentially regulated genes between the different B cell populations 
of the analysed mouse strains. The y-axes represent significances as the negative log of the q-value; x-axes 
represent the difference between the compared VSN normalised samples (a difference of 1 represents a two-fold 
upregulation). Areas highlighted in light red depict genes exhibiting a two-fold regulation or less; areas highlighted 
in light yellow depict genes regulated more than two-fold; n (number of differentially regulated genes). Labeled 
genes highlighted by filled, coloured circles represent the top 25 significant, most strongly regulated genes of 
the respective comparisons; different coloures were chosen randomly simply for easier discrimination of the 
individual genes. (A) Differentially regulated genes between Notch2IC-expressing and Notch2-deficient B cells, (B) 
differentially regulated genes between wild type Fo B and MZ B cells, (C) differentially regulated genes between 
wild type and Notch2IC-expressing MZ B cells, (D) differentially regulated genes between wild type and Notch2-
deficient Fo B cells.
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Notch2IC was constitutively expressed, whereas a fraction of  them were further downregulated in 
the absence of  Notch2 signalling in Fo B cells. Typical MZ B cell surface markers such as CD9, CD1d 
and CD38 as well as the typical activation marker CD86 (Pillai et al., 2005; Vences-Catalan and Santos-        
Argumedo, 2011; Oliver et al., 1999a), which already showed upregulation in the wild type MZ B versus            
Fo B cell populations on our arrays had similar or even further enhanced levels in Notch2IC-expressing 
cells. CD23 on the other hand is highly expressed on Fo B cells and downregulated in MZ B cells (Pillai 
and Cariappa, 2009). Notch2IC expression even further decreased CD23 expression, whereas Notch2 
deficiency enhanced its expression. MZ B cells have been shown to express higher levels of  toll-like 
receptors on their surface (Gururajan et al., 2007; Martin and Kearney, 2002). This again matched           
with differences in expression in our gene expression profile analyses, as TLR7, TLR3 and TLR4 were 
upregulated in MZ B cells compared to Fo B cells and TLR3 also in Notch2IC-expressing cells versus 
wild type MZ B cells. The sphingosine-1-phosphate receptor 3 (S1PR3), the cannabinoid receptor 2 
(Cnr2, CB2), and ICAM1, which are implicated in the migration of  MZ B cells or retaining them within 
the MZ, were upregulated in MZ B versus Fo B cells and apart from ICAM1 further upregulated by 
Notch2IC expression. Genes which were already described to be Notch target genes or upregulated 
in MZ B cell populations such as Deltex1, Hes1, CD1d, CD21, CD27, CB2, CD38 and CD23 clearly 
displayed differences in their expression strength between control and Notch2-deficient Fo B cells, 
Tables 1-4: Fold changes of candidate genes from microarray analyses known to be up- or downregulated 
in MZ B cells or by Notch2 signalling.
Table 1 Table 2
N2IC MZ B cells vs. N2KO Fo B cells
Gene symbol Fold change
CD9 13.8
Deltex1 13.6
Hes5 5.3
CD1d 4.8
Hes1 4.8
CD27 4.2
TLR7 2.7
Hey3 2.5
CD21 2.5
PD-L1 2.5
TLR3 2.4
CD38 2.3
S1PR3 2.2
Notch1 2.1
CB2 2.0
CXCR7 1.8
CD86 1.5
Icam-1 1.5
Notch2 1.5
Deltex4 1.4
Hey2 1.3
CD23 -25.8
CD19 MZ B cells vs. CD19 Fo B cells
Gene symbol Fold change
CD9 5.3
Deltex1 5.0
CD1d 4.5
Hes1 3.1
CXCR7 2.8
TLR7 2.7
CD21 2.4
PD-L1 2.2
CD86 2.0
S1PR3 1.6
CD27 1.4
Deltex4 1.4
CD38 1.3
TLR3 1.3
Icam-1 1.3
CB2 1.2
Hey2 1.1
Hes5 1.2
CD23 -7.3
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indicating that there may at least be some Notch2 signalling left in wild type Fo B cells. 
The Annotation Cluster Tool of  the bioinformatics Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) was used to identify enriched biological terms, functionally related 
groups, or other clusters among the lists of  differentially regulated genes. For this type of  analysis, 
gene lists were sorted by q-values and as the DAVID software is limited in the number of  genes it can 
analyse at a time, only genes with a q-value below a certain threshold were analysed. For comparisons 
of  wild type Fo B versus MZ B cells and Notch2IC-expressing B cells with Notch2-deficient B cells 
only genes with a q-value < 0.0149 were chosen. For the comparison of  wild type Fo B with Notch2-
deficient Fo B cells and wild type MZ B versus Notch2IC-expressing MZ B cells genes with a q-value 
< 0.0549 were analysed. Hence, the following remaining gene numbers were sub�ected to analyses with 
the DA��ID software: 3471 genes for wild type Fo B versus MZ B cells, 4099 for Notch2-deficient 
versus Notch2IC-expressing B cells, 1262 for wild type MZ B versus Notch2IC-expressing MZ B 
cells and 385 genes for the comparison of  the two Fo B cell populations. The top most significant 
and relevant annotation clusters found for the four comparisons are summarised in the tables S5 
- S8 (appendix). In addition, for comparisons between wild type MZ B with Fo B cells as well as 
with Notch2IC-expressing MZ B cells additional annotation cluster analyses were performed using 
only the subsets of  genes upregulated in MZ B versus Fo B cells or in Notch2IC-expressing versus 
wild type MZ B cells respectively, to be able to discriminate enriched terms based on an induction 
Table 3
CD19 Fo B cells vs. N2KO Fo B cells
Gene symbol Fold change
Deltex1 2.1
Hes1 1.6
CD21 1.5
Notch1 1.3
CD27 1.2
CB2 1.2
Icam-1 1.2
ADAM17 1.2
CD1d 1.2
CD38 1.2
Deltex2 1.2
TLR7 1.2
S1PR3 -1.1
CXCR7 -1.1
TLR3 -1.1
TLR4 -1.3
CD23 -1.4 
N2IC MZ B cells vs. CD19 MZ B cells
Gene symbol Fold change
Hes5 5.3
CD9 3.4
CD27 2.9
Hey3 2.6
TLR3 2.1
CD38 1.8
Notch1 1.7
Deltex1 1.7
S1PR3 1.6
CB2 1.4
Notch2 1.4
PD-L1 1.3
Hes1 1.2
Hey2 1.2
CD1d 1.1
CD21 -1.2
CXCR7 -1.3
CD23 -3.6
Table 4
Final lists of differentially regulated genes obtained by comparing Notch2IC-expressing (N2IC) and Notch2-de-
ficient (N2KO) B cells among each other and with their respective wild type counterparts (CD19) were sorted 
by significance and checked for candidate genes known to be up- or downregulated in MZ B cells or by Notch2 
signalling. Genes with a positive fold change value are upregulated in the respective population named first. TLR 
(toll-like receptor), S1PR3 (sphingosine-1-phosphate receptor 3), CB2 (cannabinoid receptor 2).
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of  Notch2 signalling (Tables S9, S10; appendix). Some of  these enriched biological terms found 
by annotation clustering were in accordance with data obtained from experiments described in the 
following chapters and in addition further strengthened them and will therefore be discussed in the 
respective context.
3.2 The impact of  Notch2 signalling and the influence of  the 
marginal zone environment on the MZ B cell phenotype
3.2.1 Notch2IC-expressing cells are able to maintain their MZ B cell phenotype 
in vitro
Our previous investigations revealed that Notch2IC-expressing MZ B cells share a lot of  similarities 
with wild type MZ B cells. Especially typical MZ B cell surface markers were upregulated in wild type 
and Notch2IC-expressing MZ B cells versus Fo B cells. As in contrast to wild type MZ B cells, Notch2 
signalling is continuously active in Notch2IC-expressing MZ B cells even in the absence of  specific 
ligands, we wanted to investigate whether Notch2IC expression is sufficient to maintain a MZ B cell 
phenotype when cells are taken out of  their MZ environment, which normaly provides the Notch2 
ligand (Tan et al., 2009). To this end, splenic B cells from control and Notch2IC//CD19Cre             +/- mice 
were isolated and cultured for up to two days without stimulation (Fig. 21). The expression of  typical 
Figure 21: In vitro cultured Notch2IC//CD19Cre+/- B cells maintain their MZ B cell phenotype. Splenic B cells 
were isolated from Notch2IC//CD19Cre+/- and CD19Cre+/- mice and cultured for up to two days without stimulation. 
Expression of CD21, CD23, CD38, CD1d and S1PR1 was analysed by flow cytometry ex vivo and after one or two 
days of in vitro culture. Exemplary dot plots and histograms of control B cells are gated on lymphocytes (ex vivo) or 
living cells (in vitro) positive for B220. Exemplary dot plots and histograms of Notch2IC-expressing B cells are gated 
on lymphocytes (ex vivo) or living cells (in vitro) positive for hCD2. Histograms depict overlays of the abundance of 
indicated molecules in control B cells (blue and green lines) and Notch2IC-expressing B cells (red and orange lines). 
Numbers indicate percentages of CD21high MZ B cells. Data is representative of two independent experiments. 
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MZ B cell surface markers such as CD21, CD23, CD1d, CD38 and S1PR1 were analysed daily. Ex 
vivo isolated Notch2IC-expressing B cells exhibited the already described expansion of  the CD21high 
CD23low MZ B cell population at the expense of  Fo B cells. Furthermore, Notch2IC-expressing cells 
displayed higher CD38, CD1d and S1PR1 levels than control B cells. On day one and two in vitro, 
in control B cells no CD21high MZ B cells could be detected anymore, whereas Notch2IC-expressing 
cells were always able to maintain higher CD21 levels than control B cells. In addition, CD38, CD1d 
and S1PR1 levels stayed increased compared to control B cells. These results suggest indeed that 
constitutive Notch2 signalling is sufficient to sustain the MZ B cell phenotype outside of  the MZ, 
however, further experiments need to be performed to affirm that other relevant MZ B cell markers 
and thus a “complete” MZ B cell phenotype can really be maintained.
3.2.2 Enhanced proliferation of  Notch2IC-expressing B cells in response to 
α-CD40 or LPS stimulation can mainly be ascribed to their MZ B cell 
phenotype
First experiments performed by F. Hampel, a former laboratory member, showed that splenic B 
cells from Notch2IC//CD19Cre+/- mice displayed highly enhanced proliferative behaviour compared 
to B cells from control mice when treated with LPS or α-CD40 in in vitro cultures. As it is known 
that specifically MZ B cell populations exhibit increased proliferation in response to LPS or α-CD40 
stimulation (Gunn and Brewer, 2006; Thomas et al., 2007; Oliver et al., 1999b), these findings further 
affirmed the MZ B cell phenotype of  Notch2IC-expressing B cells. Yet, as splenic B cells from 
Notch2IC//CD19Cre+/- mice comprise ~80 % MZ B cells compared to ~5 % in B cell populations 
of  control mice, the question remained if  the enhanced proliferative behaviour of  Notch2IC-
expressing B cells can only be attributed to their MZ B cell phenotype or if  constitutive Notch2 
signalling is additionally intensifying the proliferation rate especially after stimulation. This question 
was particularly interesting as the search for enriched biological terms among our Illumina BeadChip 
microarray data comparing Notch2IC-expressing with wild type MZ B cells, using the �Annotation 
Cluster Tool’, already pointed out that constitutive Notch2IC expression might additionally increase 
cell division rates in MZ B cell populations (Table S7, S10). To finally clarify this question, proliferation 
rates of  sort-purified wild type MZ B cells were compared to those of  MZ B cells from Notch2IC//
CD19Cre+/- mice. Wild type MZ B cells and Notch2IC-expressing MZ B cells were recovered with 
a purity of  ~97 % respectively. Sort-purified MZ B cells were labelled with carboxyfluorescein 
succinimidyl ester (CFSE) and cultured for three days without any stimuli or with LPS, α-CD40 or α-
CD40+IL-4. CFSE is a green fluorescent dye, which binds inner cell membrane proteins and hence is 
incorporated into the cell. Due to its progressive decrease within daughter cells after each cell division, 
proliferation can easily be monitored. On the basis of  the resting peak on day three (the population 
of  undivided B cells, thus exhibiting highest CFSE intensity) the percents of  divided cells (% divided) 
as well as the proliferation index (number of  divisions of  cells that underwent at least one division) 
and division index (average number of  cell divisions in total, including cells that never divided) were 
determined. These analyses, now comparing only MZ B cell populations with each other, revealed that 
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the enhanced proliferation rate of  Notch2IC-expressing cells seen in former experiments can mainly 
be ascribed to their MZ B cell phenotype. Still, Notch2IC-expressing cells showed slightly better 
proliferation rates after α-CD40 stimulation (Fig. 22). 
3.2.3 Notch2IC-expressing B cells exhibit enhanced Erk, Jnk and PI3 kinase 
signalling even in the absence of  a CD19 receptor
It is widely accepted that MZ B cells have a pre-activated phenotype in comparison to Fo B cells (Gunn 
and Brewer, 2006; Oliver et al., 1999b). In accordance, we could show that Notch2IC-expressing cells 
resemble wild type MZ B cells regarding this pre-activation, as Notch2IC-expressing MZ B cells had 
increased CD80, CD86, CD25 and ICAM1 levels compared to wild type splenic B cells (mainly Fo 
B cells) (Hampel et al., 2011). As already briefly described before (3.1.3), our microarray experiments             
also revealed that expression levels of  CD80, CD86 and ICAM1 were increased in wild type and 
Notch2IC-expressing MZ B versus Fo B cells. Beyond that, Annotation Cluster Analyses performed 
on our microarray data with genes differentially upregulated in wild type MZ B versus Fo B cells and in 
Notch2IC-expressing B cells versus wild type MZ B cells revealed enriched terms such as “regulation 
of  B cell/lymphocyte activation” and “positive regulation of  B cell/lymphocyte activation”, possibly 
also indicating that Notch2IC is additionally enhancing the natural pre-activated state of  MZ B cells. 
Apart from that enriched terms such as “protein serine/threonine kinase activity” and “positive 
regulation of  MAPKKK cascade” could also be found. Consequently, we were interested in which 
signalling pathways would possibly be involved in the activated MZ B cell phenotype. Up to now 
Figure 22: Notch2IC-expressing B cells are hyper-responsive to LPS and α-CD40 stimulation in vitro mainly 
due to their MZ B cell phenotype. (A) Splenic B cells of control and Notch2IC//CD19Cre+/- mice were enriched 
by depletion of CD43+ non-B cells. They were subsequently labeled with CFSE and cultured with the indicated 
stimuli (LPS concentration: 50 µg/ml, α-CD40 concentration: 2.5 µg/ml). After three days, proliferation profiles of 
propidium iodide-negative cells were assessed by flow cytometric analysis and are displayed in the histogram 
overlays as grey (control B cells) and white (Notch2IC-expressing B cells) graphs. Data is representative of four 
independent experiments. (B) Splenic MZ B cells of control and Notch2IC//CD19Cre+/- mice were enriched by 
depletion of CD23+ and/or CD43+ cells and further sort-purified for B220+, CD21high, CD23low cells and in the case 
of Notch2IC-expressing cells additionally for hCD2+ cells. To be able to gain enough MZ B cells for an in vitro 
culture after FACS sorting, splenic cell populations from 12 CD19Cre+/- mice and 3 Notch2IC//CD19Cre+/- mice were 
pooled. Sorted MZ B cells were labeled with CFSE and cultured with the indicated stimuli (LPS concentration: 
50 µg/ml, α-CD40 concentration: 2.5 µg/ml, IL-4 concentration: 10 ng/ml). After 2.5 days, proliferation profiles of 
propidium iodide-negative cells were assessed by flow cytometric analysis and are displayed in the histogram 
overlays as grey (control MZ B cells) and white (Notch2IC-expressing MZ B cells) graphs. Data is representative of 
three independent experiments. Proliferation index: average number of divisions of cells that underwent at least 
one division; % divided: percentage of cells that initially start to divide, also called precursor frequency; division 
index: average number of cell divisions in total. 
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it was not really possible to analyse the activity of  signalling pathways in MZ B cells in detail, since 
only low amounts of  this cell population can be isolated by sort-purification from wild type splenic 
cell suspensions. Notch2IC//CD19Cre+/- mice allowed us to perform Western blot analyses, as huge 
amounts of  Notch2IC-expressing B cells closely resembling wild type MZ B cells with respect to 
the pre-activated state could be isolated. F. Hampel previously showed and I could confirm that 
Notch2IC-expressing B cells exhibited enhanced phosphorylation of  the MAP kinases Erk and Jnk 
as well as of  the Akt kinase (Fig. 23 and Hampel et al., 2011). F. Hampel could also demonstrate that          
constitutive Notch2 signalling is able to rescue MZ B cell development in Notch2IC//CD19Cre+/+ 
mice, which lack the CD19 receptor. Respective B cells also kept their enhanced phosphorylation of  
the MAP kinases Erk and Jnk (Hampel et al., 2011). This was unexpected since CD19 has been shown            
to be essential for MZ B cell development as CD19-deficient mice are devoid of  this cell population 
(Pezzutto et al., 1987; Rickert et al., 1995; Engel et al., 1995). The CD19 receptor is quite important      
regarding the induction of  PI3K/Akt signalling (Otero et al., 2001). Therefore, we wondered if this         
specific pathway is still active even in the absence of  CD19. Beyond this we were further interested in 
investigating whether other members of  the PI3K pathway would be affected in Notch2IC//CD19Cre 
animals, apart from Akt. Figure 24 shows a simplified scheme of  the PI3K pathway containing analysed 
members. In brief, BCR cross-linking leads to a rapid phosphorylation of  the CD19 co-receptor, 
Figure 23: Notch2IC-expressing B cells exhibit 
increased levels of pErk, pJnk and pAkt. Splenic 
B cells were purified from Notch2IC//CD19Cre+/- and 
control mice. Whole-cell extracts were subjected 
to immunoblot analyses using antibodies specific 
for pAkt (pS473), pJnk, pErk and the corresponding 
non-phosphorylated forms. Equal protein loading 
was controlled by an α-tubulin and α-GAPDH 
staining. Results are representative of three 
independent experiments, further confirming 
experiments and results performed and obtained 
by F. Hampel.
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Figure 24: Simplified scheme of the PI3 kinase 
pathway including members analysed by 
Western blot. The CD19 receptor is rapidly 
phosphorylated upon BCR engagement, leading to 
the recruitment and binding of the PI3 kinase. PIP2 
is now converted to PIP3 thereby activating Akt and 
hence mTOR and the S6 kinase (p70). GSK-3 and 
FoxO1 are phosphorylated and thereby inhibited 
by Akt signalling. Tcl1B functions as an Akt co-
activator. PTEN is a 3’-phosphoinosite phosphatase 
and inhibits the PI3K/Akt signalling pathway by 
converting PIP3 back to PIP2.
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which in turn recruits the PI3 kinase, which can now convert phosphatidylinositol-4,5 bisphosphate 
(PIP2) to phosphatidylinositol-3,4,5 trisphosphate (PIP3) (Otero et al., 2001). Subsequently, the serine/      
threonine kinase Akt is recruited to the plasma membrane and phosphorylated at position serine 473 
(S473) and threonine 308 (T308), leading to the activation of  mTOR and the S6 kinase (S6K/p70). 
Moreover, Akt phosphorylates and thereby inhibits the glykogen synthase kinase 3 (GSK-3) and the 
forkhead box protein O1 (FoxO1) (Porta et al., 2014). Phosphorylated FoxO1 is translocated from the 
nucleus to the cytoplasm, where it is degraded (Tzivion et al., 2011). The T-cell leukemia/lymphoma       
protein 1B (Tcl1B) functions as an Akt co-activator (Laine et al., 2000; Auguin et al., 2004). PTEN is          
a 3’-phosphoinosite phosphatase and inhibits the PI3K/Akt signalling pathway by converting PIP3 
back to PIP2 (Porta et al., 2014).
Expression levels of  pAkt, Akt, pp70, p70, pGSK-3, GSK-3, FoxO1, PTEN and Tcl1B1/5 were 
examined by Western blot analyses. An α-tubulin staining was used as a control for equal protein 
loading. B cells from Notch2IC//CD19Cre+/- as well as from Notch2IC//CD19Cre+/+ (CD19-
deficient) mice exhibited increased levels of  pAkt, pp70, Tcl1B1/5 as well as pGSK-3 (Fig. 25), 
indicating that Notch2IC-expressing cells indeed have an increased activity of  the PI3K/Akt signalling 
pathway regardless of  their CD19 deficiency. As basal levels of  Akt and p70 were also already quite 
strongly induced in Notch2IC-expressing cells, we wanted to check whether increased expression 
levels of  the phosphorylated, active forms of  the two proteins were only based on the elevated basal 
levels. For this, pAkt, Akt, pp70 and p70 levels were quantified using densitometry. Respective GSK-
3 expression levels were used as reference as these exhibited the lowest variations among samples. 
Quantifications suggest that although basal Akt and p70 levels were already elevated due to Notch2IC 
expression the increase in expression levels of  the phosphorylated forms was even greater (Fig. 
26). Expression of  PTEN, which is known to negatively regulate PI3K signalling by reversing the 
Figure 25: Notch2IC-expressing B cells exhibit increased PI3K signalling in comparison to control B cells. 
Splenic B cells were purified from Notch2IC//CD19Cre+/-, Notch2IC//CD19Cre+/+ and corresponding control mice. 
Whole-cell extracts were subjected to immunoblot analyses using antibodies specific for pAkt (pS473), pp70/pS6K, 
pGSK-3, FoxO1, PTEN as well as Tcl1B1/5 and the corresponding non-phosphorylated forms. Equal protein loading 
was controlled by an α-tubulin staining. The results are representative of three to five independent experiments 
for Notch2IC//CD19Cre+/+ and CD19Cre+/+ animals and 7-13 for Notch2IC//CD19Cre+/- and CD19Cre+/- animals. 
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phosphorylation of  PIP3 to PIP2 and thereby antagonising further downstream signalling (Iwanami et 
al., 2009) was also increased in Notch2IC-expressing cells (Fig. 25). �et, these enhanced PTEN levels 
were in accordance with increased PI3K/Akt signalling, as activation of  this pathway also entails that 
more PIP3 is available and probably needs to be converted back into PIP2, representing a mechanism 
continuously counterregulating increased PI3K/Akt signalling. In addition, CD19-deficient B cells 
displayed reduced PTEN and increased FoxO1 levels compared to CD19Cre+/- control B cells, 
affirming the important role of  CD19 regarding the induction of  PI3K signalling. Still, Notch2IC-
expressing B cells exhibited increased PTEN and decreased FoxO1 expression than their respective 
controls (CD19Cre+/- or CD19Cre+/+). This shows that constitutive Notch2 signalling can at least 
partially rescue CD19 defects regarding the PI3K pathway. 
Although immunoblot experiments demonstrated that in Notch2IC-expressing MZ B cells the 
MAP kinases pErk and pJnk as well as the PI3K/Akt signalling were strongly induced, the question 
remained whether this increase is an intrinsic phenotype of  MZ B cells or if  it is specifically triggered 
by the expression of  the Notch2IC transgene. To this end, intracellular flow cytometrical analyses 
were performed, allowing to compare the amounts of  pErk, pJnk and pAkt in wild type MZ B with 
those in Notch2IC-expressing MZ B cells and in addition to differentiate between expression levels in 
MZ B and Fo B cells. CD21high control MZ B cells displayed clearly elevated pErk, pJnk as well as pAkt 
levels in contrast to CD21low Fo B cells (Fig. 27, left panels). In accordance with previous Western blot 
experiments, Notch2IC-expressing B cells had higher expression levels than control B cells (Fig. 27, 
center panels). �et, histogram overlays exhibited that Notch2IC-expressing MZ B cell populations had 
Figure 26: Western blot quantifications revealed increased basal and phosphorylated levels of Akt and p70 
in Notch2IC-expressing B cells. Splenic B cells were purified from Notch2IC//CD19Cre+/-, Notch2IC//CD19Cre+/+ 
and corresponding control mice. Whole-cell extracts were subjected to immunoblot analyses using antibodies 
specific for pAkt (pS473), pp70/pS6K and the respective non-phosphorylated forms. Expression levels were 
quantified by densitometry measurement of Western blot films. The results are representative of three to five 
independent experiments for Notch2IC//CD19Cre+/+ and CD19Cre+/+ animals and 7-13 for Notch2IC//CD19Cre+/- 
and CD19Cre+/- animals
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similar levels than control MZ B cells (Fig. 27, right panels), thereby implicating that higher pErk, pJnk 
and pAkt levels are mainly induced by the MZ B cell phenotype or the localisation of  MZ B cells in 
the MZ and not by Notch2IC expression.
3.2.4 Notch2IC expression is not sufficient to sustain enhanced Erk, Jnk and 
Akt signalling outside the marginal zone environment
As shown in the chapter before, wild type as well as Notch2IC-expressing MZ B cells exhibit similarly 
increased pErk, pJnk and pAkt expression levels suggesting that the increased activity of  these 
signalling pathways is rather mediated by the MZ environment than by Notch2IC expression itself. 
Therefore we assumed that constitutive Notch2 signalling is not sufficient to maintain enhanced MAP 
kinase and PI3K/Akt signalling outside this natural environment. To test this hypothesis, B cells were 
isolated from spleens of  CD19Cre+/- as well as Notch2IC//CD19Cre+/- mice and taken into in vitro 
culture without stimulation. After day one and two, protein expression levels of  pErk, pJnk, pAkt 
and the corresponding non-phosphorylated forms were analysed by subjecting whole-cell extracts 
of  these cultured cells to Western blot analyses. As results were similar for day one and two, only day 
Figure 27: Notch2IC-expressing and control MZ B cells have higher pErk, pJnk and pAkt levels than Fo B cells. 
Splenic B cells were isolated from Notch2IC//CD19Cre+/- and CD19Cre+/- mice, stained for surface markers, fixed, 
permeabilised and subsequently stained and analysed for the indicated phosphorylated signalling molecules 
by intracellular flow cytometry. Histograms are lymphocyte-gated and depict overlays of the abundance of the 
indicated molecules. Histograms on the left depict control lymphocytes gated on B220+, CD21high MZ B cells (black 
line) and CD21low Fo B cells (dark gray line), histograms in the center show B220+ hCD2+ Notch2IC-expressing 
(black line) versus B220+ control cells (light gray line) and histograms on the right display B220+ hCD2+ CD21high 
Notch2IC-expressing (black line) and B220+ CD21high control MZ B cells (light gray line). Data is representative of 
four independent experiments.
pErk
pJnk
CD19Cre+/-
B cells
pAkt
FoBs
CD21low
MZBs
CD21high
FoBs
CD21low
MZBs
CD21high
FoBs
CD21low
MZBs
CD21high
B cells
C
ou
nt
s
C
ou
nt
s
C
ou
nt
s
MZ B cells
CD19Cre
Notch2IC
CD19Cre
Notch2IC
CD19Cre
Notch2IC
CD19Cre
Notch2IC
Notch2IC
CD19Cre
Notch2IC
CD19Cre
Results
37
one is depicted here. After in vitro culture, protein levels of  pErk, pJnk and pAkt were decreased in 
Notch2IC-expressing B cells in comparison to ex vivo isolated B cells (Fig. 28 and data not shown). 
Phosphorylations of  Erk and Jnk2 were completely abrogated, whereas pAkt and pJnk1 levels were 
partially maintained. Control B cells also showed reductions in pErk, pJnk and pAkt levels, however 
tubulin and GAPDH levels were also drastically reduced, possibly implicating that more of  the 
unstimulated control B cells died, hence making it difficult to �udge if  the downregulation in control B 
cells was specific. Since constitutive Notch2 signalling was not able to maintain increased Erk and Jnk2 
phosphorylation after ex vivo isolation, it is likely 
that these signalling pathways are rather activated by 
the MZ environment than by Notch2 signalling. In 
contrast, Notch2 might at least partially contribute 
to the phosphorylation of  Akt since in contrast to 
control B cells this phosphorylation was maintained 
to some extent. In summary, these results suggest 
that enhanced Erk and Jnk2 phosphorylation 
detectable in Notch2IC-expressing MZ B cells is 
to a great part induced by the localisation within 
the MZ, while the expression of  typical MZ B cell 
surface markers seems to be directly regulated by 
Notch2 signalling as they are sustained outside of  
this environment. 
As shown in 3.2.2, α-CD40 and LPS are potent 
inducers of  MZ B cell activation and proliferation 
and Notch2IC-expressing cells exhibit a similar 
or even slightly enhanced proliferation compared 
to wild type MZ B cells in the presence of  these 
stimuli. Hence, we wanted to compare MAP kinase 
and PI3K signalling of  control and Notch2IC-
expressing B cells under these stimulatory 
conditions in vitro. B cells were isolated from 
spleens of  CD19Cre+/- and Notch2IC//
CD19Cre+/- mice and taken into in vitro culture 
with or without α-CD40 or LPS. After one and 
two days, protein expression levels of  pErk, pJnk, 
pAkt and the corresponding non-phosphorylated 
forms were analysed by subjecting whole-cell 
extracts of  these cultured cells to Western blot 
analyses (Fig. 29). In control B cells, both, LPS 
and α-CD40 stimulation enhanced Erk and Akt 
phosphorylation. Yet, α-CD40 treatment resulted 
Figure 28: Notch2IC expression is not sufficient to 
maintain enhanced pErk, pJnk or pAkt levels in 
vitro. Splenic B cells were purified from Notch2IC//
CD19Cre+/- and CD19Cre+/- control mice and directly 
analysed ex vivo and in addition cultured for up to 
two days without any stimuli. Subsequently, whole-
cell extracts were subjected to Western blot analyses 
using antibodies specific for pAkt (pS473), pErk, pJnk 
and the corresponding non-phosphorylated forms. 
Equal protein loading was controlled by an α-tubulin 
and α-GAPDH staining. The results are representative 
of two independent experiments for B cells cultured for 
two days and one experiment for B cells cultured only 
one day. The depicted Western blot was performed 
with one set of animals. 
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in a faster upregulation, as pAkt and pErk levels were already drastically increased after one day, 
while in LPS-treated cells expression was highest on day two. α-CD40 was also able to enhance pJnk 
expression peaking at day one, however after LPS treatment pJnk was slightly reduced compared to 
ex vivo levels. In contrast to control B cells, Erk signalling in Notch2IC-expressing B cells dropped 
despite α-CD40 or LPS stimulation. However, a slight rescue seems to be detectable on day two of  
in vitro culture. Similar to control cells, pJnk and pAkt levels of  Notch2IC-expressing cells were 
increased by α-CD40 stimulation, while LPS treatment led to a reduction of  pJnk and no change in 
pAkt. However, compared to ex vivo levels, α-CD40-induced increases in Erk and Akt signalling were 
more pronounced in control B cells than in Notch2IC-expressing cells. These findings indicate that 
control B cells respond better to LPS and a-CD40 stimulation than Notch2IC-expressing B cells most 
likely due to the pre-activated state of  the latter cell population.
Figure 29: Control B cells exhibit greater activation in response to LPS and α-CD40 stimulation than 
Notch2IC-expressing B cells. Splenic B cells were purified from Notch2IC//CD19Cre+/- and CD19Cre+/- control 
mice and directly analysed ex vivo and in addition cultured for up to two days with α-CD40 or LPS stimulation. 
Subsequently, whole-cell extracts were subjected to Western blot analyses using antibodies specific for pAkt 
(pS473), pErk, pJnk and the corresponding non-phosphorylated forms. Equal protein loading was controlled by α-
tubulin and α-GAPDH staining. The results are representative of two independent experiments for B cells cultured 
for two days and one experiment for B cells cultured only one day. The Western blot on the left, depicting results 
from the time points “ex vivo” and “in vitro day 1”, was performed with one set of animals. The Western blot on the 
right was performed with another independent set of mice.
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3.2.5 Notch2IC-expressing B cells spontaneously differentiate into CD138+ 
B220low plasmablasts or plasma cells in vitro
The experiments and results described in the chapters before clearly showed that Notch2IC-
expressing B cells exhibit an activated phenotype in vivo, including increased proliferation potential 
and enhanced activity of  the Erk, Jnk as well as the PI3K/Akt signalling pathways. Due to their pre-
activated phenotype, MZ B cells are known to be able to rapidly differentiate into CD138+ B220low 
antibody-secreting plasma cells (Zandvoort and Timens, 2002). To investigate whether the increased         
frequency of  MZ B cells in Notch2IC-expressing mice could lead to the (spontaneous) appearance of  
an increased frequency of  plasmablasts or plasma cells, splenic B cells were isolated from Notch2IC//
CD19Cre+/- and CD19Cre+/- control mice and analysed by flow cytometry. As plasma cells exhibit 
high CD138 and low B220 levels, B cells were stained with a mixture of  CD138, B220 and hCD2 
antibodies. Percentages of  plasma cells were low in both control and Notch2IC-expressing B cell 
populations (Fig. 30), suggesting that constitutive Notch2IC expression does not drive spontaneous 
plasma cell differentiation in vivo, although Notch2IC/CD19Cre+/- mice have a strongly increased 
proportion of  pre-activated MZ B cells. Next we wanted to know if  plasma cell development was 
inducible and subsequently possibly enhanced in in vitro cultures of  Notch2IC-expressing MZ B cells 
in comparison to control B cells, when triggered with the right stimuli. As LPS is known to be a potent 
inducer of  plasma cell differentiation in wild type B cells, Notch2IC-expressing and control B cells were 
isolated from spleens and cultured for up to three days with or without LPS stimulation. Development 
of  plasmablasts or plasma cells was checked daily by staining B cells with a mixture of  CD138, B220, 
hCD2 antibodies and a marker for dead cells and subsequently analysing them by flow cytometry 
(Fig. 31). As expected, during these three days of  in vitro culture unstimulated control B cells showed 
no signs of  plasma cell development, whereas in LPS-stimulated control B cells, CD138+ B220low 
plasma cells were clearly distinguishable on day two and three. In great contrast to this, in cultures of  
Notch2IC-expressing B cells this CD138+ B220low population already appeared spontaneously at day 
one without adding any stimuli and strongly augmented on day two. LPS stimulation did not further 
increase proportions of  CD138+ B220low cells, but rather seemed to slightly hamper spontaneous 
Figure 30: No increased plasma cell population in unimmunised Notch2IC//CD19Cre+/- compared to 
CD19Cre+/- control mice. Splenic B cells were isolated from Notch2IC//CD19Cre+/- and CD19Cre+/- mice and 
analysed for their CD138 and B220 expression by flow cytometry. Exemplary dot plots are gated on living cells 
(left and center panel) and in the case of Notch2IC-expressing cells additionally also on hCD2+ populations (right 
panel). Data is representative of five independent experiments.
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plasmablast/plasma cell formation, as on day two and three percentages of  CD138+ B220low cells were 
slightly lower after LPS stimulation than in unstimulated Notch2IC-expressing cells. Still, we noticed 
that on day one, frequencies of  CD138+ B220low cells in LPS-treated Notch2IC-expressing cells were 
higher than those in unstimulated cells. Nevertheless, highest percentages of  CD138+ B220low cells 
obtained in cultures of  unstimulated or LPS-stimulated Notch2IC-expressing B cells were always 
higher than the highest amounts of  CD138+ B220low cells obtained in LPS-treated control B cells. 
Additional gating on hCD2+ cells revealed that only cells expressing the Notch2IC transgene exhibited 
this differentiation potential, which was the case for all the results described in this chapter (Fig. 32). 
B cells that did not express hCD2 behaved like control B cells except that even after LPS stimulation 
no plasma cell development could be detected (Fig. 32). 
α-CD40 stimulation is known to enhance proliferation and survival of  in vitro cultured wild type B 
cells and to induce IgG switching. Beyond this, CD40 ligation on B cells has been shown to inhibit 
plasma cell differentiation (Satpathy et al., 2010; Randall et al., 1998). Therefore, we were interested            
in what effect α-CD40 stimulation would have on in vitro cultured Notch2IC-expressing B cells 
and whether it would be able to inhibit spontaneous plasma cell development. Experiments were 
Figure 31: In vitro cultured Notch2IC//CD19Cre+/- B cells spontaneously differentiate into CD138+ B220low 
plasmablasts/plasma cells. Splenic B cells were isolated from Notch2IC//CD19Cre+/- and CD19Cre+/- mice, 
cultured for up to three days with or without LPS stimulation and analysed for CD138 and B220 expression by flow 
cytometry. Dot plots are gated on living cells. Numbers indicate mean percentages and SD of CD138+ B220low cell 
populations. Calculations are based on three to five independent experiments for CD19Cre+/- mice and four to ten 
independent experiments for Notch2IC//CD19Cre+/- animals. 
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performed as previously described, except that B cells were now cultured in the presence of  α-CD40 
or α-CD40+LPS stimuli (Fig. 33). Indeed, stimulation with α-CD40 strongly diminished spontaneous 
plasmablast/plasma cell differentiation of  Notch2IC-expressing B cells in the absence of  LPS or 
even completely abolished the formation of  a CD138+ B220low population in LPS-treated control 
as well as in Notch2IC-expressing cells. �et, percentages of  CD138+ B220low cells were still higher 
in α-CD40-treated Notch2IC-expressing than in α-CD40 or α-CD40+LPS-treated control B cells, 
again peaking at day two of  in vitro culture. On day three of  α-CD40+LPS treatment almost all 
Notch2IC-expressing B cells were dead, possibly due to overstimulation of  already pre-activated MZ 
B cells. These experiments suggest that Notch2IC-expressing B cells still have an intrinsic potential to 
spontaneously differentiate into plasmablasts/plasma cells, which is somehow inhibited in vivo and 
can also be hampered by α-CD40 stimulation. 
Figure 32: Only Notch2IC-expressing B cells spontaneously differentiate into CD138+ B220low plasmablasts/
plasma cells in vitro. Splenic B cells were isolated from Notch2IC//CD19Cre+/- mice, cultured for up to three days 
with or without LPS stimulation and analysed for CD138 and B220 expression by flow cytometry. Exemplary dot 
plots are gated on living cells, positive or negative for hCD2. Numbers indicate percentages of CD138+ B220low cell 
populations. Data is representative of four to ten independent experiments.
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3.2.6 Spontaneous plasmablast/plasma cell development of  Notch2IC-
expressing B cells in vitro is driven by Notch2IC expression
To investigate whether the spontaneous differentiation of  Notch2IC-expressing B cells to plasmablasts 
or plasma cells in vitro was an intrinsic effect of  MZ B cells or induced by constitutive Notch2 
expression, we compared sort-purified wild type MZ B and Fo B cells with Notch2IC-expressing 
MZ B cells. To this end, splenic B cell populations were sorted according to their CD21 and CD23 
expression, with MZ B cells being CD21high CD23low and Notch2IC-expressing cells additionally hCD2+ 
and Fo B cells being CD21low CD23high. Subsequently, sort-purified cell populations were cultured 
for two days with or without LPS. Plasmablast/plasma cell differentiation was checked by a hCD2, 
CD138, B220 staining. Wild type Fo B cells did not show any signs of  plasma cell differentiation 
neither with LPS nor without stimulation (Fig. 34, left panel). An expected amount of  MZ B cells from 
control mice developed to CD138+ B220low cells, yet only after LPS stimulation (Fig. 34, central panel), 
whereas Notch2IC-expressing B cells displayed plasmablast/plasma cell formation with and without 
LPS stimulation (Fig. 34, right panel). In contrast to experiments performed with total, splenic B 
cells (see previous chapter), LPS-stimulated, sort-purified Notch2IC-expressing MZ B cells exhibited 
increased frequencies of  CD138+ B220low cells compared to unstimulated Notch2IC-expressing cells. 
A possible explanation for this difference could be that LPS accelerates plasma cell differentiation. 
Thus, the optimal time points exhibiting maximal plasmablast/plasma cell frequencies in LPS-treated 
Notch2IC-expressing B cells might have been missed in previous experiments with unsorted B cells. 
In experiments with sort-purified cells, peaks of  plasmablast/plasma cell differentiation are possibly 
Figure 33: Spontaneous differentiation of Notch2IC-expressing cells into CD138+ B220low cells in vitro can 
be hampered by α-CD40 stimulation. Splenic B cells were isolated from Notch2IC//CD19Cre+/- and CD19Cre+/- 
mice, cultured for up to three days with or without α-CD40 or α-CD40+LPS stimulation and analysed for CD138 
and B220 expression by flow cytometry. Dot plots are gated on living cells. Numbers indicate mean percentages 
and SD of CD138+ B220low cell populations. Calculations are based on two to five independent experiments for 
CD19Cre+/- mice and two to ten independent experiments for Notch2IC//CD19Cre+/- animals.
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shifted to a later time point, as cells need a certain time to recover from the sort procedure, before 
starting to proliferate or differentiate. Still, these results suggest that constitutive Notch2 signalling 
further enhances spontaneous plasma cell formation in MZ B cells as soon as cells are taken out of  
their natural environment.
3.2.7 Notch2IC-expressing CD138+ B220low cell populations spontaneously 
arising in vitro are functional antibody-secreting plasmablasts or plasma 
cells
Next we tested, whether in vitro cultured Notch2IC-expressing B cells indeed developed to functional, 
antibody-secreting plasmablasts/plasma cells. Firstly, we assessed antibody titers in the supernatant of  
in vitro cultures. For this, splenic B cells from Notch2IC//CD19Cre+/- and control mice were cultured 
for eight days with or without LPS, α-CD40 and α-CD40+LPS stimulation. On the last day, cell culture 
supernatants were collected and concentrations of  total IgM titers were determined by ELISA (Fig. 35). 
In accordance with former experiments, IgM secretion could be detected in cultures of  unstimulated 
Notch2IC-expressing B cells, but not in those of  control B cells. LPS treatment clearly increased IgM 
secretion in cultures of  control B cells, but not significantly in those of  Notch2IC-expressing B cells. 
In line with previous flow cytometrical analyses, α-CD40 stimulation decreased spontaneous IgM 
secretion in Notch2IC-expressing B cells as well as in LPS-treated control and Notch2IC-expressing 
B cells. However, regardless of  the stimulus Notch2IC-expressing B cells were always secreting greater 
amounts of  IgM compared to control B cells, which might at least partly be due to their MZ B cell 
Figure 34: Plasma cell differentiation is triggered by constitutive Notch2IC expression. Splenic cells of 
CD19Cre+/- and Notch2IC//CD19Cre+/- were sort-purified for Thy1.2-, B220+, CD21high CD23low MZ B and CD21low 
CD23high Fo B cells and in the case of Notch2IC-expressing cells also for hCD2+. Purified cell populations were 
subsequently cultured for two days with or without LPS in similar cell densities. On day two, plasma cell development 
was analysed by flow cytometry. Dot plots are gated on living cells and in the case of Notch2IC-expressing cells on 
hCD2+ populations. Data is representative of two independent experiment.
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phenotype. Concentrations of other antibody isotypes were below the detection limit.          Secondly, we 
determined the number of  IgM-, IgG1- and IgG3-secreting plasma cells by ELISPOT analyses (Fig. 
36). To this end, splenic B cells from Notch2IC//CD19Cre+/- and CD19Cre+/- control mice were 
isolated and cultured for one day without stimulation. On day one, frequencies of  living cells were 
determined. Subsequently, living cells were tranferred onto ELISPOT plates in specific cell densities, 
culturing them for additonal two days. Then the frequencies of  antibody-secreting plasma cells were 
visualised and determined. Unstimulated Notch2IC-expressing B cells displayed increased numbers 
of  IgG3-, IgM- and IgG1-secreting plasma cells. Even among 8x103 Notch2IC-expressing B cells 
were a lot more IgM-secreting cells than in cultures containing 1x105 control B cells. Together with 
the results from ELISA experiments above, these analyses prove that the CD138+ B220low cells arising 
in Notch2IC-expressing B cells even without stimulation at day two of  in vitro culture are indeed 
antibody-secreting plasma cells or plasmablasts.
Figure 35: IgM titers of in vitro cultured 
splenic B cells of Notch2IC//CD19Cre+/- and 
control mice. Splenic B cells were isolated 
from Notch2IC//CD19Cre+/- and control mice 
and taken into culture with or without LPS, α-
CD40 or α-CD40+LPS stimulation. After eight 
days, cell culture supernatants were collected 
and concentrations of total IgM titers were 
determined by ELISA. Two mice were analysed    
per group.
unstim. LPS α-CD40 α-CD40+LPS
total IgM
CD19Cre+/- Notch2IC//CD19Cre+/-
Figure 36: Unstimulated Notch2IC-expressing B cells are able to spontaneouly differentiate to IgM-, IgG3- 
and IgG1-secreting plasmablasts/plasma cells in vitro. Splenic B cells were isolated from Notch2IC//CD19Cre+/- 
(N2IC) and control mice (Ctrl) and taken into in vitro culture. After one day, amounts of living cells were determined 
and subsequently cells were plated and cultured onto ELISPOT plates in the depicted densities. After additional 
two days antibody-secreting plasma cells were visualised as brown spots by staining with 3,3’-diaminobenzidine 
(DAB). Two mice were analysed per group.
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3.2.8 Spontaneous plasmablast/plasma cell development of  Notch2IC-
expressing B cells in vitro correlates with increased Blimp-1 and Irf4 
levels
Plasma cells and their precursors are known to specifically upregulate the two transcription factors 
Irf4 and Blimp-1 (Shapiro-Shelef  and Calame, 2005). Therefore, we analysed by intracellular FACS 
analyses whether these two transcription factors are already elevated in Notch2IC-expressing MZ 
B cells in comparison to control B cells ex vivo. Splenic B cells were stained for CD21 and CD23 
expression on their surface and subsequently intracellularly for one of  the two transcription factors 
(Fig. 37). Ex vivo analyses revealed only very slightly increased Blimp-1 levels in wild type MZ B 
cells versus Fo B cells. Still, Blimp-1 expression was significantly higher in Notch2IC-expressing cells 
compared to wild type Fo B cells and compared to control MZ B cells (Fig. 37). Results obtained for 
Irf4 levels were more definite. MZ B cells exhibited higher Irf4 levels than Fo B cells and Notch2IC-
expressing cells enhanced expression levels compared to wild type MZ B cells (Fig. 37). 
Secondly, we compared the regulation of  Blimp-1 and Irf4 induction in Notch2IC-expressing and 
control B cells in the presence and absence of  stimulation during in vitro culture. Splenic B cells 
of  Notch2IC//CD19Cre+/- and control mice were isolated and cultured for up to three days with 
or without LPS stimulation and Blimp-1 and Irf4 levels were monitored on daily basis (Fig. 38). In 
cultures of  unstimulated control B cells no changes in Blimp-1 and Irf4 levels could be detected, 
whereas, unstimulated Notch2IC-expressing cells exhibited a clear upregulation of  Blimp-1 and an 
increase in the proportion of  Irf4high cells, both peaking at day two. In control cells, increases in Blimp-
1 and Irf4 could only be detected when cultured with LPS. Under these circumstances, two distinct 
Figure 37: Notch2IC-expressing MZ B cells 
express higher Blimp-1 and Irf4 levels than 
wild type MZ B cells. Splenic B cells were isolated 
from Notch2IC//CD19Cre+/- and CD19Cre+/- mice, 
stained for CD21 and CD23 surface markers, fixed, 
permeabilised and subsequently stained and 
analysed for the indicated transcription factors 
by intracellular flow cytometry. Exemplary dot 
plots are gated on B220+ lymphocytes, Notch2IC-
expressing cells additionally on hCD2+ cells. 
They depict CD21high CD23low wild type MZ B and 
CD21low CD23high wild type Fo B cells as well as 
CD21high CD23low Notch2IC-expressing MZ B cells. 
Histograms depict overlays of the abundance of 
the indicated molecules. They are gated on living, 
B220+, CD21high CD23low wild type MZ B cells 
(red line), CD21low CD23high wild type Fo B cells 
(blue line) and living, B220+ and hCD2+ CD21high 
CD23low Notch2IC-expressing MZ B cells (green 
line). Numbers represent means of medians and 
SD. Data is representative of three independent 
experiments.
ex vivo
CD19Cre+/-
MZ Bs
%
 o
f M
ax
Blimp-1
Notch2IC//CD19Cre+/-
MZ Bs
CD19Cre+/-
Fo Bs
Irf4
6.44%
85.60%
87.70%
Notch2IC//CD19Cre+/-CD19Cre+/-
C
D
21
CD23
208±25.4
274±30.1
367±16.3
1189±437
2333±891
3990±767
Results
46
populations varying in their Blimp-1 and Irf4 expression strength (Blimp-1high Irf4high and Blimp-1low 
Irf4low) could be distinguished on day two, with a nearly complete shift towards the Blimp-1high Irf4high 
population observable on day three. In LPS-treated Notch2IC-expressing cells, only small increases 
in Blimp-1 levels peaking at day two could be detected, suggesting that at day one maximal Blimp-1 
expression was already reached. Similar to unstimulated Notch2IC-expressing cells, LPS treatment 
induced a strong increase in Irf4high cells already on day one, peaking at day two and slightly decreasing 
on day three. However, in contrast to unstimulated Notch2IC-expressing cells, on day two nearly all 
LPS-treated Notch2IC-expressing cells were already Irf4high. These data underline our finding that 
Notch2IC-expressing B cells quickly differentiate to plasmablasts/plasma cells without stimulation. 
Moreover, these data implicate that LPS stimulation further accelerates plasma cell differentiation in 
Notch2IC-expressing B cells. To directly compare overall courses of  Blimp-1 and Irf4 expression of  
unstimulated and LPS-treated Notch2IC-expressing and control B cells over three days, we depicted 
Blimp-1 and Irf4 levels of  these cells in histogram overlays (Fig. 39). On day one and two, LPS-
treated Notch2IC-expressing cells exhibited highest Blimp-1 levels and highest frequencies of  Irf4high 
cells, followed by unstimulated Notch2IC-expressing cells and LPS-treated control cells (Fig. 39, 
left column). These findings confirmed our hypothesis that Notch2IC-expressing cells are faster in 
upregulating Blimp-1 and Irf4 compared to LPS-stimulated controls and that this upregulation can 
further be accelerated by LPS treatment. In addition, these overlays affirmed that with LPS treatment, 
highest Blimp-1 levels were already reached on day one in Notch2IC-expressing cells and do not further 
Figure 38: Splenic Notch2IC-expressing B cells upregulate Blimp-1 and Irf4 expression with and without 
LPS stimulation. Splenic B cells were isolated from Notch2IC//CD19Cre+/- and CD19Cre+/- mice and cultured for 
one to three days with or without LPS. On days one to three, cells were stained for the surface marker B220, fixed, 
permeabilised and subsequently stained and analysed for the indicated transcription factors by intracellular flow 
cytometry. Exemplary histograms are gated on living, B220+ cells and depict overlays of the abundance of the 
indicated molecules. Data is representative of three independent experiments.
%
 o
f M
ax
Blimp-1
in vitro day 3
Irf4
%
 o
f M
ax
in vitro day 1
unstim.
in vitro day 2
LPS unstim. LPS
CD19Cre+/- Notch2IC//CD19Cre+/-
Results
47
increase over time. While on day three Blimp-1 levels and the amount of  Irf4high cells started to drop in 
unstimulated Notch2IC-expressing cells, both transcription factors were still highly expressed in LPS-
treated Notch2IC-expressing and control cells. This finding was surprising since plasmablast/plasma 
cell frequencies decreased at day three in both LPS-stimulated and unstimulated Notch2IC-expressing 
B cells (see Fig. 31), with nearly no plasma cells detectable in cultures of  LPS-treated cells. To clarify 
why on day three Blimp-1 and Irf4 levels were still higher in LPS-treated Notch2IC-expressing cells, 
whereas in unstimulated Notch2IC-expressing cells they already dropped, we compared the Blimp-1 
and Irf4 expression levels of  CD138+ B220low cells arising in LPS-stimulated control cells with levels 
of  CD138- B220high non-plasma cells of  stimulated and unstimulated Notch2IC-expressing and control 
cells (Fig. 40). These analyses revealed that the majority of  non-plasma cells in LPS-treated Notch2IC-
expressing cells had nearly similar Irf4high levels as typical plasma cells arising in LPS-treated control 
cells (Fig. 40). Furthermore, non-plasma cells of  LPS-treated controls had higher Irf4 levels than non-
plasma cells of  unstimulated Notch2IC-expressing cells (Fig. 40). Hence, in LPS-treated Notch2IC-
expressing cells, every cell exhibited Irf4high levels, whereas in unstimulated Notch2IC-expressing cells 
only plasmablasts/plasma cells - which decreased on day three - were Irf4high. Thus, in Irf4 histogram 
overlays, the proportion of  Irf4high cells decreased in unstimulated Notch2IC-expressing cells, while 
the bulk of  LPS-stimulated cells remained Irf4high, although plasma cells were not detectable anymore. 
As already described in chapter 3.2.5, α-CD40 stimulation hampered spontaneous plasmablast/plasma 
Figure 39: Notch2IC-expressing B cells cultured with or without LPS, exhibit an accelerated Blimp-1 and Irf4 
induction compared to LPS-treated wild type B cells. Splenic B cells were isolated from Notch2IC//CD19Cre+/- 
and CD19Cre+/- mice and cultured with or without LPS. On day one to three, cells were stained for B220, fixed, 
permeabilised and subsequently stained and analysed for the indicated transcription factors by intracellular 
flow cytometry. Exemplary histograms depict overlays of the abundance of the indicated molecules. They are 
gated on living, B220+ B cells and in the case of Notch2IC-expressing B cells on living, hCD2+ cells. To illustrate 
the fast dynamics in expression levels, histograms of two different experiments are depicted for day two. Data is 
representative of two independent experiments.
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cell development in Notch2IC-expressing cells. In accordance, among the different in vitro cultures 
of  Notch2IC-expressing cells, those treated with α-CD40 had lower Blimp-1 expression levels than 
unstimulated or LPS-treated cells. However, increases in Irf4 levels could still be detected with α-
CD40 stimulation (Fig. 41). These data show that α-CD40 stimulation led to the upregulation of  Irf4 
but not Blimp-1, which might explain why α-CD40 treatment leads to an inhibition of  plasma cell 
differentiation in cultures of  Notch2IC-expressing cells. In summary, the expression strength and the 
Figure 40: LPS-stimulated non-plasma cells have higher Irf4 levels than unstimulated non-plasma cells. 
Splenic B cells were isolated from Notch2IC//CD19Cre+/- and CD19Cre+/- mice and cultured with or without LPS. 
On day three, cells were stained for B220 and CD138, fixed, permeabilised and subsequently stained and analysed 
for Irf4 by intracellular flow cytometry. (A) Exemplary dot plot gated on living cells depicting CD138high B220low 
plasma cells (PCs) and CD138low B220high non-plasma cells (non-PCs) with respective Irf4 levels (histograms) of 
LPS-treated Notch2IC-expressing cells. (B) Exemplary histograms are gated on living cells and display overlays of 
the abundance of Irf4 of CD138high B220low control plasma cells (PCs) with CD138low B220high non-plasma cells (non-
PCs) (both represented in dot plots) of unstimulated Notch2IC-expressing B cells and LPS-treated control and 
Notch2IC-expressing B cells. Line colours in histograms correspond to colour codings of the different populations 
in respective dot plots. Data is representative of two independent experiments.
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Figure 41: Notch2IC-expressing B cells cultured with α-CD40 have lower Blimp-1 levels than cells cultured 
with or without LPS. Splenic B cells were isolated from Notch2IC//CD19Cre+/- mice and cultured with or without 
LPS or α-CD40. On day one to three, cells were stained for B220, fixed, permeabilised and subsequently stained 
and analysed for the indicated transcription factors by intracellular flow cytometry. Exemplary histograms depict 
overlays of the abundance of the indicated molecules. They are gated on living, hCD2+ cells. Data is representative 
of two independent experiments.
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course of  Blimp-1 and Irf4 expression in Notch2IC-expressing cells together with the results from 
former experiments strongly suggest that fully functional plasmablasts or plasma cells are indeed 
arising in in vitro cultures of  Notch2IC-expressing B cells. Furthermore, probably due to the pre-
activated state of  Notch2IC-expressing cells, plasmablast/plasma cell development seems accelerated 
in unstimulated Notch2IC-expressing cells compared to LPS-treated control B cells and even more in 
LPS-treated Notch2IC-expressing cells.
3.3 The role of  Notch2 signalling in immune responses
3.3.1 Notch2IC//CD19Cre+/- mice are impaired in their TI-2 immune response
MZ B cells are known to play a decisive role in the production of  natural antibodies (Casali and 
Schettino, 1996; Cerutti et al., 2013) and in TI immune responses, by rapidly recognising antigens 
and by secreting low-affinity IgM and IgG3 antibodies (Martin et al., 2001). Notch2IC//CD19Cre    +/- 
mice have increased MZ B cell numbers, yet they exhibit decreased basal IgG3 titers and a disturbed 
TD immune response, the latter probably due to decreased Fo B cell numbers (Hampel et al., 2011).    
Still, when taken into in vitro culture, Notch2IC-expressing B cells rapidly develop into antibody-
secreting plasmablasts or plasma cells without being stimulated. So, although constitutive Notch2IC- 
expression together with the positioning of  the MZ B cells in the MZ somehow seems to form an 
inhibitory environment suppressing the intrinsic plasma cell differentiation potential of  Notch2IC-
expressing MZ B cells, we wanted to investigate whether this in vivo inhibiton could possibly also 
entail defects in TI-2 immune responses (NP-Ficoll) in Notch2IC/CD19Cre+/- mice. To check this, 
Notch2IC//CD19Cre+/- and control animals were primarily immunised intraperitoneally (i.p.) with 50 
µg 4-hydroxy-3-nitrophenylacetyl (NP) con�ugated to Ficoll. NP-specific plasma cell numbers as well 
as serum titers of  NP-specific antibodies were determined by ELISPOT and ELISA, respectively, 
seven and 14 days after immunisations. On day seven as well as on day 14, sera of  immunised 
Notch2IC//CD19Cre+/- mice contained significantly lower levels of  NP-specific IgM and IgG3 titers 
than those of  control animals (Fig. 42). Furthermore, in contrast to controls, no NP-specific IgG3-
secreting plasma cells could be detected among splenic cells of  immunised Notch2IC//CD19Cre+/- 
mice (Fig. 43), which was in accordance with the decreased NP-specific IgG3 antibody titers in sera 
Figure 42: Notch2IC//CD19Cre+/- 
have reduced antigen-specific IgM 
and IgG3 serum titers after TI-2 
immunisation. Notch2IC//CD19Cre+/- 
and CD19Cre+/- control mice were injected 
intraperitoneally with 50 µg NP-Ficoll. NP-
specific IgM and IgG3 concentrations were 
measured by ELISA of blood serum taken 
seven and 14 days after injection. Points 
represent data from individual animals 
and horizontal bars mark the mean value. 
CD19Cre+/- controls (Ctrl, green triangles); 
Notch2IC//CD19Cre+/- (blue squares); 
* p < 0.05; ** p < 0.01; *** p < 0.001 in 
comparison to controls. CD19Cre+/- Notch2IC//CD19Cre+/-
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re
la
tiv
e 
un
its
re
la
tiv
e 
un
its
0 7 14 days 0 7 14 days
***
**
**
*
Results
50
of  Notch2IC//CD19Cre+/- mice after immunisation with NP-Ficoll. However, in comparison to 
controls, Notch2IC//CD19Cre+/- mice exhibited an extremely high density of  IgM-secreting plasma 
cells independent of  the immunisation status of  the animals (Fig. 43). Even control wells only coated 
with bovine serum albumin (BSA) revealed high numbers of  these IgM-secreting plasma cells (data 
not shown). Similar results were obtained with ELISPOT analyses on day 14 after immunisation (data 
not shown). �et, both, immunised and unimmunised Notch2IC-expressing MZ B cells exhibited a 
very high amount of  NP-IgM-secreting antibodies able to recognise NP-BSA. This indicates that 
Notch2IC-expressing MZ B cells differentiate to plasma cells, secreting immunisation-independent 
polyreactive antibodies as soon as they are taken into culture. In summary, these data suggest that 
in spite of  the enlarged MZ B cell population, Notch2IC//CD19Cre+/- mice are unable to mount 
a normal immune response to the TI-2 antigen NP-Ficoll. However, after ex vivo isolation, B cells 
rapidly develop to plasmablasts/plasma cells secreting polyreactive antibodies.
3.3.2 Notch2IC//CD19Cre+/- mice are impaired in their immune response to 
the TI-1 antigen NP-LPS
MZ B cells are equipped with polyreactive BCRs and high levels of  TLRs for a quick recognition of  
conserved microbial patterns such as LPS (Bendelac et al., 2001; Martin and Kearney, 2002; Treml et al., 
2007) and they are known to rapidly differentiate to antibody-secreting plasma cells after LPS stimulation 
(Oliver et al., 1999b). Since Notch2IC//CD19Cre +/- mice are hampered in their TI-2 immune response 
to NP-Ficoll, we wanted to know if  they are also inhibited in their TI-1 immune response to NP-LPS. 
Preliminary ELISA data using sera of  two Notch2IC//CD19Cre+/- and two control mice analysed 
seven days after immunisation with 50 µg NP-LPS suggest that Notch2IC-expressing mice could also 
have slight defects in their response to TI-1 antigens, as NP-specific IgG3, but not IgM titers were 
decreased (data not shown). However, LPS - in contrast to NP-Ficoll - activates B cells in a polyclonal 
way irrespective of  the BCR specificity. Thus, it is possible that defects in TI-1 immune responses 
could be masked by the strong activation of  all MZ B cells in these immunisation experiments with 
50 µg NP-LPS. So we asked whether lower NP-LPS concentrations would lead to immune reactions 
Figure 43: Notch2IC//CD19Cre+/- splenic B cells do not develop into antigen-specific IgG3-secreting plasma 
cells after TI-2 immunisation, yet they seem to carry polyreactive IgM receptors. Notch2IC//CD19Cre+/- and 
control mice were injected intraperitoneally with 50 µg NP-Ficoll. Seven days after injection, splenic cells were 
isolated and transferred in triplicates for 1.5 - 2 days onto ELISPOT plates (1x106 cells/well). NP-specific IgM- and 
IgG3-secreting plasma cells were visualised and determined. Experiment was performed with three animals for 
each genotype and treatment.
unimm. imm. imm. imm. imm. unimm.
CD19Cre+/- Notch2IC//CD19Cre+/-
unimm. imm. imm. imm. imm. unimm.
NP17-IgM NP17-IgG3
CD19Cre+/- Notch2IC//CD19Cre+/-
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resembling those with NP-Ficoll and thus reveal significant defects also in TI-1 immune reactions 
in Notch2IC-expressing animals. To this end, Notch2IC//CD19Cre+/- and CD19Cre+/- control 
mice were immunised with lower NP-LPS concentrations (5-15 µg) per animal and analysed after 
seven days. On the day of  analysis, blood sera were taken and serum titers of  NP-specific IgM and 
IgG3 were determined by ELISA. Measurements of  antigen-specific antibody titers revealed that 
Notch2IC//CD19Cre+/- mice had diminished NP-IgM and NP-IgG3 titers (Fig. 44). Furthermore, the 
Notch2IC//CD19Cre+/- mouse immunised with 15 µg NP-LPS still exhibited decreased NP-specific 
antibody titers in comparison to control mice immunised with only 10 µg. Moreover, determination 
of  NP-specific antibody-secreting plasma cells by ELISPOT revealed that among B cells of  control 
mice immunised with 10 µg NP-LPS, increased amounts of  NP-IgG3- and NP-IgM-secreting plasma 
cells could be detected in comparison 
to unimmunised animals (Fig. 45). In 
contrast, irrespective of  the NP-LPS 
concentrations, in wells with Notch2IC-
expressing cells no NP-IgG3 or NP-IgG1 
spots could be detected (Fig. 45 and data 
not shown). ELISPOT wells for NP-IgM 
exhibited again a very high, most likely 
also in part unspecific background staining 
(Fig. 45) as already seen in unimmunised 
and NP-Ficoll immunised mice (see 3.3.1, 
Fig. 43). Although experiments need to 
be repeated with more animals and with 
varying NP-LPS concentrations, these 
first results suggest that Notch2IC//
CD19Cre+/- mice indeed are also impaired 
Figure 44: Notch2IC//CD19Cre+/- mice are impaired in their TI-1 immune response to low NP-LPS 
concentrations. Notch2IC//CD19Cre+/- and control mice were immunised intraperitoneally with 5 - 15 µg NP-LPS. 
Concentrations of NP-specific antibody titers of the indicated isotypes were measured by ELISA of blood serum 
taken seven days after injection. Points represent data from individual animals and horizontal bars mark the mean 
value. CD19Cre+/- controls (green triangles); Notch2IC//CD19Cre+/- (blue squares); unimmunised CD19Cre+/- control 
mice (white circles).
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Figure 45: Notch2IC-expressing splenic B cells do not 
develop into antigen-specific IgG1- or IgG3-secreting 
plasma cells after TI-1 immunisation, yet they seem to be 
polyreactive. Notch2IC//CD19Cre+/- (N2IC) and control (Ctrl) 
mice were immunised intraperitoneally with 10-15 µg NP-
LPS. Seven days after injection, splenic cells were isolated and 
transferred in triplicates for 1.5-2 days onto ELISPOT plates 
(1x106 cells/well). Subsequently, NP-specific IgM-, IgG3- and 
IgG1-secreting plasma cells were visualised and determined. 
Experiment was performed with two animals for each genotype 
and treatment, except the 15 µg treatment in the Notch2IC//
CD19Cre+/- mouse, which was only performed once.
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in their TI-1 immune response. With respect to the role of  Notch2 in immune responses and plasma 
cell differentiation, we could show so far that Notch2IC-expressing MZ B cells are spontaneously 
and rapidly able to develop to antibody-secreting plasmablasts or plasma cells in vitro. On the other 
hand, in vivo plasma cell frequencies among cells of  the spleen and bone marrow were not increased 
compared to controls and TI immune responses were drastically reduced. Only highly polyreactive 
IgM antibodies were detected irrespective of  the immunisation state and immunisations did not induce 
any class switching. We hypothesise that Notch2IC-expression forces MZ B cells to stay in the MZ, 
so that MZ B cells cannot move into the follicle and hence cannot develop to plasma cells. As a first 
attempt to reveal potential defects in the migration capacity of  Notch2IC-expressing MZ B cells, we 
performed so called “marginal zone clearance” experiments. It is known that LPS injections in mice 
lead to a clearance of  the MZ as all MZ B cells migrate into the follicle after LPS stimulation (Martin 
and Kearney, 2002). To investigate whether this LPS-triggered relocalisation of  Notch2IC-expressing 
B cells could still be induced, we treated control and Notch2IC//CD19Cre+/- mice with different NP-
LPS concentrations and assessed the clearance of  the MZ by immunohistochemistry. Notch2IC//
CD19Cre+/- as well as control mice were treated with 2.5-50 µg NP-LPS. After five to six hours post 
injection, spleens were isolated and frozen in Tissue-Tek® for later cryosections and subsequent 
immunohistochemistry. Splenic sections were stained with α-IgM to detect B cells, α-CD3 for T cells 
and α-MOMA-1 for metallophilic macrophages lining the marginal sinus. In control mice marginal 
zone clearance could be induced down to NP-LPS concentrations as low as 5 µg. In spleens from mice 
treated with only 2.5 µg NP-LPS a thin line of  MZ B cells located within the MZ was still visible (Fig. 
46, upper row), suggesting that this concentration was too low to induce complete migration into the 
follicle. In Notch2IC//CD19Cre+/- mice an injection with 50 µg NP-LPS led to an almost complete 
migration of  MZ B cells into the follicle, making splenic sections resemble those of  an untreated wild 
type mouse (Fig. 46, lower row, left picture). In Notch2IC-expressing mice treated with 20 µg NP-LPS, 
a great proportion of  MZ B cells could still be detected within the follicle, however already to a lesser 
extent than with 50 µg. The fraction of  Notch2IC-expressing cells relocating to the follicle diminished 
with decreasing NP-LPS concentrations, so that at a concentration of  5 µg no difference could be 
observed between treated and untreated mice (Fig. 46, lower row). Experiments investigating the LPS-
induced MZ clearance suggest that Notch2IC-expressing MZ B cells are still able to migrate into the 
follicle, if  they are activated by a sufficiently strong stimulus, such as high NP-LPS concentrations 
(~50-20 µg). However, in response to weaker stimulation, such as low NP-LPS concentrations or 
NP-Ficoll, they remain within the MZ. This implicates that the migration potential of  Notch2IC-
expressing MZ B cells is not completely disturbed, but impaired after immunisation with lower NP-
LPS concentrations. To unravel other potential factors affecting TI immune responses in Notch2IC//
CD19Cre+/- mice, we took a closer look at antigen capturing and transport after immunisations with 
the TI-2 antigen 2,4,6-trinitrophenyl (TNP) conjugated to Ficoll.
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3.3.3 Notch2IC//CD19Cre+/- mice exhibit defects in their SIGN-R1+ 
macrophage population and in antigen capturing 
Next to the MZ B cells, the splenic MZ comprises different types of  macrophages. Marginal 
metallophilic macrophages (MOMA-1+) lining the marginal sinus and marginal zone macrophages 
(MARCO+), which are located within the MZ interspersed between the MZ B cells (Mebius and 
Kraal, 2005). A subset of  MARCO+ macrophages also expresses the SIGN-R1 receptor. SIGN-R1+ 
macrophages have been shown to capture antigens out of  the circulation, engulf  and process them for 
the subsequent presentation to MZ B cells, which in turn are essential for the subsequent transport of  
the antigens into the follicle (Arnon et al., 2013; Cinamon et al., 2008; Ferguson et al., 2004). Mice with              
defects in SIGN-R1+ macrophages underpin the important role of  SIGN-R1+ macrophages in antigen 
capturing and presentation (Koppel et al., 2008; Kang et al., 2006). Hence, we were interested whether             
this cell population was still present and normaly distributed in Notch2IC//CD19Cre+/- mice. Splenic 
cryosections of  Notch2IC//CD19Cre+/- and control mice were analysed by immunofluorescent or 
immunohistochemical stainings for the presence and distribution of  SIGN-R1+ macrophages. In 
sections of  control mice, SIGN-R1+ 
macrophages were detectable as a nearly 
closed ring, positioned within the MZ 
and lying clearly outside of  the marginal 
sinus, which is lined by MOMA-1+ 
macrophages (Fig. 47, left column). In 
Notch2IC//CD19Cre+/- mice, on the 
other hand, SIGN-R1+ macrophages 
were scarce and more scattered, however 
still correctly localised within the MZ 
(Fig. 47, right column). So it seems that 
constitutive Notch2 signalling is either 
directly or indirectly - by increasing 
MZ B cell numbers - influencing the 
frequency and/or positioning of  SIGN-
R1+ macrophages. To be able to track 
antigen capturing as well as the transport 
into the follicle and to check if  this could 
still be induced in Notch2IC-expressing 
animals, Notch2IC//CD19Cre+/- and 
control mice were treated with 50 µg 
TNP-Ficoll. Mice were taken down 
after one or five hours and the presence 
and localisation of  TNP+ cells was 
assessed by immunohistochemistry and 
Figure 47: SIGN-R1+ macrophages seem reduced in 
Notch2IC//CD19Cre+/- mice. Immunofluorescent and 
immunohistochemical stainings of splenic cryosections (8 
µm) of Notch2IC//CD19Cre+/- and CD19Cre+/- mice for SIGN-
R1+ macrophages (α-SIGN-R1, red or blue) located within the 
MZ, MOMA-1+ metallophilic macrophages (α-MOMA-1, green) 
lining the marginal sinus and IgM+ B cells (α-IgM, red). Depicted 
photomicrographs are representative for two independent 
experiments. Scale bar: 250 µm.   
CD19Cre+/- Notch2IC//CD19Cre+/-
α-SIGN-R1 α-MOMA-1
α-SIGN-R1
α-SIGN-R1 α-IgM 250µm
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immunofluorescence on splenic cryosections. In control mice, one hour post in�ection, TNP+ cells 
could be detected within the MZ outside of  the MOMA-1+ ring of  macrophages lining the marginal 
sinus (Fig. 48A+B, left panels). Five hours after injection, TNP+ cells had clearly migrated into the 
follicle in control animals (Fig. 48C+D, left panels). In great contrast to this, fewer, scattered TNP+ 
cells could be detected in the marginal zones of  Notch2IC//CD19Cre+/- mice after one hour (Fig. 
48A+B, right panels) and nearly no TNP+ cells were visible within the follicle five hours post in�ections 
(Fig. 48C+D, right panels). In summary, this indicates that antigen capturing is impaired in Notch2IC-
expressing mice and no antigen transport into the follicle takes place.
3.3.4 Notch2fl/fl//CD19Cre+/- mice have a reduced TI-2 immune reponse, but 
functional antigen capturing and transport into the splenic follicle
As already mentioned in preceding chapters, SIGN-R1+ MZ macrophages are implicated in antigen 
capturing and presentation (Aichele et al., 2003; Koppel et al., 2008). Under normal circumstances they            
are localised outside of  the marginal sinus, interspersed within the MZ (Koppel et al., 2008). However,     
MZ B cells have been shown to be the key B cell population responsible for transporting antigen from 
the MZ into the follicle (Arnon et al., 2013; Ferguson et al., 2004; Cinamon et al., 2008). In Notch2IC//             
Figure 48: Notch2IC//CD19Cre+/- mice exhibit defects in antigen capturing and transport into the follicle. 
Immunofluorescent stainings of splenic cryosections of Notch2IC//CD19Cre+/- and CD19Cre+/- mice one (A-B) and 
five hours (C-D) after intraperitoneal injections (i.p.) of 50 µg TNP-Ficoll. Sections (8 µm) were stained for TNP+ cells 
(α-TNP-Pe, red) and MOMA-1+ metallophilic macrophages (α-MOMA-1, green) lining the marginal sinus. Depicted 
photomicrographs are representative for two independent experiments. Scale bars: 250 µm.   
CD19Cre+/- Notch2IC//CD19Cre+/- CD19Cre+/- Notch2IC//CD19Cre+/-
5 hours post 50 µg TN
P
-Ficoll i.p.
A B
C DCD19Cre+/- Notch2IC//CD19Cre+/- CD19Cre+/- Notch2IC//CD19Cre+/-
1 hour post 50 µg TN
P
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250µm
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α-TNP-Pe
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CD19Cre+/- mice, SIGN-R1+ macrophages are reduced, however, these remaining macrophages seem 
to fullfill their role in capturing TNP-Ficoll. Still, no transport of  antigen into the follicle could be 
detected, implicating that MZ B cells are possibly not able to migrate into the follicle when activated 
by the antigen TNP-Ficoll. To investigate whether antigen transport into the follicle can also take 
place in the absence of  MZ B cells, we analysed antigen capturing and transport in Notch2-deficient 
mice, which are devoid of  MZ B cells (Fig. 49). Firstly we checked whether Notch2fl/fl//CD19Cre+/- 
mice still had normal positioned and normal frequencies of  SIGN-R1+ macrophages, although 
Figure 49: Notch2fl/fl//CD19Cre+/- mice are 
devoid of MZ B cells. The upper row displays 
immunohistochemical stainings of splenic 
cryosections (8 µm) of Notch2fl/fl//CD19Cre+/- 
and CD19Cre+/- mice for MOMA-1+ metallophilic 
macrophages (α-MOMA-1, dark blue) lining 
the marginal sinus, for IgM+ B cells (α-IgM, red) 
and for CD3+ T cells (α-CD3, blue). Arrowheads 
indicate marginal zone. The lower row displays 
flow cytometrical analyses of control and 
Notch2-deficient splenic cells for their CD21 and 
CD23 expression. Exemplary dot plots are gated 
on B220+ lymphocytes. Data is representative of 
three independent experiments. Scale bar: 250   
µm.
C
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21
CD23
CD19Cre+/- Notch2fl/fl//CD19Cre+/-
7.25% 0.70%
72.51% 87.90%
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Figure 50: SIGN-R1+ macrophages are 
slightly reduced, but present in Notch2fl/fl//
CD19Cre+/- mice. Immunofluorescent and 
immunohistochemical stainings of splenic 
cryosections (8 µm) of Notch2fl/fl//CD19Cre+/- 
and CD19Cre+/- mice for SIGN-R1+ macrophages 
(α-SIGN-R1, red or blue) located within the MZ, 
MOMA-1+ metallophilic macrophages (α-MOMA-
1, green) lining the marginal sinus and IgM+ B cells 
(α-IgM, red). Depicted photomicrographs are 
representative of two independent experiments. 
Scale bar: 250 µm.
CD19Cre+/- Notch2fl/fl//CD19Cre+/-
α-SIGN-R1 α-MOMA-1
α-SIGN-R1
α-SIGN-R1 α-IgM 250µm
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they are devoid of  MZ B cells. Analysis of  this macrophage population by immunofluorescent or 
immunohistochemical stainings on splenic cryosections of  Notch2fl/fl//CD19Cre+/- and control 
mice revealed that there is only a faint reduction in the frequency and localisation of  these cells in 
Notch2-deficient mice (Fig. 50). To further analyse if  antigen capturing and especially transport was 
still functional in these mice, Notch2fl/fl//CD19Cre+/- and control animals were treated with 50 µg 
TNP-Ficoll. Spleens were isolated one and five hours after in�ection and cryosections were analysed 
by immunofluorescent stainings with α-TNP-Pe for cells bearing TNP-Ficoll on their surface. In 
control animals, one hour after injection TNP+ cells were clearly located within the MZ, whereas 
after five hours TNP+ cells could be detected within the splenic follicle (Fig. 51A-D, left panels). 
Surprisingly, similar antigen capturing and transport could be seen in Notch2-deficient mice (Fig. 51A-
D, right panels). These results show that SIGN-R1+ macrophages, which are important for antigen 
capturing and presentation, are still present and functional in Notch2-deficient mice and that the 
antigen transport into the follicle is still warranted, although MZ B cells are missing. 
Mouse models with defects in their MZ B cell population have been shown to exhibit alterations in their 
TI immune responses (reviewed in Martin and Kearney, 2002). However, from our previous results 
we inferred that immune responses to TI antigens would be normal in Notch2fl/fl//CD19Cre+/- mice, 
although they lack MZ B cells. In line with this is the publication of  Tanigaki and colleagues, showing 
Figure 51: Antigen capturing and transport into the follicle is similar in control and Notch2fl/fl//CD19Cre+/- 
mice. Immunofluorescent stainings of splenic cryosections of Notch2fl/fl//CD19Cre+/- and CD19Cre+/- mice one (A-
B) and five hours (C-B) after intraperitoneal (i.p.) injection of 50 µg TNP-Ficoll. Sections (8 µm) were stained for 
TNP+ cells (α-TNP-Pe, red) and MOMA-1+ metallophilic macrophages (α-MOMA-1, green) lining the marginal sinus. 
Depicted photomicrographs are representative of two independent experiments. Scale bars: 250 µm.   
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that mice with a B cell-specific RBP-J� knockout in which Notch signalling is completely abrogated 
and hence MZ B cell development abolished, exhibit a normal TI-2 response (Tanigaki et al., 2002). 
To examine the TI immune response in the absence of  Notch2 signalling, Notch2fl/fl//CD19Cre+/- 
and CD19Cre+/- control mice were immunised with NP-Ficoll. NP-specific plasma cells as well as 
serum titers of  NP-specific antibodies were determined by ELISPOT and ELISA, respectively seven 
days after immunisation. Sera of  immunised Notch2fl/fl//CD19Cre+/- mice contained significantly 
lower levels of  NP-specific IgM and IgG3 titers than those of  control animals (Fig. 52). In addition, 
in comparison to controls, no NP-specific IgG3- and reduced numbers of  NP-specific IgM-secreting 
plasma cells could be detected among splenic cells of  immunised Notch2fl/fl//CD19Cre+/- mice (Fig. 
53). These analyses indicate that Notch2fl/fl//CD19Cre+/- mice are hampered in their TI-2 immune 
Figure 52: Notch2fl/fl//CD19Cre+/- have 
reduced antigen-specific IgM and IgG3 
serum titers after TI-2 immunisation. 
Notch2fl/fl//CD19Cre+/- and control mice were 
injected intraperitoneally with 50 µg NP-Ficoll. 
NP-specific IgM and IgG3 concentrations were 
measured by ELISA in serum taken seven days 
after injection. Points represent data from 
individual animals and horizontal bars mark 
the mean value. Controls (green triangles); 
Notch2fl/fl//CD19Cre+/- (blue squares); 
unimmunised controls (white circles); ** p < 
0.01; *** p < 0.001 in comparison to immunised 
controls.
Figure 53: Notch2fl/fl//CD19Cre+/- mice have 
reduced numbers of antigen-specific IgM-, 
IgG1- and IgG3-secreting plasma cells after 
TI-2 immunisation. Notch2fl/fl//CD19Cre+/- and 
control mice were injected intraperitoneally 
with 50 µg NP-Ficoll. Seven days after injection, 
splenic cells were isolated and transferred in 
triplicates for 1.5-2 days onto ELISPOT plates 
(1x106 cells/well). Subsequently, NP-specific 
IgM-, IgG3- and IgG1-secreting plasma cells 
were visualised and determined as brown 
spots. Experiment was performed with three 
animals for each genotype and treatment.
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response to NP-Ficoll. In summary, Notch2fl/fl//CD19Cre+/- are impaired or delayed in their TI-2 
immune response to NP-Ficoll, probably due to the lack of  MZ B cells. �et, antigen capturing by 
SIGN-R1+ macrophages and antigen transport into the follicle is still functional in these mice.
3.4 The role of  Notch2 in lymphomagenesis
3.4.1 Constitutive, B cell-specific Notch2 expression seems not to be sufficient 
to strongly drive B cell lymphomagenesis
Mutations in the notch genes predominantly resulting in constitutively active Notch signalling have 
been shown to be implicated in various disease including B cell malignancies. Of  special interest for 
us were recent publications showing that mutations in the notch2 gene were specific for SMZL (Troen 
et al., 2008; Kiel et al., 2012; Rossi et al., 2012). �oung Notch2IC//CD19Cre +/- mice display a slight 
splenomegaly and elevated levels of  the proto-oncogene c-myc, which is known to be implicated in 
cell growth, proliferation and apoptosis (Wade and Wahl, 2006). Furthermore, due to their MZ B cell           
phenotype, Notch2IC-expressing cells exhibit increased proliferation, especially in response to LPS and 
α-CD40 stimulation (Hampel et al., 2011). To explore whether constitutive Notch2 signalling would 
lead to an earlier onset of  lymphoma development in Notch2IC//CD19Cre+/- mice compared to 
lymphoma spontaneously arising in old wild type mice (older than 19 months), we assembled cohorts 
of  26 Notch2IC//CD19Cre+/- and 19 CD19Cre+/- animals and let them age. Animals were euthanised 
when exhibiting first signs of  morbidity or when a maximum age of  22 months was reached. Table 5 is 
Table 5: Overview of all analysed aged Notch2IC//CD19Cre+/- and control mice.
Mouse
number GT
Age
(months)
Sp weight
(mg)
Sp cells
(counts)
IgM+ B cells 
(counts)
CD3+/Thy1.2+
T cells (counts)
IgM+ hCD2+
B cells (counts)
663 CD19 3,0 116 8,7E+07 4,2E+07 3,1E+07 n.a.
652 CD19 4,0 98 4,2E+07 1,5E+07 1,5E+07 n.a.
485 CD19 6,0 95 8,3E+07 3,7E+07 2,8E+07 n.a.
515 CD19 6,0 n.d. 1,3E+08 6,1E+07 4,3E+07 n.a.
516 CD19 6,0 n.d. 7,9E+07 3,5E+07 2,8E+07 n.a.
2610 CD19 12,0 147 6,0E+07 3,4E+07 1,7E+07 n.a.
69 Ctrl 12,0 83 2,7E+07 1,3E+07 9,8E+06 n.a.
80 Ctrl 13,0 110 3,8E+07 2,1E+07 1,2E+07 n.a.
2612 CD19 14,0 85 3,4E+07 1,5E+07 9,8E+06 n.a.
7638 CD19 15,0 n.d. 1,1E+08 6,1E+07 3,8E+07 n.a.
292 CD19 16,0 125 2,2E+08 1,1E+08 8,1E+07 n.a.
7891 CD19 17,0 165 7,6E+07 4,6E+07 2,0E+07 n.a.
24 Ctrl 17,0 102 3,9E+07 2,9E+07 5,3E+06 n.a.
7745 CD19 17,5 211 1,0E+08 3,3E+07 1,8E+07 n.a.
353 CD19 18,0 200 8,1E+07 4,8E+07 1,7E+07 n.a.
7461 CD19 19,0 83 4,3E+07 2,4E+07 1,5E+07 n.a.
7576 CD19 19,0 120 1,8E+08 9,6E+07 6,4E+07 n.a.
7640 CD19 19,0 89 2,5E+07 n.d. n.d. n.a.
7578 CD19 19,5 97 1,8E+08 9,8E+07 4,9E+07 n.a.
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giving an overview of  all analysed mice, including genotype, age, splenic weight, total splenic cell numbers 
as well as cell numbers of  IgM+ and IgM+ hCD2+ cells as well as CD3+ or Thy1.2+ T cells. Due to the 
expansion of  MZ B cells, which are larger than Fo B cells, spleens of  Notch2IC//CD19Cre+/- mice were 
on averge 1.5-fold heavier than spleens of  control mice (Hampel et al., 2011). Examining spleens of  aged 
mice (4 to 22 months) now revealed that in addition to this initial difference, old Notch2IC//CD19Cre+/- 
mice had on average even bigger spleens than young Notch2IC//CD19Cre+/- mice and the respective old 
control mice (Fig. 54). In comparison, in control mice no big difference could be detected between splenic 
weights of  young and old mice. Still, plotting splenic weight against the age of  the mice, uncovered the 
huge variation among splenic weight data of  old Notch2IC//CD19Cre+/- mice (Fig. 55). In these graphs 
it again seemed as if  there was a slight positive correlation between the splenic weight and older age of  
Notch2IC//CD19Cre+/- mice, yet, due to the great variation, statistical correlation analysis didn’t reveal 
Mouse
number GT
Age
(months)
Sp weight
(mg)
Sp cells
(counts)
IgM+ B cells 
(counts)
CD3+/Thy1.2+
T cells (counts)
IgM+ hCD2+
B cells (counts)
653 N2IC 4,0 150 7,2E+07 3,5E+07 2,3E+07 3,0E+07
7890 N2IC 4,0 711 2,8E+08 1,2E+08 4,5E+07 9,1E+07
621 N2IC 6,0 167 6,3E+07 3,9E+07 1,1E+07 3,0E+07
498 N2IC 6,0 n.d. 1,8E+08 8,9E+07 5,9E+07 6,7E+07
499 N2IC 6,0 n.d. 7,0E+07 2,8E+07 2,8E+07 2,2E+07
961 N2IC 12,0 354 1,0E+08 4,5E+07 3,8E+07 3,6E+07
948 N2IC 12,0 616 1,2E+08 3,5E+07 5,2E+07 2,4E+07
7592 N2IC 13,0 2524 2,7E+09 1,3E+09 2,8E+08 1,3E+09
968 N2IC 13,0 312 1,2E+08 6,3E+07 2,6E+07 4,5E+07
952 N2IC 14,0 171 1,8E+08 6,9E+07 6,1E+07 5,7E+07
7594 N2IC 15,0 n.d. 8,8E+07 5,3E+07 3,6E+07 4,1E+07
297 N2IC 16,0 250 1,8E+08 7,3E+07 8,6E+07 3,2E+07
959 N2IC 16,0 123 2,1E+07 8,8E+06 5,7E+06 6,2E+06
7595 N2IC 18,5 n.d. 1,8E+08 7,0E+07 7,5E+07 6,1E+07
374 N2IC 18,5 629 7,7E+07 1,9E+07 2,0E+07 1,6E+07
341 N2IC 19,0 211 4,5E+07 2,5E+07 1,3E+07 2,4E+07
302 N2IC 19,0 771 1,6E+08 4,8E+07 2,5E+07 3,9E+07
7596 N2IC 19,0 535 7,4E+07 3,0E+07 1,8E+07 2,6E+07
293 N2IC 19,5 390 5,7E+07 2,6E+07 1,8E+07 2,2E+07
7577 N2IC 19,5 108 1,8E+07 8,1E+06 5,3E+06 5,2E+06
373 N2IC 20,0 818 2,8E+08 7,0E+07 5,0E+07 5,7E+07
335 N2IC 20,5 2200 1,8E+08 5,7E+07 2,1E+07 5,5E+07
342 N2IC 20,5 911 2,8E+08 1,2E+08 6,5E+07 1,1E+08
343 N2IC 22,0 422 1,0E+08 7,8E+07 3,2E+07 7,0E+07
344 N2IC 22,0 614 1,8E+08 6,6E+07 3,8E+07 5,7E+07
380 N2IC 22,0 139 2,2E+07 6,8E+06 8,8E+06 5,4E+06
Cohorts of Notch2IC//CD19Cre+/- (N2IC) and control mice (CD19Cre+/- or wildtype) were aged up to 22 months. 
Mice were analysed when showing first signs of illness. Table summarises the genotype (GT), age, splenic (Sp) 
weight, total splenic cell numbers, IgM+ splenic B cell numbers, splenic T cell numbers and numbers of IgM+ hCD2+ 
splenic cells of all analysed mice. Ctrl (wildtype mice), n.a. (not applicable).
Table 5 continued:
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any significance (Fig. 55). Despite this increase in splenic size in aging Notch2IC//CD19Cre+/- mice, 
no difference could be detected regarding total splenic cell numbers (Fig. 56A). To assess whether an 
expansion of  one or more B cell clones (mono- or polyclonality) took place in old mice - which would 
confirm lymphomagenesis - a first Southern blot analysis was undertaken with DNA probes from total 
splenocytes of  eleven Notch2IC//CD19Cre+/- and seven CD19Cre+/- mice. Tested animals were aged 
between 12 and 20.5 months. Unfortunately two CD19Cre+/- probes droped out and couldn’t be analysed 
later on. With a radioactively-labeled IgH-probe on membrane-bound DNA, one could either detect 
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Figure 54: Splenic weight of aged and young Notch2IC//CD19Cre+/- and control mice. Cohorts of Notch2IC//
CD19Cre+/- and control mice were aged up four to 22 months. Mice were analysed when showing first signs of 
illness and splenic weights were determined. Points represent data from individual animals and horizontal bars 
mark the mean value. Outliers (red circles), old control mice (filled green circles); old Notch2IC//CD19Cre+/- mice 
(filled blue circles); young control mice (blank green circles); old Notch2IC//CD19Cre+/- mice (blank blue circles). * 
p < 0.05; ** p < 0.01; *** p < 0.001 in comparison to respective controls.
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old CD19Cre+/- old Notch2IC//CD19Cre+/-
Figure 55: Correlation of splenic weight with age in Notch2IC//CD19Cre+/- and control mice. Cohorts of 
Notch2IC//CD19Cre+/- and control mice were aged up to 22 months. Mice were analysed when showing first signs 
of illness and splenic weights were determined. The graph on the left shows the correlation of splenic weights 
with age of all analysed mice, whereas the graph on the right depicts the same without the two outliers in the red 
circle. Points represent data from individual animals and trendlines of linear regression analyses are included in 
diagrams. Control mice (green); Notch2IC//CD19Cre+/- mice (blue).
Results
62
and visualise the native, germline configuration of  the IgH-locus or one or more other distinct bands 
representing the expansion of  one or more B cell clones equipped with the same BCR rearrangement. 
Two (#7461 and #353) out of  five (40 %) control mice showed additonal bands at the age of  18 and 19 
months. In Notch2IC//CD19Cre+/- mice, seven (#7592, #373, #7577, #7595, #293, #302, #342) out 
of  eleven (64 %) animals clearly showed mono- or polyclonality. Two animals (#374 and #7596) showed 
faint bands. Further analyses with mice aged about 19 months will be necessary to be able to determine 
a significant difference in lymphoma development between Notch2IC//CD19Cre+/- and control mice. 
In addition, Southern blot analyses of  younger Notch2IC//CD19Cre+/- mice are planned in the near 
future to clarify whether lymphoma also develop at earlier time points. Tumor development not always 
correlated with an increase in splenic size (Fig. 57, table 5) or with stronger forms of  morbidity in mice 
and until now it looks as if  its onset was relatively late. These results suggest that constitutive Notch2 
signalling drives the development of  indolent lymphoma, however, with a late onset and a long latency. 
Figure 57: Southern blot analysis of 
aged Notch2IC//CD19Cre+/- and control 
mice. Southern blot of EcoRI-digested DNA 
isolated from total splenocyte preparations. A 
radioactively-labeled IgH-probe was used to 
check the configurations of the IgH-locus in B 
cells of depicted animals. The arrow points to 
the band indicating the germline configuration 
of the respective sample as found in B cells 
and in any other cell type. Additional bands 
representing changes in the IgH-locus and 
hence mono- or polyclonality of the analysed 
B cell population are indicated by asterisks. 
B cells of following mice exhibited mono- or 
polyclonality: Control animals #7461 and #353 
as well as Notch2IC-expressing animals #7592, 
#373, #7577, #7595, #293, #302 and #342 (red). 
Mice #374 and #7596 exhibited only faint 
additional bands (orange).
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Figure 56: Total splenic cells as well as IgM+ and IgM+ hCD2+ splenic cell populations of aged Notch2IC//
CD19Cre+/- and control mice. Cohorts of Notch2IC//CD19Cre+/- and control mice were aged up to 22 months. Mice 
were analysed when showing first signs of illness. (A) Graph shows total splenic cell numbers of old Notch2IC//
CD19Cre+/-  (blue) and control mice (green). Points represent data from individual animals and horizontal bars mark 
the mean value. (B) Graphs show numbers of IgM+ and hCD2+ splenic cells (left) and IgM+ hCD2+ splenic cells (right) 
of old Notch2IC//CD19Cre+/- (blue, orange) and control mice (green) correlated to age. Points represent data from 
individual animals and trendlines of linear regression analyses are included in diagrams. Values of mouse #7592 were 
extrem outliers (see table 5) and were therefore not included in (B).
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3.4.2 Constitutive Notch2IC expression alters the phenotype of  B cells in aging 
mice irrespective of  tumor development
To investigate whether possible tumor development and aging would induce changes in splenic cell 
populations of  Notch2IC//CD19Cre+/- and control animals with regard to frequency or cell numbers, 
extensive FACS analyses were performed. As most important differences could be detected in CD21, 
CD23, IgM, IgD as well as in B220 and hCD2 expression in the spleen, bone marrow and lymph nodes, 
these stainings will be described and discussed in detail. In our first Southern blot analysis, mouse 
#7592 (13 months) exhibited the most distinct and biggest band clearly pointing at a monoclonal 
tumor population (Fig. 57), which was also clearly distinguishable by flow cytometry. In contrast to 
young Notch2IC//CD19Cre+/- animals harbouring almost only CD21high CD23low IgMhigh IgDlow MZ 
B cells in their spleens, all lymphocytes of  this tumor mouse had shifted to a B220low CD21low CD23low 
IgMlow-Int hCD2+ phenotype with most of  them being IgDhigh (Fig. 58A, upper rows). The fact that 
all B cells were hCD2+ implies that only Notch2IC-expressing B cells had expanded. Lymphocytes 
within BM and LN exhibited a similar phenotype (Fig. 58A), indicating that the tumor cell population 
had infiltrated other lymphoid organs. However, none of  the other Notch2IC//CD19Cre+/- animals 
displaying additional bands in Southern blot analysis exhibited this special, distinct kind of  “tumor 
phenotype”. B cell populations of  the majority of  aged Notch2IC-expressing animals resembled each 
other regardless if  an additional band was present in Southern blot analysis or not, suggesting that 
alterations in surface marker expression were rather induced by aging than by tumor formation. Figure 
58 depicts exemplary Notch2IC-expressing and control mice representing and summarising major 
phenotypes observed in flow cytometrical analyses of  all analysed aged animals. Splenic lymphocytes 
of  aged Notch2IC-expressing mice exhibited reduced percentages of  IgM+ and hCD2+ (Fig. 56B) 
as well as of  B220+ cells (Fig. 58). Gating on IgM+ cells, however, revealed that remaining IgM+ B 
cells were all hCD2+ and frequencies of  IgM+ hCD2+ cells were not significantly reduced (Fig. 56B), 
indicating that reductions in percentages of  hCD2+ cells were caused by a general decrease in IgM+ 
total B cell numbers. Furthermore, among IgM+ and among hCD2+ cell populations, the percentage 
of  B220low cells increased with age, implying that B220 expression is downregulated in IgM+ B cells. 
Beyond that, IgM+ hCD2+ showed downregulation of  CD21 and although hCD2+ cells were those 
exhibiting still highest CD21 expression, these higher levels did not reach original levels expressed by 
MZ B cells in young Notch2IC//CD19Cre+/- mice. Almost no IgD+ cells could be detected among 
lymphocytes, whereas there were still populations of  IgMhigh cells, which were all hCD2+ in accordance 
with their MZ B cell phenotype. In most Notch2IC//CD19Cre+/- mice, lymphocytes of  the lymph 
nodes and bone marrow exhibited a similar CD21 downregulation and IgM, IgD expression as in 
splenic cells (data not shown). Quite similar alterations in surface marker expressions could be detected 
among other aged Notch2IC//CD19Cre+/- mice, not yet tested for tumor development by Southern 
blot analysis, starting at 15-16 months and aggravating with age (data not shown). In contrast to 
Notch2IC//CD19Cre+/- animals, control mice showed no drastic aging-induced changes in CD21, 
CD23, IgM, IgD or B220 expression (Fig. 58B, #7576 as example). Only the two mice (#353 and 
#7461), which developed tumors, exhibited clear alterations (Fig. 58B, #7461 as example). Both mice 
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exhibited an expansion of  an IgMhigh IgDlow B cell population in the spleen. In addition the typical 
CD21high CD23low MZ B cells could not be detected anymore. Fo B cells, however, could be detected 
at normal frequencies and expressed normal CD21, CD23, IgM, IgD levels in these two animals. The 
expanded IgMhigh IgDlow population was also detectable in the bone marrow of  these two mice (Fig. 58B, 
#7461), suggesting that tumor cells had spread into other organs. In summary, present results from 
our analyses indicate that constitutive Notch2IC expression might drive lymphoma development, but 
only with a late onset and long latency. It further seems that B cells of  Notch2IC-expressing mice aged 
15 months and older exhibit changes (especially downregulation) in their surface marker expression 
irrespective of  tumor development. This fact together with the observation that tumor development 
was not always correlated with increased splenic weight or stronger signs of  sickness in mice, suggest 
that Southern blot analyses are necessary to be able to judge possible tumor development. Collectively, 
our data indicates that constitutive Notch2IC-expression is not a strong oncogen in B cells.
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Figure 58 (depicted on previous page): Results of representative FACS analyses, depicting splenic cells of 
aged Notch2IC//CD19Cre+/- and control mice. Cohorts of Notch2IC//CD19Cre+/- (Notch2IC) and control mice 
(CD19Cre) were aged up to 22 months. Mice were analysed when showing first signs of illness. Splenic cells 
were subsequently isolated and analysed via FACS analyses for their CD21, CD23, IgM, IgD and B220 expression. 
Depicted dot plots are gated as indicated on lymphocytes, B220+ (in controls) or hCD2+ cells (in Notch2IC//
CD19Cre+/-). Animals marked in red displayed additional bands, animals marked in green no additional bands in 
Southern blot analysis. Mice marked in black were not tested by Southern blot. (A) Dot plots display results of FACS 
analyses of four exemplary animals representing results of all analysed Notch2IC//CD19Cre+/- mice aged up to 22 
months. Histograms show overlays of B220 levels of splenic lymphocytes and IgM+ splenic cells of old and young 
Notch2IC//CD19Cre+/- and control mice with and without additional bands in Southern blot analysis. (B) Results of 
FACS analyses of two exemplary control animals representing results of all analysed control mice aged up to 19 
months. Sp (spleen), BM (bone marrow), LN (lymph nodes), n.d. (not determined).
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4. Discussion
Notch receptors play crucial roles during various developmental steps in many different tissues. In 
lymphocytes mainly Notch1 and 2 are expressed, with Notch1 being necessary for T cell development 
(Han et al., 2002; Radtke et al., 1999; Pui et al., 1999), while Notch2 is essential for MZ B cell 
differentiation (Saito et al., 2003). Mutations concerning the Notch receptors in general have been 
shown to be implicated in the development of  various tumors. Constitutive active Notch1 is especially 
transforming for T cells, but also Notch2 and 3 signalling have been shown to induce T cell leukemias 
(Tzoneva and Ferrando, 2012; Pui et al., 1999; Bellavia et al., 2000; Rohn et al., 1996). However, Notch  
mutations have recurrently also been found in several B cell lymphomas. Especially, alterations in 
the notch2 gene, resulting in an enhancement of  the corresponding signalling pathway, are the most 
frequent ones found in splenic marginal zone lymphomas (SMZL) (Troen et al., 2008; Kiel et al., 
2012; Rossi et al., 2012) as well as diffuse large B cell lymphoma (DLBCL) (Lee et al., 2009) and seem 
to be relatively specific for these type of  tumor as they are absent from other B cell lymphomas. To 
investigate the role of  Notch2 signalling in B cell activation and immune responses as well as the role 
of  a constitutively active Notch2 signal on lymphoma development, two conditional transgenic mouse 
strains, allowing a Cre/loxP-dependent expression of  a truncated Notch2 receptor (Besseyrias et al., 
2007) or the ligand-independent expression of  the intracellular part of  Notch2 (Notch2IC) (Hampel 
et al., 2011) were used. In addition, I attempted at distinguishing direct Notch2 effects on the MZ B                
cell phenotype from those supplied by the marginal zone.
4.1 Gene expression profiles of  Notch2IC-expressing MZ B 
and Notch2-deficient Fo B cells resemble their wild type 
counterparts, yet still exhibiting clear differences
Notch2 deficiency such as in Notch2fl/fl//CD19Cre+/- mice leads specifically to the absence of  MZ 
B cells, while a constitutively active Notch2 pathway results in an expansion of  this cell population 
within the MZ even in the absence of  the BCR co-receptor CD19, normaly important in MZ B cell 
development (Besseyrias et al., 2007; Hampel et al., 2011). Furthermore, Notch2 could directly or             
indirectly also be implicated in providing MZ B cells with localisation and retention signals for the 
MZ (Tan et al., 2009; Simonetti et al., 2013). In previous experiments we could already show that 
Notch2-deficient Fo B cells as well as Notch2IC-expressing MZ B cells resemble their respective wild 
type counterparts with respect to their localisation and known typical surface marker expression. In 
addition, Notch2IC-expressing B cells also exhibited a pre-activated state, characterised by enhanced 
proliferation and the expression of  activation markers (Hampel et al., 2011). To dissect in detail the         
differences in gene expression profiles between Notch2-deficient and wild type Fo B cells as well as 
between Notch2IC-expressing and wild type MZ B cells, and to possibly differentiate between Notch2 
target genes and those induced by the respective environment, we performed whole mouse-genome 
gene expression profiling using Illumina BeadChip microarrays. Hierarchical clustering analysis revealed 
that independent of  constitutive Notch2 expression or ablation, MZ B cells and Fo B cells primarily 
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grouped according to their cell-type identity. �et, already on the next subjacent clustering level, four 
clusters could be separated from each other: one cluster comprising wild type MZ B cells clearly 
separated from the one containing Notch2IC-expressing MZ B cells, in addition, a wild type Fo B 
cell cluster and a cluster containing Notch2-deficient Fo B cells. Several aspects of  these observations 
demonstrate the good quality of  our microarray results. Firstly, we could not observe any further 
outliers apart from the two, which already completely dropped out during quality controls, hence 
before further data analyses. Secondly, the appearance of  three instead of  two clusters among Fo B 
cell populations could clearly be attributed to a mild amplification bias, which was considered in all 
subsequent analyses. And finally, gene expression profiles of  Notch2IC-expressing and wild type MZ 
B cells strongly resembled each other, which is in accordance with the previously discovered similarities 
among both cell types (Hampel et al., 2011). Accordingly, obtained lists containing differentially         
regulated genes reflect “real”, technically unbiased differences in expression. Apart from the quality 
control, hierarchical clustering in line with PCA and Volcano plot analyses revealed that Fo B and MZ 
B cells greatly differ in their gene expression profiles. Furthermore, wild type and Notch2-deficient Fo 
B cells are more closely related to each other compared to wild type and Notch2IC-expressing MZ B 
cells. Still, constitutive Notch2IC-expression or Notch2 ablation resulted in clear differences in gene 
expression profiles of  these cells compared to their respective wild type counterparts. In PCA, wild 
type MZ B cell samples in fact seemed slightly more scattered than the other groups. This might be 
due to mild, negligible contaminations with dead cells or other cell populations. Those contaminations 
become more noticable and hence carry more weight in data of  small, sort-purified populations, 
such as 5 % of  total B cells for wild type MZ B cells, in comparison to data from sort-purifications 
of  big populations. Accordingly, this could result in a greater variance among wild type MZ B cell 
data, appearing as if  Notch2IC-expressing and wild type MZ B cells are less similar than wt and 
Notch2-deficient Fo B cell populations. However, we think that these possible, slight contaminations 
only affect comparisons of  wild type MZ B cell samples among each other, than the relation to the 
other analysed cell populations. The fact that wild type MZ B cells are still clearly a group on their 
own underpinnes this argument. Results from hierarchical clustering, PCA and Volcano plot analyses 
suggest that in contrast to Notch2-deficient Fo B cells, wild type Fo B cells apparently still get some 
Notch2 signal, as some markers typical for MZ B cells and thus possibly Notch2 target genes were 
upregulated in wild type versus Notch2-deficient Fo B cells. So, it could either be that all Fo B cells 
get a very weak Notch2 signal or that only few Fo B cells get a normal Notch2 signal. We think that 
the second scenario is more likely, as CD21 is a Notch2 target (Strobl et al., 2000) and only few 
wild type Fo B cells are CD21high and hence receive most likely a Notch2 signal. The just mentioned 
CD21high population could also represent Fo II B cells (pre-MZ B cells) (Cariappa et al., 2007a), which 
consequently have Notch2 signalling. �et, as this CD21high wild type Fo B cell population is very small 
only genes strongly regulated by Notch2 signalling emerge in our microarray gene lists. On the other 
hand it seems that even wild type MZ B cells do not permanently get a strong Notch2 signal as it 
is the case for Notch2IC-expressing B cells. However, the number of  differentially regulated genes 
suggested that wild type Fo B and Notch2-deficient Fo B cells are more closely related to each other 
than those of  Notch2IC-expressing and wild type MZ B cells. One reason accounting for differences 
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among the MZ B cell populations might be that in Notch2IC//CD19Cre+/- mice Notch2 expression 
is independent of  Dll1 binding, while wild type MZ B cells have to compete for Dll1, as its expression 
is quite restricted in wild type spleens (Sheng et al., 2008; Tan et al., 2009). Another possibility could be            
that Notch2 signalling is much stronger in Notch2IC-expressing cells than in wild type MZ B cells as 
the Notch2IC transgene is placed under the very strong CAGGS promoter. The fact that known MZ 
B or Fo B cell markers were clearly up- or downregulated in the respective analysed populations again 
affirmed the good quality of  our microarrays. Among those were the characteristic MZ B cell surface 
and activation markers CD9, CD1d, CD21, CD86 and CD38 as well as CD23, which is a typical 
marker for Fo B cells. Known direct Notch2 targets such as members of  the Hes, Hey and Deltex 
family were clearly upregulated in Notch2IC-expressing MZ B cells versus wild type ones. Many MZ B 
cell markers were further upregulated by Notch2IC expression and some of  them were downregulated 
in Notch2-deficient compared to wild type Fo B cells. All these findings led us to the assumption that 
our gene lists are a quite promissing source to identify further currently still unknown candidate genes 
that are regulated by Notch2 signalling and not by the MZ environment. Thus, these gene lists can 
be used to get deeper insights into Notch2 target genes implicated in MZ B cell differentiation and 
immune responses. 
4.2 Notch2IC-expressing B cells show enhanced proliferation 
mainly due to their MZ B cell phenotype
Cell cycle analyses of  directly ex vivo isolated splenic B cells revealed that more Notch2IC-expressing 
B cells were in S or G2/M phase compared to control B cells from CD19Cre+/- mice (Hampel et 
al., 2011). However, these differences were only small. No differences could be detected among 
survival curves of  unstimulated Notch2IC-expressing and control B cells over three days of  in vitro 
culture and in accordance with this, proliferation experiments using carboxyfluorescein succinimidyl 
ester (CFSE) performed on day three of  unstimulated in vitro cultures also displayed only slightly 
increased proliferation rates in Notch2IC-expressing versus control B cells (Hampel et al., 2011). On     
the other hand, similar CFSE experiments with LPS- and α-CD40-treated, in vitro cultured B cells 
clearly demonstrated that, compared to control B cells, proliferation was much stronger in Notch2IC-
expressing cells after stimulation. MZ B cells are well-known to have a pre-activated phenotype and 
to rapidly start proliferating after LPS stimulation or CD40 ligation (Gunn and Brewer, 2006; Oliver 
et al., 1999b; Thomas et al., 2007; Hampel et al., 2011). Hence, since in these previous experiments 
Notch2IC-expressing B cell populations - including ~80 % MZ B cells - were always compared to total 
splenic B cells from control mice with only ~5 % MZ B cells, it was not clear whether the investigated 
strong increase in proliferation was only a typical, natural MZ B cell phenotype or an additional effect 
of  constitutive Notch2 signalling. By performing CFSE proliferation experiments using sort-purified 
wild type and Notch2IC-expressing MZ B cells, which were cultured with LPS or α-CD40 for 2.5 
days, I could show that stimulated Notch2IC-expressing MZ B cells had quite similar or marginally 
enhanced proliferation potentials than similarly treated control MZ B cells. These results indicated 
that the strongly enhanced cell division rate specifically after stimulation is indeed mainly a typical 
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MZ B cell phenotype. Moreover, the experiment showed that Notch2IC expression has reinforcing 
effects on cell proliferation. The enhanced proliferation potential detectable when comparing LPS- or 
α-CD40-stimulated wild type and Notch2IC-expressing MZ B cells is in agreement to data analysis 
of  our Illumina BeadChip arrays. Annotation cluster analyses comparing differentially regulated genes 
between wild type and Notch2IC-expressing MZ B cells revealed enriched biological terms such as 
“positive regulation of  B cell/lymphocyte proliferation” indicating that constitutive Notch2 signalling 
might additionally slightly enhance intrinsic, natural proliferation potentials of  MZ B cells. The reason 
why in CFSE experiments we could only detect small increases in proliferation rates of  Notch2IC-
expressing compared to control MZ B cells could stem from the fact that Notch2 is not only inducing 
proliferation, but at the same time also apoptosis. Hence, the biggest part of  Notch2IC-expressing 
cells was already dead when proliferation experiments were performed so that possible differences 
were underestimated. In line with this theory, annotation cluster analyses performed on our microarray 
data, provided enriched terms such as “cell death” or “apoptosis” for the comparison of  MZ B and 
Fo B cells in general but also for wild type versus Notch2IC-expressing MZ B cells. Furthermore, 
previous data of  our group, showing that Notch2IC indeed drives EBV-transformed B cell lines into 
cell cycle, but at the same time also induces the expression of  pro-apoptotic genes, is also in agreement 
with the proposed model (Kohlhof et al., 2009). In addition, cell cycle experiments undertaken by           
A. Draeseke, another former member of  our group, showed that until day two of  in vitro culture 
unstimulated Notch2IC-expressing B cells had a distinctly greater cell division rate than control B cells. 
However, on day three most of  the Notch2IC-expressing cells were dead, suggesting again that B cells 
constitutively expressing Notch2IC proliferate faster but also attain an apoptotic state more rapidly. 
When these experiments were performed with B cells expressing not only constitutive Notch2, but 
additionally also a ligand-independent, constitutively active CD40 receptor, this premature induction 
of  apoptosis could be inhibited, while at the same time enhanced proliferation rates were maintained 
(A. Draeseke, PhD thesis). And last but not least, in vitro cultured Notch2IC-expressing cells were 
apparently more rapidly consuming nutrients within cell culture media (identified by means of  yellow 
coloured medium) possibly due to this higher rate of  proliferation, implicating that the maximum 
division rate achievable in vitro was possibly already reached (personal observation). Accordingly, it 
could be that in vivo, Notch2IC-expressing B cells only have slightly elevated cell division rates, but 
that these rates further increase as soon as co-stimulatory factors such as CD40 or BAFF are present 
or when Notch2IC-expressing cells are taken out of  their natural environment. Hence, it could well be 
that CFSE proliferation analyses of  LPS- or α-CD40-stimulated MZ B cells performed already after 
one or two days in vitro would result in an even stronger difference in the proportion of  cell divisions 
in stimulated Notch2IC-expressing compared to control MZ B cells. And finally, this data could also 
indicate that Notch2 induced proliferation is in large part somehow contained in vivo, possibly by the 
MZ environment.
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4.3 Increased Erk, Jnk, Akt levels in Notch2IC-expressing MZ 
B cells in vivo
In former experiments we could already clearly show that Notch2 is instructive for MZ B cell 
development even in the absence of  the BCR co-receptor CD19 (Hampel et al., 2011), which has 
been shown to impact on MZ B cell differentiation (Engel et al., 1995; Rickert et al., 1995; Martin 
and Kearney, 2000). Thus, Notch2IC//CD19Cre+/+ mice, whose CD19 locus is disrupted due to 
the insertion of  the Cre recombinase into both alleles, displayed a similar phenotype as Notch2IC//
CD19Cre+/- animals, including increased activation of  the MAP kinases Erk and Jnk (Hampel et al.,   
2011). In this work we additionally demonstrated that constitutive Notch2 signalling could not only             
overcome the MZ B cell deficiency induced by a CD19 knockout, but that B cells of  Notch2IC//
CD19Cre+/+ mice exhibited enhanced PI3K/Akt signalling in comparison to respective control B 
cells. This was surprising as CD19 is known to be a major trigger of  this signalling pathway (Buhl 
et al., 1997; Carter et al., 1997; Otero et al., 2001) and CD19-deficient mouse splenic B cells display 
reductions in Akt signalling (Otero et al., 2001). In B cells of  Notch2IC//CD19Cre+/- animals, levels 
of  pAkt and its targets pp70 (pS6K) and pGSK-3 were higher compared to control cells, while FoxO1 
protein levels, which are negatively regulated by Akt signalling were decreased. All of  these findings 
clearly pointed at an enhanced PI3K/Akt signalling in Notch2IC-expressing cells. In addition greater 
amounts of  Tcl1B, a co-activator of  Akt, could also be detected. However, expression levels of  PTEN, 
known to negatively regulate the PI3K/Akt pathway, were also enhanced by constitutive Notch2 
signalling. Most likely the overall turnover of  the whole PI3K/Akt pathway is amplified in MZ B cells 
and thus, also the amounts of  members of  counterregulatory mechanisms are increased ensuring that 
PI3K signalling is not continuously active and thus overshooting. pAkt, pp70 (pS6K) and pGSK-3 
levels in B cells of  Notch2IC//CD19Cre+/+ mice were also clearly increased compared to cells of  
CD19Cre+/+ controls, suggesting that Notch2IC expression fully rescues defects in PI3K signalling of  
CD19-deficient cells. Yet, expression levels of  FoxO1 and PTEN show that the rescue is only partial. 
It is not clear how PI3K/Akt signalling is induced by constitutive Notch2 signalling in the absence 
of  a CD19 receptor. One possibility could be that Notch2 is somehow directly exerting influence on 
members of  this pathway, as ligand-dependent activated NotchIC has already been shown to induce 
phosphorylation of  Akt via the mTOR-RICTOR complex (Perumalsamy et al., 2009). Another     
possibility could be that it increases the expression of  G-protein coupled receptors and/or integrins 
on the surface of  MZ B cells, which then in turn could take over the downstream activation of  PI3K/
Akt activation. One candidate mediating PI3K signalling might be the S1PR3 receptor, which was 
clearly upregulated by Notch2 in our microarray when comparing wild type and Notch2IC-expressing 
MZ B cells and which has been shown to be able to induce PI3K (Takuwa et al., 2011). As integrins      
are also known to act upstream of  the CD19 co-receptor and to activate PI3K signalling (discussed 
in Pillai and Cariappa, 2009), we checked for genes encoding integrins that exhibited upregulation 
by Notch2 in our microarrays. Preliminary analysis already revealed a couple of  candidates such as 
Itga10 and Itgae on our gene list comparing wild type and Notch2IC-expressing MZ B cells. Not 
only the phosphorylated forms of  Akt and the Akt targets p70 and GSK-3 were increased but also 
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their basal protein levels. Since we did not find enhanced levels of  PI3K members, such as Akt and 
Akt target genes in our microarray experiments, we suggest that these proteins are regulated on a 
posttranscriptional level. Apart from these findings, we could also demonstrate that pErk, pJnk and 
pAkt levels of  ex vivo isolated Notch2IC-expressing cells were similar to those found in ex vivo isolated 
wild type MZ B cells and that both expressed increased levels compared to Fo B cells. It has already 
been shown that MZ B cells exhibit increased Akt phosphorylation (Meyer-Bahlburg et al., 2009). We     
could add to this finding that also the MAPK Erk and Jnk display increased phosphorylation in MZ B 
cells further underlining their hyper-activated state. By cultivating Notch2IC-expressing and control B 
cells in vitro, we tested whether the expression of  MZ B cell surface markers and the increased activity 
of  signalling pathways is mediated by the expression of  Notch2IC or the MZ environment. Although 
in vitro cultured Notch2IC-expressing B cells were able to maintain the expression of  typical MZ B 
cell surface markers, they rapidly lost enhanced Erk, Jnk and PI3K/Akt levels, with greatest reductions 
in Erk and Jnk, suggesting that the natural environment of  the MZ is providing additional signals 
resulting in greater amounts of  the MAP kinases Erk and Jnk as well as Akt. 
4.4 Notch2IC-expressing MZ B cells spontaneously differentiate 
to functional, antibody-secreting plasmablasts/plasma cells 
in vitro, but not in vivo
Next to their established important role in T cell-independent immune responses and their 
characteristic property to rapidly differentiate to antibody-secreting plasma cells (Martin et al., 2001), 
MZ B cells represent a major source of  natural, mostly IgM antibodies (Holodick et al., 2014; Casali     
and Schettino, 1996; Cerutti et al., 2013). �et, although Notch2IC//CD19Cre  +/- mice have highly 
increased numbers of  MZ B cells, no increased frequencies of  plasma cells could be detected in vivo 
in unimmunised animals. This was in accordance with previous already published experiments of  
our group, illustrating that basal antibody titers of  unimmunised Notch2IC//CD19Cre+/- mice were 
similar to those in control animals, except IgG3 titers which were surprisingly even reduced (Hampel 
et al., 2011). However, when taken into in vitro culture without any stimulation, Notch2IC-expressing           
cells spontaneously started to differentiate into antibody-secreting plasmablasts or plasma cells with 
highest frequencies reaching up to 30 % in unstimulated cells at day two. LPS stimulation did not further 
enhance this differentiation, but frequencies were still a lot larger than in LPS-treated control B cells. 
We found that when LPS-stimulated control and Notch2IC-expressing B cells as well as unstimulated 
Notch2IC-expressing cells were additionally treated with α-CD40, no or reduced plasmablast/plasma 
cell formation could be detected. This is in line with a previous observation demonstrating that ligation 
of  the TNF receptors CD40 and CD27 inhibits terminal differentiation of  plasma cells via Jnk and 
in part also via Erk (Satpathy et al., 2010). Secreted IgM titers found within cell culture supernatants            
and the amount of  antibody-secreting cells detected by ELISPOT analyses largely correlated with the 
amount of  CD138+ B220low cells detected by flow cytometry, confirming their plasmablastic/plasma 
cell phenotype. The reason why secreted IgM titers in supernatants seemed lower than the amount 
expected from the great number of  IgM-secreting cells detected by ELISPOTs, could be rooted in the 
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fact that CD138+ B220low cells possibly contain many pre-plasmablasts, which are IgM+, but do not yet 
secrete large amounts of  antibodies. MZ B cells are known to carry polyreactive BCRs (Bendelac et al.,            
2001). So, as these strong signals in IgM-specific ELISPOT analyses were obtained in immunsied as              
well as in unimmunised Notch2IC-expressing mice, this could be a typical feature of  MZ B cells, which  
remains unnoticed in analyses with wild type B cells, as MZ B cell populations are underrepresented. 
Another possibility is that the induction of  constitutive Notch2 signalling already in late stages of  B 
cell development in the BM, leads to a slightly premature migration of  MZ B cells out of  the BM and 
into the MZ, thereby possibly skipping terminal V(D)J recombination events, thus leading to MZ B 
cells which carry a BCR which exhibits even stronger polyreactivity than a normal MZ B cell BCR 
would do. To clarify this, ELISPOT analyses need to be performed with sorted wild type MZ B cells 
and Notch2IC-expressing cells. In summary, these first experiments indicate that Notch2IC-expressing       
MZ B cell have an intrinsic potential to spontaneously differentiate to functional, antibody-secreting 
plasmablasts or plasma cells as soon as they are taken out of  their natural MZ environment. The 
fact that Notch2IC-expressing B cells do not spontaneously differentiate to plasma cells in vivo, but 
exhibit enhanced plasmablast/plasma cell differentiation after ex vivo isolation even in the absence 
of  stimulation suggests that the MZ forms an inhibitory environment for plasma cell differentiation. 
This is in accordance with observations that after antigen encounter, activated MZ B cells can only 
develop to fully mature plasma cells when they are able to migrate into the follicle and subsequently 
out into the red pulp (Shapiro-Shelef  and Calame, 2005; Sze et al., 2000). MZ B cells are known to 
shuttle continuously between the MZ and the follicle. The key mechanism underlying this shuttling is 
the alternating up- and downregulation of  the S1PR1, another important signal mediating the correct 
localisation of  MZ B cells (Arnon et al., 2013). There are indications that Notch2 signalling could be            
essential for MZ B cells to be able to migrate and to localise within the MZ (Simonetti et al., 2013).    
Consequently we think that constitutive Notch2 signalling interferes with the migration capacity of  
MZ B cells, thereby possibly retaining MZ B cells within the MZ and subsequently inhibiting their 
spontaneous development into plasma cells. Possible candidates underlying this inhibition could be 
various integrins, chemokines or other molecules/receptors shown to be implicated in the retention 
of  MZ B cells within the MZ. S1PR3 and CB2 for example could be interesting candidates, because 
firstly they were among the genes in our microarray differentially upregulated by Notch2 and secondly, 
S1PR3 and CB2 have been shown to be at least in part involved in the migration of  MZ B cells to 
the MZ and their retention in it (Muppidi et al., 2011; Cinamon et al., 2004). S1PR3 has in addition            
been shown to be the key chemotactic receptor in B cells responsible for the migration towards S1P 
(Cinamon et al., 2004) and CD27 or CD40 are both TNFR known to inhibit plasma cell development 
(Satpathy et al., 2010). 
Additional experiments using sort-purified MZ B cells indicated that the spontaneous plasmablast/
plasma cell differentiation of  Notch2IC-expressing MZ B cells in vitro is in some way triggered 
and/or accelerated by constitutive Notch2 expression and not just a natural, instrinsic MZ B cell 
feature, as unstimulated wild type MZ B cells did not develop into plasma cells unless stimulated with 
LPS. Nonetheless, as antigen-activated B cells first of  all undergo a burst of  proliferation, before 
differentiating into plasma cells (Shapiro-Shelef  and Calame, 2005), one could assume that strong 
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proliferation is a prerequisite for subsequent plasma cell differentiation. Knowing this, one cannot 
completely rule out that wild type MZ B cells also have the intrinsic potential for spontaneous plasma 
cell differentiation in vitro, but as their proliferation capacity is possibly lower as the one in Notch2IC-
expressing MZ B cells, plasmablasts or plasma cells would arise belatedly. Thus, it could be that 
plasmablast/plasma cell development in unstimulated Notch2IC-expressing B cells is an indirect 
effect of  enhanced proliferation, which in consequence could lead to a premature induction of  plasma 
cell differentiation. In contrast to in vitro cultured total B cell populations, sort-purified, LPS-treated 
Notch2IC-expressing cells exhibited a greater CD138+ B220low population on day two of  in vitro culture 
than those without stimulation. It could be that the stressfull sort procedure is delaying the onset of  
proliferation and differentiation as it takes some time for the cells to recover. The higher percentage 
of  plasma cells in LPS-treated than in untreated Notch2IC-expressing B cells, might indicate that LPS 
stimulation further accelerates plasma cell differentiation of  Notch2IC-expressing B cells. Hence, the 
peak of  plasma cell development within LPS-treated Notch2IC-expressing B cells might have been 
missed in previous experiments with unsorted cells. The finding that antibody titers in cell culture 
supernatants were quite similar between unstimulated and LPS-treated Notch2IC-expressing B cells 
further confirms this theory. Hence, further experiments are planned in which Notch2IC-expressing 
B cells are cultured in the presence of  LPS and possible plasma cell development is checked at various 
time points (after 24 h, but before 48 h of  culture) via flow cytometry to be able to assess the peak in 
plasma cell differentiation under these circumstances. 
Blimp-1 as well as Irf4 are both transcription factors, which are essential for and strongly upregulated 
during plasma cell development (Shapiro-Shelef  and Calame, 2005). Hence, analyses on the Blimp-1 
and Irf4 expression levels during in vitro cultures not only additionally underpinned the plasmablast/
plasma cell phenotype of  the CD138+ B220low B cell population arising in Notch2IC-expressing cells, 
but also gave deeper insights into the course of  its development under various conditions. Ex vivo 
isolated Notch2IC-expressing MZ B cells had clearly increased Blimp-1 and Irf4 levels compared 
to wild type Fo B cells and even higher levels of  Irf4 than wild type MZ B cells. Blimp-1 amounts 
were similar or marginally increased in Notch2IC-expressing cells compared to wild type MZ B cells, 
which is in accordance with data from Fairfax and colleagues, showing that only a small subset of  
wild type MZ B cells expresses low but detectable levels of  Blimp-1, which are higher than those 
of  splenic Fo B cells (Fairfax et al., 2007). Wild type MZ B cells are known to be in a pre-activated                
state to be able to rapidly respond to pathogens by quickly differentiating into plasma cells (Martin et  
al., 2001). The increased levels of Blimp-1 and Irf4 already in ex vivo isolated Notch2IC-expressing             
cells compared to wild type MZ B cells could be an explanation why Notch2IC-expressing cells are 
so fast at spontaneously differentiating into antibody-secreting plasmablasts/plasma cells in vitro. 
The observation that in those highly pre-activated Notch2IC-expressing MZ B cells, Irf4 levels 
exhibited stronger increases than Blimp-1 levels compared to wild type MZ B cells, was in accordance 
with literature showing that the onset of  Irf4 expression during B cell activation and subsequent 
plasma cell development is much earlier than the one of  Blimp-1 (Oracki et al., 2010). Furthermore,     
it could be that Irf4 is directly regulated by Notch2 and hence strongly upregulated in Notch2IC-
expressing MZ B cells. In agreement with the fact that Notch2IC-expressing cells differentiate into          
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plasmablasts/plasma cells more rapidly, an extremely fast upregulation of  Blimp-1 and Irf4 could 
be detected in cultures of  unstimulated Notch2IC-expressing cells, peaking at day two concomitant 
with highest plasma cell/plasmablast frequencies. In control B cells, such a distinct rise in Blimp-
1 and Irf4 levels could only be detected in LPS-treated cultures. Here, expression levels peaked at 
day three, again in accordance with highest percentages of  plasma cells. �et, Notch2IC-expressing 
cells were faster (highest levels on day two) compared to LPS-treated control cells (highest levels on 
day three). Although unstimulated Notch2IC-expressing cells always exhibited highest plasma cell or 
plasmablast frequencies on in vitro day two, the course of  Blimp-1 and Irf4 expression levels in LPS-
treated cells suggests that Notch2IC-expressing B cells are differentiating even more rapidly to plasma 
cells/plasmablasts with LPS stimulation and that similar or even greater amounts of  plasma cells/
plasmablasts than in unstimulated cells would have been detectable after 1.5 days of  in vitro cultures, 
a time point which we did not yet analyse. 
To find out which signalling pathways are responsible for driving or inhibiting plasma cell differentiation 
we analysed Western blot analyses originally performed to investigate MAPK and PI3K signalling in 
B cells during in vitro culture. We could see that in in vitro cultures of  LPS-treated control cells as 
well as of  unstimulated and LPS-stimulated Notch2IC-expressing cells, in which plasmablast/plasma 
cell populations appeared, pJnk levels - predominantly pJnk2 - were always downregulated compared 
to ex vivo levels. This indicates that pJnk needs to be downregulated for plasma cell development. 
pErk levels on the other hand were also strongly downregulated in unstimulated and LPS-stimulated 
Notch2IC-expressing cells, whereas in LPS-treated control B cells they were upregulated compared 
to ex vivo levels. However, these seemingly contradictory findings are in accordance with results from 
other research groups, showing that apparently Erk signalling is differentially regulated in LPS-treated 
and GC B cells. In GC B cells, which are mainly derived from Fo B cells the activation of  Erk1 and 
2 after BCR ligation leads to the induction of  Blimp-1 and the appearance of  plasma cells (�asuda et  
al., 2011). �et, continuous Erk activation via chronic BCR activation for example, possibly mimicking            
self-reacting B cells, inhibited LPS-induced plasma cell development (Rui et al., 2006; Rui et al., 2003).        
Hence, it might be that in cultures of  control B cells, which mainly consist of  Fo B cells with low 
pErk levels, LPS-stimulation is able to enhance Erk signalling. In contrast, in cultures of  Notch2IC-
expressing cells, mainly comprising MZ B cells, which already exhibit high pErk levels, LPS treatment 
leads to a downregulation of  Erk signalling. In summary, we suggest that high levels of pErk and pJnk       
naturally occuring in MZ B cells are inhibitory for plasma cell differentiation and probably need to 
be downregulated during TI immune responses. α-CD40 stimulation strongly inhibited plasmablast 
differentiation in Notch2IC-expressing B cells, indicating that TNF receptor signalling could also be 
involved in the inhibition of  plasma cell differentiation occuring in the MZ. By applying different 
small chemical inhibitors Satpathy and colleagues could already show that CD40 inhibits terminal 
plasma cell differentiation via Jnk and partially also via Erk. In accordance, we could observe that 
α-CD40-treated Notch2IC-expressing and control B cells exhibited highest levels of  phosphorylated 
Erk and Jnk again indicating that elevated amounts of  pErk and pJnk - in this case induced by α-CD40 
treatment - are responsible for the hampered plasmablast development. The contribution of  NF�B 
signalling in the inhibition or induction of  plasma cell differentiation still needs to be determined. 
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Similar experiments with short-term stimulations of  only a few hours are planned to analyse initial 
changes in signalling pathways as soon as cells are taken out of  their environment and treated with 
different stimuli (Satpathy et al., 2010).
4.5 Notch2IC//CD19Cre+/- mice are impaired in their TI 
immune response, antigen capturing and the subsequent 
transport into the follicle
MZ B cells are well established as key players in TI immune responses (Martin et al., 2001). �et, although 
Notch2IC-expressing MZ B cells exhibit a pre-activated phenotype and have the intrinsic potential for 
spontaneous plasmablast development, which is somehow inhibited in vivo, we were quite surprised 
to discover that after immunisation with the TI-2 antigen NP-Ficoll, or with low concentrations of  
the TI-1 antigen NP-LPS, Notch2IC//CD19Cre+/- mice had clearly reduced antigen-specific IgM 
and IgG3 titers, implicating that they were impaired in their TI-2 and partially also in their TI-1 
immune response. Immunisation with high amounts of  NP-LPS (50 µg) however, revealed no defects 
in the antigen-specific IgM response, but a reduction in NP-IgG3 titers, pointing at additional, specific 
problems in isotype switching. We think that one aspect contributing to the hampered TI immune 
reactions is, that constitutive Notch2 signalling impacts on the migration capacity of Notch2IC-         
expressing MZ B cells. Treating mice with LPS (i.p.) is known to induce the clearance of  the MZ five 
to six hours post injection (Cinamon et al., 2004). In wild type mice, concentrations as low as 5 µg still               
led to a complete relocalisation of  all MZ B cells into the follicle. In contrast to this, nearly complete 
clearance could only be achieved with 50 µg NP-LPS in Notch2IC//CD19Cre+/- mice and diminished 
with declining amounts of  injected LPS. This data clearly points to a defect in stimulation-induced 
migration of  Notch2IC-expressing MZ B cells. In agreement with experiments showing that S1PR1, 
which is implicated in the positioning of  MZ B cells in the MZ, is downregulated in response to LPS 
(Cinamon et al., 2004), these data suggest that, under normal conditions, TI antigens, which activate MZ 
B cells induce a downregulation of  certain localisation signals so that MZ B cells are able to move into 
the follicle and then into the red pulp to develop to fully mature plasma cells (Hargreaves et al., 2001).    
We propose that in Notch2IC//CD19Cre+/- mice, constitutive Notch2 signalling forces MZ B cells to 
stay within the MZ by inhibiting the downregulation of  such localisation signals. Immunisations with 
the TI-2 antigen NP-Ficoll only activate MZ B cells carrying an antigen-specific BCR. Thus, treating 
Notch2IC//CD19Cre+/- with this rather “weak” antigen is possibly not strong enough to overcome 
Notch2IC-induced MZ localisation signals. Consequently, MZ B cells cannot further develop to 
plasma cells and immunised mice cannot build up a functional response to this sort of  antigens. High 
concentrations of  NP-LPS, on the other hand, strongly activate nearly all MZ B cells in a polyclonal 
fashion as they interact with the BCR and TLRs, irrespective of  their antigen-specificity. In addition, 
as already mentioned before, LPS induces a drastic downregulation of  the S1PR1, normaly implicated 
in positioning MZ B cells in the MZ (Cinamon et al., 2004). Hence, it could be that changes induced           
by high concentrations of  “strong” antigens such as NP-LPS are sufficient to overcome localisation 
signals induced by Notch2IC and that in these circumstances Notch2IC-expressing MZ B cells would 
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indeed be able to differentiate into plasma cells, although constitutive Notch2IC expression might still 
interfere with isotype switching. Constitutive Notch2 signalling might also inhibit the natural shuttling 
of  MZ B cells in and out of  the MZ, although this still needs to be investigated.
Another explanation for the hampered TI immune responses comes along with our finding that 
SIGN-R1+ macrophages, known to be implicated in antigen capturing and presentation to MZ B cells 
(Kang et al., 2004; Kang et al., 2006; Lanoue et al., 2004) are reduced and scattered in Notch2IC//
CD19Cre+/- mice. Hence, only few TNP-Ficoll antigen is captured within the MZ and in line with 
the defective migration potential of  Notch2IC-expressing MZ B cells, absolutely no transport of  
antigen into the follicle could be detected five hours post in�ection. So it could be that reduced antigen 
capturing due to reduced SIGN-R1+ macrophages in combination with a defective antigen-induced 
MZ B cell migration into the follicle are the cause for the reduced immune reponse to the TI-2 antigen 
NP-Ficoll. However, recent publications challenge the contribution of  SIGN-R1+ macrophages in 
TI immune responses. Aichele and colleagues could show that no antigen capturing was taking place 
when they depleted the MZ of  its macrophages. Even so, a protective T cell response was induced 
in these animals (Aichele et al., 2003). Moreover, Kraal and colleagues could prove that the depletion             
of  MZ macrophages did not impact on the immune response to NP-Ficoll (Kraal et al., 1989). These     
results indicate that the defective migration capacity of  Notch2IC-expressing B cells possibly has a 
greater impact on the defective TI-2 immune response than the reduction in SIGN-R1+ macrophages. 
As LPS seems more suitable to overcome the forced MZ localisation, it would be interesting to 
investigate, whether the transport of  TNP-LPS antigen is still possible in Notch2IC//CD19Cre+/- 
mice. However, the reason how and why constitutive Notch2 expression in B cells impacts on SIGN-
R1+ macrophages remains to be elucidated. So in summary, we propose that Notch2 signalling needs 
to be downregulated - at least for a short term - enabling antigen triggered MZ B cells to migrate into 
the follicle and subsequently into the red pulp to be able to fully differentiate into mature antibody-
secreting plasma cells. Additional experiments using the S1PR1 inhibitor FT�720 are planned to test 
whether MZ B cells can be relocated to the follicle without being triggered by antigens and, if  this is 
the case, to test whether spontaneous plasma cell differentiation can be triggered also in vivo when 
“unactivated” MZ B cells are just forced out of  their natural MZ environment.
4.6 Notch2fl/fl//CD19Cre+/- mice show reduced TI-2 immune 
response, despite intact antigen capturing and transport 
into the follicle
As already discussed before, MZM and MZ B cells seem to cooperate during immune responses. 
SIGN-R1+ macrophages are key players in antigen capturing and presentation within the MZ (Batista 
and Harwood, 2009) and MZ B cells play a decisive role in transporting antigens from the MZ to                
the follicle (Arnon et al., 2013). You and colleagues could show by means of immunofluorescent             
stainings on splenic cryosections that in mice devoid of  MZ B cells, such as in CD19 knockout or 
Notch2-deficient mouse strains, or in animals where MZ B cells were forced out of  the MZ, SIGN-
R1+ macrophages are drastically reduced or missing. Thus, they claimed that the correct localisation of  
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SIGN-R1+ macrophages in the MZ is dependent on the concomitant presence of  MZ B cells within 
this splenic compartment. They also showed that in mice with missing or not correctly located SIGN-
R1+ macrophages, TNP-Ficoll capturing was not detectable by immunofluorescent stainings anymore 
and thus deduced that it is not taking place (�ou et al., 2011; �ou et al., 2009). Therefore, we were           
surprised to see that populations of  SIGN-R1+ macrophages were only slightly - if  at all - reduced 
on splenic cryosections of  Notch2-deficient mice. Besides, antigen capture and transport assays using 
TNP-Ficoll showed that in MZ B cell-deficient Notch2fl/fl//CD19Cre+/- mice, trapping of  TNP-Ficoll 
within the MZ and transporting it into the follicle was still possible to the same extend as in wild 
type animals. The discrepancy between our and the published results are currently unclear. However, 
the still functional TNP-Ficoll trapping in Notch2fl/fl//CD19Cre+/- mice strongly implies that SIGN-
R1+ signals visible on our splenic cryosections are specific and indeed depict functional SIGN-R1+ 
macrophages as otherwise capturing would not be taking place. In accordance with our observations 
were experiments performed by Cinamon and colleagues, which showed that BM chimeras reconstituted        
with S1PR1-deficient fetal liver cells have normal frequencies of  MZ macrophages, although MZ B 
cells are localised within the follicle (Cinamon et al., 2004). �ou and colleagues also mention the fact           
that when CD19 knockout mice age beyond 10 to 12 weeks, some animals begin to accumulate MZ B 
cells and thereby recover their SIGN-R1+ cell population. However, such a rescue of  MZ B cells could 
not be detected in our analysed Notch2-deficient mice. So, altogether we think that Notch2-deficient 
mice still have SIGN-R1+ macrophages and that antigen capturing and transport is still functional in 
these mice. These findings implicate that despite the absence of  MZ B cells, TNP-Ficoll is captured 
and probably transferred from macrophages in the MZ to Fo B cells positioned within the follicle. 
Nevertheless, Notch2fl/fl//CD19Cre+/- mice exhibited reduced antigen-specific IgM and IgG3 plasma 
cell numbers and hence antibody titers in response to TI-2 immunisations with NP-Ficoll. This finding 
is in line with experiments obtained from various mouse models exhibiting defects in their MZ B cell 
population and hence in their TI immune response, thereby underpinning the important role that MZ 
B cells adopt in this type of  immune response (Guinamard et al., 2000; Tanigaki et al., 2002; Sha et al.,           
1995). Yet, on the other hand RBP-J� knockout mice, in which the MZ B cell population is also absent,                  
display a normal immune response to the TI-2 antigen NP-Ficoll (Tanigaki et al., 2002). In these mice 
neither Notch1IC nor Notch2IC can bind to the transcription factor RBP-J� and thus no transcription 
of  Notch target genes takes place. This finding together with recent results of  experiments performed 
in our group (not shown in this work) point at potential different roles of  Notch1 and Notch2 during 
immune responses, especially plasma cell differentiation. Further investigations are currently being 
performed to unravel these different mechanisms. Apart from that, we also want to investigate if  Fo B 
cells in Notch2fl/fl//CD19Cre+/- mice are perhaps after all able to take over the role of  MZ B cells in 
response to NP-Ficoll immunisations, but that reactions are delayed, as Fo B cells are not designated 
to rapidly react to TI antigens. This would explain why antigen-specific titers are so low on day seven 
after immunisation. Currently, immunisation experiments analysing antibody titers 14 days post NP-
Ficoll immunisation are planned to investigate whether the reaction of  Fo B cells to NP-Ficoll in these 
mice is only retarded or indeed permanently reduced due to the lack of  MZ B cells.
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4.7 Constitutive Notch2 signalling is not acting as a strong 
oncogene in B cells, yet it alters the characteristic phenotype 
of  B cells in aging mice
Notch genes belong to the rare gene group that exhibit haploinsufficiency, implicating  that organisms 
are quite sensitive to changes in notch gene dosage. So it is not surprising that most Notch-associated 
malignancies are based on activating mutations of  the corresponding genes. These sort of  mutations 
have also been found in various B cell lymphomas. Since we are working on the role of  Notch2 
signalling in MZ B cell development and lymphomagenesis the following facts were of  special interest 
for us: 30 % of  SMZL exhibit recurrent mutations in the Notch signalling pathway, with the most 
frequent ones being localised in the PEST domain of  the notch2 gene, thereby leading to an increased 
stability of  the receptor and thus to enhanced Notch2 signalling. Hence, we were especially interested in 
whether aging Notch2IC//CD19Cre+/- mice would at some point exhibit signs of  splenic lymphoma. 
From the data we have at the moment, we can say that although young Notch2IC-expressing B cells 
clearly exhibit increased levels of  the proto-oncogene c-myc, a slight splenomegaly, and an increased 
proliferative potential, constitutive Notch2 signalling alone is not acting as a strong oncogene in B cells. 
First analyses on the B cell populations of  old mice by Southern blot revealed that more Notch2IC//
CD19Cre+/- than control mice carried B cell populations exhibiting mono- or polyclonality, indicating 
that constitutive Notch2 signalling has mild oncogenic effects. However, the fact that most of  
these animals were already relatively old and that a large fraction of  our mouse cohort aged without 
showing any signs of  morbidity although at the time point of  analysis, some had quite obvious signs 
of  splenomegaly exceeding the one already seen in young Notch2IC//CD19Cre+/- mice, suggests the 
development of  indolent lymphomas with a long latency and a late onset. The probability of  natural, 
Notch2IC unrelated tumor development increases with age. In line with this, two control mice also 
developed tumors at the age of  18 and 19 months. Therefore, further experiments are planned to 
prove that Notch2IC-expressing mice develop significantly more lymphomas than control animals 
and to determine the onset of  lymphoma development in Notch2IC//CD19Cre+/- animals. To this 
end, small cohorts of  mice will systematically be analysed at different time points between six and 19 
months. One possible reason why constitutive Notch2 signalling is not a strong oncogene could be that 
Notch2IC-expressing cells not only proliferate better but also go into apoptosis more rapidly. So an 
additional survival signal would be needed to drive lymphomagenesis. CD40 is a promising candidate as 
preliminary proliferation experiments and lymphoma analyses of  mice expressing Notch2IC together 
with a ligand-independent, constitutive active CD40 receptor specifically in B cells, indicate that these 
mice develop lymphomas at younger age and in in vitro cultures, cells not only proliferate better, but 
also survive longer than cells with a Notch2IC alone.
In old Notch2IC-expressing mice, frequencies of  splenic IgM+ B cells were slightly and B220 levels 
strongly diminishing with age and in addition B cells were in general loosing their characteristic CD21high 
CD23low MZ B cell phenotype, irrespective of  tumor formation. A publication from Birjandi and 
colleagues comparing MZ B cell and MZ macrophage populations in old mice (18 to 23 months) to 
those in young mice (two to six months), revealed that in aged mice there was great variability regarding 
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the appearance and shape of  the MZ as well as the frequency and localisation of  cells within this zone. 
While in young mice the MZ was a very distinct ring encircling the white pulp, in old mice it was highly 
diffuse and difficult to discern. Yet, there were still some individual old mice with a splenic architecture 
similar to those in young animals (Bir�andi et al., 2011). Our finding that CD21 is downregulated in old 
Notch2IC-expressing mice together with the fact that apparently the microarchitecture of  the splenic 
MZ starts to dissolve when mice are aging, suggests that old Notch2IC-expressing B cells loose their 
localisation in the MZ and hence their typical MZ B cell phenotype. One possible explanation for this 
age-related change in surface marker expression could be that due to constitutive Notch2 signalling 
MZ B cells are in a state of  permanent activation. Thus, after some time these cells become kind of  
exhausted or anergic and as a counterregulatory mechanism start to downregulate their typical surface 
markers.
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5. Summary
Notch2 is pivotal for the generation of  MZ B cells. However, it is still unclear whether Notch2 is only a differentiation signal or an additional localisation signal for MZ B cells in the MZ 
and whether it is only needed for the generation of  MZ B cells or for the maintenance of  the MZ B 
cell phenotype. In addition, the regulation and role of  Notch2 in antigen-activated MZ B cells during 
immune responses has not yet been studied in detail. Increased Notch2 signalling has been found in 
diverse B cell malignancies, but whether its constitutive expression is sufficient to induce lymphomas 
is not known. To get further insights into these roles of  Notch2 signalling, we used two transgenic 
mouse strains previously established in our group allowing the Cre/loxP dependent, B cell-specific 
expression of  a defective Notch2 receptor or a constitutively active, intracellular form of  Notch2 
(Notch2IC). We could previously show that Notch2IC expression via CD19-Cre induces a strong 
differentiation towards MZ B cells, while mice with a defective Notch2 signal in B cells lack MZ B cells. 
To find Notch2 regulated genes and distinguish them from those induced by the cell type or the cell��s 
environment, we performed a whole mouse-genome gene expression profiling comparing Notch2IC-
expressing MZ B and Notch2-deficient Fo B cells with their corresponding wild type counterparts. 
These Illumina BeadArrays revealed that cells of  the same cell type clustered, apparently being quite 
similar according to their gene expression profile. Still, Notch2IC-expressing and Notch2-deficient Fo 
B cells clearly differed from their wild type counterparts, suggesting that not only MZ B but also wild 
type Fo B cells receive a Notch2 signal and that Notch2 signalling is weaker in wild type MZ B than in 
Notch2IC-expressing B cells or probably not constitutively active as in Notch2IC-expressing cells. 
We could also demonstrate that Notch2IC-expressing B cells exhibit similar or possibly slightly 
increased rates of  proliferation, in particular after α-CD40 stimulation and apoptosis than wild type 
MZ B cells. Notch2IC-expressing B cells displayed similarly enhanced PI3K and MAPK signalling 
as wild type MZ B cells, even in the absence of  the CD19 receptor. However, when taken into in 
vitro culture, Notch2IC-expressing B cells were not able to sustain these enhanced signalling pathway 
activity, although typical MZ B cell surface markers were maintained. This suggests that the enforced 
Erk, Jnk and Akt signalling, but not the expression of  typical MZ B cell markers is in great part 
conferred by the MZ environment. 
MZ B cells are believed to contribute to the pool of  natural antibodies and to be key players in T 
cell-independent (TI) immune responses. Still, despite the high number of  MZ B cells, Notch2IC//
CD19Cre+/- mice exhibited no rise in plasma cell frequencies in vivo, although Notch2IC-expressing 
cells were able to spontaneously and rapidly differentiate to antibody-secreting plasma cells in vitro. 
Immune responses to the TI-2 antigen NP-Ficoll and to the TI-1 antigen LPS - here especially to 
low concentrations - were hampered, correlating with a reduced migration of  Notch2IC-expressing 
cells into the follicle. In addition, SIGN-R1+ macrophages, important players in antigen capturing 
and subsequent presentation to MZ B cells were scarce, but apparently still functional in Notch2IC//
CD19Cre+/- mice. These results suggest that Notch2 signalling drives plasma cell development, but 
their differentiation is inhibited as long as Notch2IC-expressing B cells are localised in the MZ. We 
think that a persistent localisation in the MZ due to a potential misregulation of  the migration capacity 
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of  Notch2IC-expressing cells could be the main underlying cause for the suppression of  spontaneous 
plasma cell development in vivo, the defective TNP-Ficoll antigen transport into the follicle and the 
impaired reaction to TI antigens. This consequently implies that Notch2 signalling has to be switched 
off, when MZ B cells encounter antigen, so that they can migrate into the follicle to differentiate to 
plasma cells. 
Furthermore, we studied TI immune responses in mice with B cell-specific Notch2 ablation. These 
mice exhibited normal frequencies of  SIGN-R1+ macrophages and, consequently, intact antigen 
capturing. Surprisingly, antibody titers after TI-2 immunisation were reduced, but antigen transport 
into the follicle was still functional, although MZ B cells are missing in these animals. These findings 
suggest that antigen transport into the follicle can be performed by other cell types than MZ B cells, 
but that the presence of  MZ B cells is essential for an adequate, quick response to TI-2 antigens. 
A proportion of  aged Notch2IC//CD19Cre+/- mice developed lymphoma, however, not before 
reaching an advanced age and with mostly mild or no symptoms of  morbidity. These data suggest 
that Notch2IC alone is not a strong oncogene in B cells, but may drive the development of  indolent 
lymphoma with long latency and late onset.
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6. Zusammenfassung
Notch2 Signale sind essentiell für die Entwicklung von Marginalzonen (MZ) B-Zellen. Dennoch ist immer noch nicht ganz klar, ob Notch2 nur ein Differenzierungssignal für MZ B-Zellen 
ist oder zusätzlich noch als Signal zur Lokalisation in der MZ dient. Des Weiteren ist nicht bekannt, 
ob es nur zur Bildung der MZ B-Zellen beiträgt oder auch benötigt wird, um den typischen MZ B-
Zellphänotyp aufrecht zu erhalten. Auch die Rolle von Notch2 und dessen Regulierung in Antigen-
aktivierten MZ B-Zellen während der Immunantwort wurde bisher noch nicht genauer untersucht. 
��erstärkte Notch2 Signale konnten in verschiedenen B-Zelltumoren identifiziert werden, aber ob eine 
alleinige, dauerhafte verstärkte Expression ausreicht, um zur Lymphomentstehung zu führen ist noch 
unklar. Um mehr Einblicke in all diese Funktionen des Notch2 Signalweges zu erhalten, haben wir 
uns zwei, in unserem Labor etablierte transgene Mauslinien zu Nutze gemacht. Diese Mauslinien 
exprimieren abhängig vom Cre/loxP System entweder einen defekten Notch2 Rezeptor oder eine 
konstitutiv aktive, intrazelluläre Form des Notch2 Rezeptors (Notch2IC) spezifisch in B-Zellen. Wir 
konnten bereits zeigen, dass eine Notch2IC Expression mittels CD19-Cre zu einer Verschiebung der 
B-Zell-differenzierung hin zu MZ B-Zellen führt, wohingegen Tieren mit einem defekten Notch2 
Rezeptor die MZ B-Zellen fehlen. Um Notch2 regulierte Gene zu finden und diese von Genen 
unterscheiden zu können, welche vom Zelltyp oder der Umgebung der Zelle induziert werden, 
haben wir eine Mausgenom Genexpressionsanalyse durchgeführt. In dieser haben wir Notch2IC-
exprimierende MZ B-Zellen und Notch2-defiziente follikuläre (Fo) B-Zellen mit den entsprechenden 
Wildtyp Populationen verglichen. Die Auswertung dieser Illumina Microarrays zeigte, dass Zellen 
vom gleichen Zelltyp ein recht ähnliches Genexpressionsprofil haben und demzufolge „clustern“. 
Dennoch unterschieden sich Notch2IC-expimierende und Notch2-defiziente Zellen deutlich von 
ihren entsprechenden Wildtyp Populationen. Dies deutet zum einen darauf  hin, dass nicht nur MZ B-, 
sondern auch Wildtyp Fo B-Zellen ein Notch2 Signal erhalten, zum anderen, dass das Notch2 Signal 
in Wildtyp MZ B-Zellen entweder schwächer ist, als in Notch2IC-exprimierenden Zellen oder nicht 
konstitutiv aktiv, wie dies bei Notch2IC-exprimierenden Zellen der Fall ist. 
Notch2IC-exprimierende Zellen zeigten im Vergleich zu Wildtyp MZ B-Zellen eine ähnliche oder 
leicht erhöhte Apoptoserate und Proliferation, Letzteres insbesondere nach α-CD40 Stimulation. 
Darüberhinaus wiesen Notch2IC-exprimierende Zellen - auch in Abwesenheit des CD19 Rezeptors - 
und Wildtyp MZ B-Zellen eine ähnlich erhöhte Aktivität der PI3K und MAPK Signalwege auf. Jedoch 
waren Notch2IC-exprimierende B-Zellen nicht in der Lage diese verstärkten Signale in vitro aufrecht 
zu erhalten, obwohl sie die Expression typischer MZ B-Zellmarker beibehalten konnten. Dies könnte 
bedeuten, dass großteils die MZ zur Erhaltung der verstärkten Erk, Jnk und Akt Signale, jedoch nicht 
zur Expression der MZ B-Zellmarker beiträgt. 
MZ B-Zellen tragen zum Pool der natürlichen Antikörper bei und spielen eine entscheidende Rolle bei 
der T-Zellunabhängigen (TI) Immunantwort. Jedoch wiesen Notch2IC//CD19Cre+/- Mäuse trotz der 
hohen Anzahl an MZ B-Zellen, in vivo keine erhöhte Anzahl an Plasmazellen auf, obwohl Notch2IC-
exprimierende Zellen in vitro spontan und schnell zu Antikörper-sekretierenden Plasmazellen 
differenzieren konnten. Darüberhinaus war die Immunantwort auf  das TI-2 Antigen NP-Ficoll, sowie 
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die Reaktion auf  das TI-1 Antigen NP-LPS - hier vor allem niedrige Konzentrationen - gehemmt, was 
mit einer verminderten Wanderung von Notch2IC-exprimierenden Zellen in den Follikel korreliert war. 
Nur wenige, allerdings noch funktionale SIGN-R1+ Makrophagen, welche beim „Antigen-capturing“ 
und der darauffolgenden Antigenpresentation eine wichtige Rolle spielen, waren in diesen Mäusen 
detektierbar. Diese Ergebnisse legen nahe, dass Notch2 Signale die Plasmazellentwicklung treiben, 
aber dass die Differenzierung gehemmt ist, solange Notch2IC-exprimierende Zellen in der MZ sind. 
Wir denken, dass eine dauerhafte Lokalisation in der MZ, aufgrund einer möglichen Deregulation 
des Migrationspotentials Notch2IC-exprimierender Zellen, der Hauptgrund sein könnte, welcher der 
spontanen Plasmazellbildung in vivo, dem defekten Antigentransport von TNP-Ficoll in den Follikel 
und der verminderten Immunreaktion auf  TI Antigene zugrunde liegt. Folglich muss das Notch2 
Signal abgeschaltet werden, sobald MZ B-Zellen auf  ein Antigen treffen, damit die Migration in den 
Follikel und somit die Entwicklung zu Plasmazellen stattfinden kann.
Wir haben zudem die TI Immunantwort in Mäusen mit B-Zell-spezifischer Notch2-Defizienz 
analysiert. Diese Tiere wiesen eine normale Anzahl an SIGN-R1+ Makrophagen, sowie intaktes 
„Antigen-capturing“ auf. Die TI-2-spezifischen Antikörpertiter waren �edoch vermindert, wobei der 
Antigentransport in den Follikel noch statt fand, obwohl die MZ B-Zellen in diesen Tieren fehlen. 
Dies könnte darauf  hinweisen, dass der Antigentransport nicht unbedingt durch MZ B-Zellen 
erfolgen muss, aber dass MZ B-Zellen für eine adequate, schnelle Antwort auf  TI-2 Antigene benötigt 
werden. 
Ein Teil der alten Notch2IC//CD19Cre+/- Mäuse entwickelte in fortgeschrittenem Alter B-
Zelllymphome, wobei die meisten dabei nur leichte oder keine Krankheitszeichen aufwiesen. 
Dies deutet darauf  hin, dass Notch2IC alleine in B-Zellen nicht als starkes Onkogen wirkt, aber 
höchstwahrscheinlich in fortgeschrittenem Alter zur Entstehung indolenter Lymphomen mit langer 
Latenzzeit beiträgt.
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7. Material
7.1 Mouse strains
I) CD19-Cre (Rickert et al., 1997)
BALB/c or C57BL/6 mouse strain with the Cre recombinase gene placed into the cd19 locus, thereby 
disrupting the cd19 gene. The expression of  the Cre gene is regulated by the CD19 promoter.
II) Notch2ICflSTOP (Hampel et al., 2011)
BALB/c mouse strain that is conditional transgenic for the notch2IC and human CD2 gene placed into 
the rosa26-locus. A loxP sites-flanked STOP cassette upstream of  the notch2IC and human CD2 gene 
prevents transgene expression. Only in the presence of  Cre, the STOP cassette is excised and notch2IC 
and human CD2 are expressed under the control of  the very strong CAGGS promoter and an IRES 
element, respectively.
III) Notch2fl/fl (Besseyrias et al., 2007)
BALB/c mouse strain in which the exons d an e (coding for the C-terminal part of  the RAM23 domain 
and nuclear localisation sequence) of  the endogenous notch2 gene are flanked by loxP sites. Only in the 
presence of  Cre, the functional, intracellular part of  the endogenous notch2 gene is excised.
IV) BALB/c
These mice were used to keep the Notch2IC-expresssing and Notch2-deficient mouse strains on a 
pure BALB/c background. If  needed BALB/c mice were purchased from The Jackson Laboratory.
7.2 Primer, enzymes and Southern blot DNA probe 
Oligonucleotides were all synthesised by Metabion, Martinsried.
Primers for PCR and sequencing reactions:
Restriction endonucleases were purchased from New England BioLabs and MBI Fermentas GmbH. Taq 
DNA polymerase was purchased from Life TechnologiesTM. Proteinase K was purchased from Sigma-
Aldrich.
Primer name Primer sequence (5´ to 3´)
CD19c AACCAGTCAACACCCTTCC
CD19d CCAGACTAGATACAGACCAG
Cre7 TCAGCTACACCAGAGACGG
Notch2 sense GAGAAGCAGAGATGAGCAGATA
Notch2 antisense GTGAGATGTGACACTTCTGAGC
Notch2IC 25 rev ATCCCGGTCTCCGTATAGTG
Notch2IC 33 fw CCCTTGCCCTCTATGTACCA
Rosa fw1 (60) CTCTCCCAAAGTCGCTCTG
Rosa rev2 (62) TACTCCGAGGCGGATCACAAGC
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The DNA probe for Southern blotting binds to a sequence between the J4- and Eµ-segment of  the 
mouse IgH locus. It was isolated from the mouse IgH by digestion with the restriction enzymes NaeI 
and EcoRI. The fragment was cloned into a bluescript-vector and can now be isolated via restriction 
digest with EcoRI and HindIII from the plasmid (kindly provided by Stefano Casola). 
7.3 Antibodies
I) Primary Antibodies for immunoblotting
II) Secondary Antibodies for immunoblotting
All secondary antibodies were coupled to horseradish peroxidase.
III) Antibodies for immunohistochemistry and immunfluorescence
Antigen Manufacturer Source kDa Dilution Diluent
Akt Cell Signaling Rabbit 60 1:1000 TBST, 5 % (w/v) BSA
Erk Cell Signaling Rabbit 42, 44 1:1000 TBST, 5 % (w/v) BSA
FoxO1 Cell Signaling Rabbit 78-82 1:1000 TBST, 5 % (w/v) BSA
GAPDH Calbiochem Mouse 40 1:10000 TBST, 5 % (w/v) BSA
GSK-3 Cell Signaling Rabbit 46-51 1:1000 TBST, 5 % (w/v) BSA
Jnk Cell Signaling Rabbit 46, 54 1:1000 TBST, 5 % (w/v) BSA
p70 Cell Signaling Rabbit 70-85 1:1000 TBST, 5 % (w/v) BSA
pAkt (Ser) Cell Signaling Rabbit 60 1:1000 TBST, 5 % (w/v) BSA
pErk Cell Signaling Rabbit 42, 44 1:1000 TBST, 5 % (w/v) BSA
pGSK-3 Cell Signaling Rabbit 46-51 1:1000 TBST, 5 % (w/v) BSA
pJnk Abcam Rabbit 46, 54 1:500 TBST, 5 % (w/v) BSA
pp70 Cell Signaling Rabbit 70-85 1:1000 TBST, 5 % (w/v) BSA
PTEN Cell Signaling Rabbit 54 1:1000 TBST, 5 % (w/v) BSA
Tcl1B 1/5 Santa Cruz Goat 14 1:1000 TBST, 5 % (w/v) BSA
Tubulin Cell Signaling Mouse 55 1:1000 TBST, 5 % (w/v) BSA
Antigen Manufacturer Source Dilution Diluent
Anti-rabbit IgG Cell Signaling Goat 1:2000 TBST, 5 % (w/v) milk powder
Anti-mouse IgG Cell Signaling Horse 1:2000 TBST, 5 % (w/v) milk powder
Anti-goat/sheep IgG Sigma-Aldrich Mouse 1:20000 TBST, 5 % (w/v) milk powder
Antigen Manufacturer Source Coupled to Dilution
Mouse CD3 By courtesy of  E. Kremmer Rat  / 1:2
Mouse IgM Sigma-Aldrich Goat Peroxidase 1:100
Mouse MOMA-1 BMA Biomedicals Rat  / 1:100
Anti-rat IgG2 Jackson Laboratories Mouse Biotin 1:250
Anti-rat Jackson Laboratories Goat Alexa Fluor 488 1:100
Mouse SIGN-R1 BMA Biomedicals Rat Biotin 1:200
Streptavidin Life TechnologiesTM / Alexa Fluor 594 1:200
Streptavidin Sigma-Aldrich / Alkaline phosphatase 1:400
Anti-TNP BD Bioscience Hamster Pe 1:100
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IV) Antibodies for ELISA and ELISPOT
Primary antibodies for ELISAs and ELISPOTs:
IgM, II/41; IgG1, A85-3; IgG3, R2-38 (BD Bioscience).
Concentrations: 0.5 mg/ml
Capture antigen for NP-specific ELISAs and ELISPOTs:
NP17/16-BSA (Biosearch Technologies)
Biotinylated secondary antibodies:
IgM-Bio, R6-60.2; IgG1-Bio, A85-1; IgG3-Bio, R40-82 (BD Bioscience)
Concentrations: 0.5 mg/ml
Detection with Horseradish Peroxidase (HRP) Avidin D (Vector Laboratories)
Isotype controls for ELISAs:
Purified mouse IgM, IgG1 or IgG3 κ isotype control
Concentrations: 0.5 mg/ml
7.4 Software
Adobe Illustrator CS3
Adobe Photoshop CS3
Adobe InDesign CS3
GraphPad Prism 4
Epson Scanner program
Microsoft Excel
Microsoft Word
FlowJo
ImageJ
Axio Vision Zeiss
Glucore Omix Explorer
Pathway Studio
Bead Studio R
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8. Methods
8.1 Mice-associated methods
8.1.1 Mouse breeding
Mice carrying the notch2ICflSTOP allele were crossed to the CD19-Cre mouse strain (on a BALB/c or 
C57BL/6 background) to generate mice (Notch2IC//CD19Cre+/-) expressing the transgene from 
the pro-B cell stage with a gradual increase in Cre-mediated recombination during proceeding B 
cell differentiation (Rickert et al., 1997). Notch2IC//CD19Cre+/+ mice were generated by crossing 
Notch2IC//CD19Cre+/- to CD19-Cre mice. Analyses of  the PI3K pathway, of  potential lymphoma 
development in aging mice and in vitro proliferation assays (CFSE) were performed on a mixed 
background. All other experiments were performed on a pure BALB/c background. Mice carrying 
the notchfl/fll allele were crossed to the CD19-Cre mouse strain to generate mice with a truncated 
Notch2 receptor lacking the intracellular signalling domain from the pro-B cell stage on (Notch2fl/fl//
CD19Cre+/-). All analyses with these mice were performed on a pure BALB/c background.
Mice were analysed at eight to 20 weeks of  age, unless stated otherwise. Mice that were monitored 
for the development of  lymphomas or leukemic disease were kept under special observation. They 
were analysed as soon as first signs of  illness became noticable or at the age of  22 months as from 
this timepoint on the incidence of  unspecific, spontaneous tumors increases exponentially. All mice 
were bred and maintained in specific pathogen-free conditions. All experiments were performed 
in compliance with the German animal welfare law and have been approved by the Institutional 
Committee on Animal Experimentation and the government of  Upper Bavaria.
8.1.2 Isolation of  primary lymphocytes
Mice were euthanised by CO2 gassing for 5 min and were subsequently dissected. Peritoneal cells 
were harvested by rinsing the peritoneal cavity with ~8 ml 1 % B cell medium (BCM) (1x RPMI 1640 
(Gibco), containing 1 % (v/v) heat-inactivated fetal calf  serum (FCS) (PAA Cell culture Company), 
1 % (v/v) penicillin streptomycin, 1 % (v/v) sodium pyruvate, 1 % (v/v) L-glutamine, and 52 µM 
�-mercaptoethanol (all purchased from Gibco)) and aspirating it with a syringe. Spleen and inguinal 
lymph nodes were taken out as whole organs and were maintained in 1 % BCM on ice until further 
procedures. To isolate cells from the bone marrow, tibia bones were dissected and cut and the cavity 
was rinsed with 1 % BCM. To receive single cell suspensions, spleen and lymph nodes were passed 
through a 70 µm capillary cell strainer (Corning). Single cell suspensions from spleen and bone marrow 
were depleted from erythrocytes by lysis with the hypotonic 1x RBC lysis buffer (eBioscience) for 3 
min at room temperature (RT). Bloody cell suspensions from the peritoneal cavity were discarded 
completely to ensure that only cells from the peritoneum were analysed. Cells were kept on ice during 
the entire procedures and were generally centrifuged for 10 min at 300 x g at 4°C in a Rotanta 460 R 
centrifuge (Hettich Zentrifugen). Isolation of  splenic B cells was performed by depletion of  CD43+ 
non-B cells by magnetic cell separation (MACS), using α-CD43 beads and LS columns according to 
the manufacturer��s specifications (Miltenyi Biotec). This resulted in a purity of  85 to 95 % B cells. 
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For subsequent CFSE proliferation assays (8.1.5.2) with sort-purified wild type MZ B cells, splenic 
cell suspension were not only subjected to depletions of  CD43+ non-B cells, but in addition also to 
depletions of  the majority of  CD23+ Fo B cells by using simultaneously α-CD23 beads. By this means, 
MZ B cells were already pre-purified and enriched prior to sorting, hence leading to a reduction of  
sorting time as direct sorting was not feasible, as it would have taken to long and hence stressed 
the cells so that their survival and proliferation in subsequent in vitro cultures and especially CFSE 
proliferation experiments would have been affected.
8.1.3 Determination of  cell numbers
A “Neubauer” counting chamber was used to determine the cell density of  obtained cell suspensions 
from different organs via light microscopy (Zeiss Axio ��ert.A1 with phase contrast filter). To this end 
10 µl cell suspension were pre-diluted adequately in 1 % BCM. 10 µl of  this dilution were pipetted 
into the counting chamber and cells within two to four of  the chambers’ big squares were counted. 
Only cells that appeared round and bright were included. Cell suspension densities were calculated 
as follows: Mean of  counted cells x dilution factor x 104 (counting chamber factor). For cell number 
determination using trypan blue, cell suspensions were diluted 1:2 in trypan blue (Gibco). 10 µl of  this 
dilution were then immediately pipetted into the counting chamber and unstained (living) cells were 
counted. 
8.1.4 Freezing of  cells
For cell storage for subsequent Southern blot or Western blot analyses, cell pellets containing at 
least 1x107 cells were washed twice with PBS (Gibco). After discarding PBS, cell pellets were shortly 
vortexed to loosen cells to avoid clogging in subsequent analyses. Cell pellets were stored at -80°C.
8.1.5 In vitro culture of  primary splenic mouse lymphocytes
8.1.5.1 In vitro culture with different stimuli
Cell culture was performed under sterile conditions in a laminar flow (BDK). Cells were grown in an 
incubator (Binder) at 37°C, 5 % CO2 and 95 % air humidity. Splenic cells in total or MACS- purified 
splenic B cells were cultured up to eight days in 10 % BCM (containing 10 % (v/v) FCS) with or without 
stimuli in 96-well round-bottom (5x105-1x106 cells/well) (Corning) or conical-bottom (1,25x105-4x105 
cells/well) plates (Neolab) unless stated otherwise. Stimuli included LPS (50 μg/ml; E. coli 055:B5; 
Sigma-Aldrich), IL-4 (10 ng/ml; mouse recombinant; Sigma-Aldrich), α-CD40 antibody (2.5 μg/ml; 
eBioscience (HM40-3)). At different time points, cells were sub�ected to flow cytometrical analyses 
(see 8.1.6) or to protein isolation for subsequent Western blot analyses (see 8.4).
 
8.1.5.2 In vitro proliferation (CFSE) assay
For proliferation assays, sort-purified cell populations or MACS-purified splenic B cells were washed 
with RPMI 1640 and subsequently labeled with RPMI 1640 containing 5- (and 6)-carboxyfluorescein 
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diacetate N-succinimidyl ester (CFSE, Molecular Probes, final concentration 5 μM) for 5 min at 37°C 
(incubator) in a concentration of  5x106 cells/ml. For this, cell pellets were first resuspended with 
pre-warmed (37°C) RPMI 1640 without CFSE (utilising half  of  the final volume used for labeling). 
Then the cell suspension was mixed with a similar volume of  RPMI 1640 containing CFSE (double 
concentrated) and placed into the incubator. CFSE binds to proteins on the inner cell membrane 
and is consequently transferred equally to each daughter cell upon cell division, leading to declining 
fluorescence intensity. To stop the labeling reaction, cells were twice abundantly washed with ice-cold 
10 % BCM, before resuspending them in 1 ml 10 % BCM. CFSE-labeled cells were cultured for up 
to five days in 96-well plates (1.25x105 - 5x105 cells/well) in 200 μl 10 % BCM/well and were analysed 
by flow cytometry every day. Percents of  divided cells (% divided), the proliferation index (number 
of  divisions of  cells that underwent at least one division) and division index (average number of  cell 
divisions in total, including cells that never divided) were calculated using the “proliferation platform” 
of  the FlowJo software (BD Biosciences) according to the FlowJo manual.
8.1.6 Flow Cytometry
8.1.6.1 Analysis of  murine lymphocytes by flow cytometry
Single cell suspensions prepared from various lymphoid organs or in vitro cultured splenic cells were 
surface-stained (20 min on ice, protected from light) with a combination of  Fitc-, Pe-, PerCP-, APC-, 
Alexa Fluor 700-, Horizon V450- and Brilliant Violet 421-conjugated monoclonal antibodies, diluted 
in MACS buffer (Miltenyi Biotec). Antibodies specific for B220, Blimp-1, CD1d, CD2 (human), 
CD19, CD21, CD23, CD25, CD38, CD80, CD86, CD138, ICAM-1, IgD, IgM, Irf4, S1PR1, Thy1.2-
Bio were purchased from BD Biosciences. Prior and after staining, cells were washed with MACS 
buffer. Measurement on the LSRFortessaTM required filtering of  cell suspensions into a FACS tube 
equipped with a nylon mesh (Corning) before flow cytometrical analyses. Data were analysed from 
viable, lymphocyte-gated cells as determined from forward and side scatter as well as from TO-PRO-
3 iodide, 4′,6-Diamidin-2-phenylindol (DAPI), propidiumiodide (PI) or the LI��E/DEAD® Fixable 
Blue Dead Cell Stain kit (all Life TechnologiesTM), which are all intercalating fluorescent dyes that 
bind DNA and thus only stain dead cells that are permeable for the dye to diffuse into the nucleus. 
All analyses were performed on a LSRFortessaTM or a FACSCaliburTM flow cytometer (both from BD 
Biosciences) and results were analysed using FlowJo software. 
8.1.6.2 Intracellular analysis of  murine lymphocytes by flow cytometry
Freshly isolated splenic cell suspensions or cells from in vitro cultures were washed with PBS and 
stained for 30 min at RT or on ice with 1 µl/ml LIVE/DEAD® Fixable Blue Dead Cell Stain Kit 
diluted in PBS. This dye ensured that in spite of  the subsequent permeabilisation and fixation steps, 
living and dead cells could still be discriminated from each other later on in the analysis. After a 
washing step in MACS buffer, surface-staining of  cells with a combination of  different antibodies (as 
in 8.1.6.1) was performed. After an additional washing step, cell suspensions were fixed for 15 min at 
RT with 4 % paraformaldehyde (PFA) (Carl Roth), again followed by two washing steps. Cells were 
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now either kept in MACS buffer at 4°C light-protected over night and further processed the next day 
or directly permeabilised by washing them with PBS containing 1 % bovine serum albumin (BSA) 
(AppliChem) and 0.5 % Saponin (VWR). Staining reactions using antibodies against intracellularly 
measured factors was performed at RT for 30 to 60 min. These antibodies were conjugated to Fitc, 
Pe or APC and diluted in PBS/1 % BSA/0.5 % Saponin. Before filtering, cells were washed and 
resuspended in MACS buffer. Flow cytometrical analyses were done on a LSRFortessaTM. All staining 
steps were performed in darkness.
8.1.6.3 Fluorescence-associated cell sorting (FACS)
The day prior to sorting, 15 ml falcons were filled with pure heat-inactivated FCS and kept at 4°C over 
night. On the day of  the experiment, FCS was tilted, replaced by 1 ml 1 % BCM and falcons were 
placed in a cooled (4°C) holder of  the cell sorter. This procedure assured that cells were collected in 
cooled 1 % BCM directly after sorting to minimise unspecific cell activation or apoptosis due to stress 
from a prolonged contact to PBS (sheath fluid of  the sorter) and the sorting procedure itself. Single 
cell suspension from spleens were washed with MACS buffer, surface-stained with a combination of  
Fitc-, Pe-, PerCP-, APC-conjugated monoclonal antibodies, diluted in MACS buffer. Subsequently, 
cells were washed and resupended in 700 - 1500 µl MACS buffer. Prior to sorting, cells were filtered 
into a FACS tube equipped with a nylon mesh (Corning) to avoid clogging of  the cell sorter. Cell 
sorting procedures were performed in the “purity mode” using a 70 µm nozzle. Only lymphocyte-
gated cells as determined from forward and side scatter were sorted. Sorted cell populations were 
rechecked for their purity by normal flow cytometry analysis on the sorter. In general, a purity between 
97 to 98 % of  lymphocyte-gated cells was obtained. All cell sorting experiments were performed on a 
FACS AriaIIIuTM (BD Biosciences). For sort-purifications of  wild type and Notch2IC-expressing MZ 
B cells for subsequent CFSE proliferation experiments, splenic cell suspensions of  12 wild type and 
three Notch2IC//CD19Cre+/- mice on average were pooled to be able to gain enough MZ B cells for 
in vitro cultures. 
8.1.7 T cell-independent immunisation of  mice
Mice at the age of  eight to 16 weeks were immunised with 2.5 - 50 μg NP-LPS or 50 μg TNP-/NP-
Ficoll (all Biosearch Technologies). NP-LPS antigen stocks were quickly centrifuged before usage and 
the supernatant was transferred to a new tube to remove any precipitation. Finally, desired amounts 
of  each antigen was resuspended in 200 or 100 µl sterile PBS for intraperitoneal or intravenous 
injections.
8.1.8 Enzyme-linked immunosorbent assay (ELISA)
To determine concentrations of  secreted antibodies in sera or cell culture supernatants with a certain 
antigen specificity and/or a certain immunoglobulin isotype, blood serum or cell culture supernatants 
were collected and ELISAs were performed.
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8.1.8.1 Preparation of  serum from murine blood
On living mice, blood was collected from the caudal mouse vein using a glass capillary (Hirschmann-
Laborgeräte). When dissecting mice seven or 14 days after immunisation or in regular analyses without 
immunisation, blood was directly collected from the heart with a pipette. The blood was incubated 
on ice for at least three hours and subsequently centrifuged at 9.000 x g and 4°C for 10 min in a 
microcentrifuge (Eppendorf, 5417 R). The supernatant was transferred to a new reaction tube and the 
procedure was repeated once to guarantee pure serum. Serum was rapidly frozen at -80°C to avoid 
any antibody degradation.
8.1.8.2 Preparation of  cell culture supernatant for ELISA
After four to eight days of  cell culture, cells were centrifuged for 10 min at 4°C and 300 x g. Supernatants 
were carefully transferred into a new reaction tube and subsequently immediately frozen at -80°C to 
avoid any antibody degradation. 
8.1.8.3 Detection of  specific standard immunoglobulin titers
Maxisorb 96-well plates (Nunc) were coated over night at 4°C with 5 μg/ml of  immunoglobulin 
isotype-specific rat α-mouse antibodies (depending on the isotype: IgM, II/41; IgG1, A85-3; IgG3, 
R2-38, all from BD Bioscience), diluted in 0.1 M NaHCO3 (pH 9.2). All the following procedures 
were performed at RT. Wells were blocked with PBS, 1 % (w/v) milk powder (Carl Roth) solution 
for 60 min. Subsequently, cell culture supernatant (always diluted 1:2) or different dilutions of  serum 
(both diluted in 1 % (w/v) milk powder solution) were applied to the wells and incubated for 60 
min, then incubated 30 min with 1 μg/ml  biotin-con�ugated secondary antibodies specific for the 
different antibody isotypes (depending on the isotype: IgM-Bio, R6-60.2; IgG1-Bio, A85-1; IgG3-
Bio, R40-82, all from BD Bioscience), followed by a 60 min incubation with 2.5 µg/ml Horseradish 
Peroxidase (HRP) Avidin D (Vector Laboratories), diluted in 0.1 M NaHCO3 (pH 9.2). The amount 
of  bound HRP was detected by incubation with o-phenylenediamine dihydrochloride (Sigma-Aldrich) 
in 0.1 M citric acid buffer (0.1 M citric acid, 0.1 M Tris) containing 0.015 % (v/v) H2O2 that serves as 
substrate for the reaction. Following each incubation step, plates were washed three times with PBS. 
The absorbance was determined at 405 nm, using a microplate reader (Photometer Sunrise RC, Tecan) 
and antibody concentrations were determined by comparing them with isotype-specific standards 
(IgM, G155-228; IgG1, MOPC-31-C; IgG3, A112-3).
8.1.8.4 Detection of  NP-specific immunoglobulin titers
NP-specific immunoglobulin titers of  different isotypes were determined by NP-specific ELISA with 
the same procedure as described above, but using NP17-BSA as capture antigen. Plates were therefore 
coated over night at 4°C with 5 μg/ml NP17-BSA (Biosearch Technologies) to detect NP-specific 
IgG1, IgM and IgG3 antibodies, respectively.
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8.1.9 Enzyme-linked immunosorbent spot (ELISPOT) assay
ELISPOT assays were performed to visualise and enumerate small numbers of  B cells secreting 
antigen-specific antibodies. Until the day of  ELISPOT development, all steps were undertaken under 
steril conditions using a laminar flow. Membranes of  ELISPOT plates (Merck Millipore) were either 
coated with 5 µg/ml immunoglobulin isotype-specific antibodies (as in 8.1.8.3) or with 25 µg/ml 
NP17-BSA as capture antigen (see 8.1.8.4) or with PBS containing sterile 25 µg/ml BSA (NEB) as 
control at 4°C over night. The next day plates were washed three times with sterile PBS and incubated 
for at least 2 h at 37°C with 10 % BCM. Blocking solution was tilted and cells were disseminated 
in different densities into the wells and cultured for 1.5 - 2 days at 37°C in 200 µl 10 % BCM. 
Antibodies that are being produced during these days are now directly captured and immobilised on 
the ELISPOT membrane after being secreted by the activated B cell. At the desired timepoint, cells 
were discarded, ELISPOT plates were washed six times with PBST (PBS containing 0.025 % Tween20 
(Carl Roth) and incubated for 2 h at 37°C with 1 µg/ml biotin-conjugated secondary antibodies 
specific for the different antibody isotypes (as in 8.1.8.3) diluted in PBS with 1 % BSA (AppliChem). 
Plates were again washed six times with PBST and subsequently incubated with 2.5 µg/ml Horseradish 
Peroxidase (HRP) Avidin D diluted in PBS with 1 % BSA for 45 min (max. 1 h) at RT and light-
protected. Prior to development plates were washed three times with PBST and three times with PBS. 
DAB (3,3’-diaminobenzidine) solution (highly cancerogenic!) was prepared by  dissolving one tablet 
(Sigma-Aldrich) in 5 ml bidest. water. Plates were then incubated with DAB solution for ~5 min until 
brown spots were visible. DAB solution was carefully discarted, plates were thoroughly rinsed with 
bidest. water and finally air-dried. Now, each spot that developed during the assay represents a single 
antibody-secreting cell. Hence, ELISPOT assays yield qualitative (type of  immune protein) as well as 
quantitative (number of  responding cells) information.
 
8.1.10 Immunohistochemistry and Immunofluorescence
Spleens were embedded in O.C.T. Tissue Tek (Sakura) and were frozen on dry-ice. Embedded organs 
were stored at -20°C, wrapped in aluminum foil to avoid air contact. Sections of  8 μm in thickness were 
cut, using a cryostat (Leica Microsystems) and were air-dried over night. Sections were fixed for 10 min 
in 100 % (v/v) acetone. Subsequently, slides were dried for ~5 min at RT again, excessive Tissue Tek 
was removed with a scalpel and sections were surrounded with a Pap-Pen to keep buffers and antibody 
solutions on the tissue later on. Sections were incubated with PBS for 5 min, with quenching buffer 
(PBS containing 10 % (v/v) goat serum, 1 % (w/v) BSA) for 20 min to block non-specific binding sites. 
Afterwards, sections were incubated for each 15 min in two different blocking buffers (Avidin/Biotin 
Blocking Kit; Vector Laboratories). Between procedures for blocking, sections were washed for 5 min 
in PBS, whereas before and after labeling procedures, sections were washed with PBS, each three times 
for 5 min. Subsequently, labeling was performed by incubating sections with different antibodies and 
streptavidin-conjugated alkaline phosphatase (SA-AP) (Sigma-Aldrich), diluted in PBS/1 % BSA, each 
for 1 h. Antibodies conjugated to streptavidin were detected in blue using Blue Alkaline Phosphatase 
Substrate Kit III (Vector Laboratories). Antibodies conjugated to peroxidase were stained in red due 
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to a reaction with 3-amino-9-ethylcarbazole (AEC) after treatment with the Peroxidase Substrate 
Kit AEC (Vector Laboratories). Staining reactions were stopped submerging sections in PBS. All 
incubation and washing steps were performed at RT in a wet chamber. Sections were air-dried and 
subsequently embedded in gelatin or ProLong® Gold antifade reagent (Life TechnologiesTM) before 
a coverslip was put on top. Slides were inspected and pictures were obtained using light (Axioskop 
equipped with an AxioCam Mrc5, Zeiss) or fluorescent microscopy (Axiovert 200 M equipped with 
an AxioCam MRm, Zeiss). Pictures were edited using Adobe Photoshop software.
8.2 DNA-related techniques
8.2.1 DNA isolation
8.2.1.1 Isolation of  genomic DNA from murine tails
DNA was isolated from each analysed mouse for subsequent genotyping to be able to differentiate 
between control and transgenic mice. For this, DNA from small pieces of  murine tails was isolated 
according to a slightly modified procedure derived from Laird (Laird et al., 1991). A small piece of  
murine tail was incubated shaking either over night (o.n.) or for 3 h at 56°C in 500 μl lysis buffer (100 
mM Tris/HCl pH 8, 5 mM EDTA, 0.2 % (w/v) SDS, 200 mM NaCl) with 100 μg/ml (o.n.) or 200 
µg/ml (3 h) proteinase K. 170 μl of  a saturated (> 5 M) NaCl solution were added to the samples 
to precipitate proteins, followed by a centrifugation step (10 min, 4°C, 10.000 x g). The supernatant 
was transferred into a new reaction tube. DNA was then precipitated by adding 600 μl 100 % (v/v) 
isopropyl alcohol and inverting reaction tubes. Samples were again centrifuged as described above. 
Subsequently, the supernatant was removed and the DNA was washed once by adding 1 ml 70 % (v/
v) ethanol, air-dried afterwards, and ultimately dissolved in 100 μl TE (10 mM Tris/HCl pH 8, 1 mM 
EDTA pH 8) by shaking for several hours at 37°C.
8.2.1.2 Isolation of  genomic DNA from primary murine lymphocytes
Frozen cell pellets containing ~1x107 cells were thawed and shortly vortexed subsequently to loosen 
cells. Cells were then incubated shaking over night at 56°C in 1 ml lysis buffer (see 8.2.1.1) containing 
200 µg/ml proteinase K. Precipitation of  proteins with NaCl was performed as in 8.2.1.1. Subsequently, 
the 1 ml supernatant was transferred into a new reaction. 500 µl of  it were mixed with 500 µl 100 
% isopropyl alcohol respectively and successively centrifuged (see 8.2.1.1) within the same tube to 
precipitate the DNA. Supernatant was discarded, DNA pellets were washed with 1 ml 70 % (v/v) 
ethanol, air-dried afterwards and dissolved in 50 μl TE by shaking for several hours at 37°C.
8.2.2 DNA analysis
8.2.2.1 Polymerase Chain Reaction (PCR)
For genotyping of  transgenic mice, PCR (Saiki et al., 1985; Saiki et al., 1988) was applied to amplify 
and to detect specific regions in the DNA obtained from their tail DNA. PCRs were always performed 
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in thermal cyclers (Biometra). Following reaction mixture (primers from Metabion, DMSO from Carl 
Roth, residual components from Thermo Scientific) was used in different variations:
Reaction batch  1x   Reaction cycle
Taq (10x) buffer  2.5 μl    Starting temperature 95°C 5��
MgCl2 (50 mM)   1 or 1.5 μl   Cyclic denaturation 95°C 45����
dNTP mixture (10 mM)  0.5 μl    Cyclic annealing 55-63°C 45����
Primer sense    0.1 or 0.25 μl   Cyclic elongation 72°C 1-2��
Primer antisense   0.1 or 0.25 μl   Final elongation 72°C 10��
TaqPol  (5 U/μl)  0.15 μl    Cooling to 10°C
DNA (about 5 ng)   1-1.5 μl  # cycles 30-35
DMSO (100 %)   0.25 μl
H2O     to 25 μl
8.2.2.2 Agarose gel electrophoresis of  DNA
Agarose gel electrophoresis was performed according to (Sambrook and Russell, 2000), to determine 
the yield of  a DNA isolation or PCR reaction. Gels contained 1x TAE (40 mM Tris/HCl, 20 mM 
acetic acid, 1 mM EDTA pH 8.5), 5 μg/ml ethidium bromide, and 1.5 - 2 % (w/v) agarose (Biozym). 
Electrophoresis was performed in a gel electrophoresis chamber (PEQLAB Biotechnologie GmbH) 
with 1x TAE buffer at 90 to 100 V for one to two hours.
8.2.3 Southern blotting (Southern et al., 1997)
This method was used for the identification of  mono- or polyclonality of  potential tumor cells. 
Thereby, electrophoretically separated DNA is transferred from an agarose gel to a nitrocellulose 
membrane, and the hybridisation of  a radioactively labeled DNA probe to the denatured DNA on the 
membrane allows the detection of  specific DNA fragments as definite bands on the membrane. 
8.2.3.1 Restriction digest of  genomic DNA
Genomic DNA from primary splenic lymphocytes was digested by specific enzymes for the subsequent 
performance of  a Southern blot. The restriction buffer mix (1 mM Spermidin, 1 mM DTT, 100 μg/ml 
BSA, 50 μg/ml RNase, enzyme specific buffer, 50 U of  the respective enzyme) was added to DNA 
from primary lymphocytes dissolved in TE buffer. Digestion took place at 37°C for 16 hours. 
8.2.3.2 Gelelectrophoresis and blotting
After digestion as described in 8.2.3.1, the samples were electrophoretically separated on a 0.8 % 
(w/v) agarose gel together with a standard 1 kb DNA ladder (Life TechnologiesTM) overnight. Having 
recorded the separated DNA and standard in the gel on a UV luminescent screen together with a 
ruler, the gel was incubated in 0.25 M HCl for 25 min to fragment the DNA. To equilibrate the gel 
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for the following DNA transfer, the gel was shortly rinsed in water and subsequently incubated for 
40 min in alkaline transfer buffer (0.4 M NaOH, 0.6 M NaCl) to denature the DNA. Afterwards, the 
DNA was blotted from the gel to a nylon membrane (ImmobilonTM Ny+ membrane, Millipore) o.n. 
from top to bottom by capillary pressure of  the transfer buffer. After transfer, the slots of  the gel were 
marked on the membrane with a soft pencil and the membrane was rinsed shortly in 2x SSC (0.3 M 
NaCl, 0.03 M NaCitrate, pH 6.5) for neutralisation. Then, DNA was cross-linked to the membrane 
by baking for one hour at 80°C. 
8.2.3.3 Hybridisation & detection
In order to prevent unspecific binding, the 2x SSC-wetted membrane was pre-hybridised in pre-heated 
hybridisation solution (1 M NaCl, 50 mM Tris, pH 7.5, 10 % (w/v) dextran sulfate, 1 % (w/v) SDS, 
250 μg salmon sperm DNA/ml) for at least six hours at 65°C, before incubation with the radioactively 
labeled probe. Applying Random Prime Labeling Kit (GE Healthcare) according to manufacturer’s 
instructions, 50 ng DNA probe were labeled with 50 μCi α32-dCTP (Hartmann Analytic). Subsequently, 
the labeled probe fraction was separated from the non-incorporated nucleotides using a G50 sephadex 
column (GE Healthcare) according to manufacturer��s specifications. For denaturation, the probe was 
incubated for five minutes at 100°C and was quenched for 2 min on ice. The membrane was incubated 
over night at 65°C in the hybridisation solution, containing pre-hybridisation buffer with labeled 
probe. Afterwards, the membrane was rinsed three times each for 10 min in pre-heated washing 
buffer (0.5x SSC, 0.5 % (w/v) SDS) at 60°C to wash off  unbound probe. Washing was stopped when 
radioactivity reached 150 counts. Radioactivity was visualised by autoradiography, using radiosensitive 
films (Biomax MS PE Applied Biosystems 35x43 cm, KODAK), exposed for one day at -80°C in a 
Biomax cassette.
8.3 RNA-related techniques
8.3.1 Isolation & quantification of  total RNA
Total RNA from sort-purified B cell populations of  interest (see 8.1.6.3) was isolated directly after 
sorting using the peqGOLD TrifastTM reagent according to manufacturer��s specifications (PEQLAB 
Biotechnologie GmbH). Briefly, up to 1x106 sort-purified, splenic cells were centrifuged (10 min at 
300 x g at 4°C) and the supernatant was removed. As resuspension of  cell pellets before lysis with 
the peqGOLD TrifastTM reagent was critical for subsequent RNA isolation, a small amount (~50 
µl) of  supernatant (not more than 10 % of  the reagent’s volume) was spared and used for cell pellet 
resuspension. Subsequently, cells were lysed by applying 1 ml peqGOLD TrifastTM reagent, followed 
by quick and vigorous mixing by pipetting. Probes were incubated for 5 min at RT. Chloroform (200 
µl/1 ml reagent) was added and probes were shaken for 15 sec, followed by an additional incubation 
step of  6 min at RT. After separating the aqueous phase (RNA) from the phenol-chloroform phase 
(proteins) and interphase (DNA) by centrifugation (5 min, 12.000 x g, RT), the aqueous phase was 
transferred into a new reaction tube. RNA was precipitated by applying 100 % (w/v) isopropyl 
alcohol (500 µl/1 ml reagent). Probes were inverted and incubated for 10 min on ice, followed by 
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centrifugation at 12.000 x g for 10 min at 4°C. RNA pellets were washed two times with 75 % (w/
v) ethanol (10 min, 12.000 x g, 4°C) and then air-dried. As complete drying drastically reduces the 
solubility of  RNA, pellets were monitored during drying and nuclease-free water (AmbionR) was 
added as soon as no ethanol residues were visible anymore. RNA was dissolved by passing the solution 
several times through a pipette tip and incubating it for 10 min at 56 to 60°C. After an immediate 
first determination of  the RNA quantity using a nanophotometer (see paragraph below), aliquots (~2 
µl) of  each RNA sample - needed for later Bioanalyzer analyses - were transferred into new reaction 
tubes. Subsequently, original RNA samples and respective aliquots were stored at -80°C. As repeated 
freeze-thaw cycles would affect RNA integrity, the generation of  specific aliquots for later Bioanalyzer 
analyses assured that original RNA samples would only have to be thawed once on the day of  cRNA 
amplification.
To determine and calculate RNA concentration, its absorbance at 260 nm was measured utilising a 
nanophotometer (Nanodrop 2000, Thermo Fisher Scientific). The ratio of  the readings at 260 and 
280 nm (OD260/OD280) provides an estimation of  the purity of  the RNA preparation, with respect 
to contaminants that absorb UV, such as proteins. Pure RNA has an OD260/OD280 ratio of  ~1.8. 
RNA that was prepared for subsequent microarray experiments was additionally controlled for its 
quantity, quality and integrity by capillary gel electrophoresis using the RNA 6000 Nano Kit (Agilent 
Technologies) on an Agilent 2100 Bioanalyzer (Agilent Technologies) according to the manufacturer’s 
specifications. Only RNA samples with a RNA integrity number (RIN) greater than seven and with a 
graph clearly pointing to an intact, not contaminated RNA (see 3.1.1, Fig. 12) were further utilised.
8.3.2 cRNA synthesis
Total RNA of  the B cell populations of  interest was labeled and linearly amplified to cRNA in 
a commercial form of  the classical procedure by Eberwine (Van Gelder et al., 1990). cRNA was 
synthesised using the IlluminaR TotalPrepTM RNA Amplification Kit according to manufacturer��s 
specifications (Life TechnologiesTM). All kit reagents (except enzymes) were thawed at RT and mixed 
thoroughly before use. RNA and kit reagents were kept on ice during the whole procedure unless 
stated otherwise. All centrifugation steps undertaken during purification were performed at 10,000 x 
g at RT.
First strand cDNA synthesis by reverse transcription
A maximum volume of  11 µl total RNA (50 to 500 ng) was transferred into a nonstick, sterile, RNase-
free, 0.5 ml microcentrifuge tube (Life TechnologiesTM). If  necessary nuclease-free water was added to 
bring all samples to 11 µl. 9 µl of  Reverse Transcription Master Mix was added to each RNA sample. 
Samples were mixed thorougly by pipetting up and down, placed in a thermal cycler (Biometra) and 
incubated for 2 h at 42°C. Samples were then immediately placed on ice. 
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Second strand cDNA synthesis
80 µl of  well mixed Second Strand Master Mix were added to each sample. Samples were mixed 
thoroughly and placed for 2 h into a thermal cycler at 16°C. The lid of  the thermal cycler was disabled 
before and was not completely closed as a lid temperature over RT would inhibit the reaction. Samples 
were subsequently immediately placed on ice again. 
cDNA purification
Nuclease-free water (Life TechnologiesTM) (at least 20 µl/sample) was preheated to 55°C before 
starting with the purification. 250 µl cDNA Binding Buffer were added to each sample. Samples were 
mixed, transferred to the center of  the cDNA Filter Cartridges (placed within a washing tube) and 
centrifuged for 1 min. Flow-through was discarded and each filter was replaced into its washing tube. 
500 µl of  Washing Buffer was added to the filters followed by a centrifugation step of  1 min again. 
Flow-through was tilted and filters including their washing tube were additionally centrifuged for 1 
min. Filters were then transferred to cDNA Elution Tubes and 20 µl of  preheated, nuclease-free water 
were applied to the center of  the filters. Samples were now left at RT for 2 min and finally centrifuged 
for 1 min to obtain the double-stranded cDNA within the eluate.
cRNA synthesis by in vitro transcription
cDNA probes (~17.5 µl) were again transferred into nonstick, sterile, RNase-free, 0.5 ml microcentrifuge 
tubes and 7.5 µl of  the well mixed In Vitro Transcription (IVT) Master Mix was pipetted to each 
sample. Probes were mixed and incubated for 14 h at 37°C within a thermal cycler (lid temperature 
100°C). Subsequently samples were placed on ice and mixed with 75 µl nuclease-free water.
Second Strand Master Mix (for a single 100 µl reaction)
Amount Component
63 µl Nuclease-free water
10 µl 10x Second Strand Buffer
4 µl dNTP Mix
2 µl DNA polymerase
1 µl RNase H
IVT Master Mix (for a single 25 µl reaction)
Amount Component
2.5 µl T7 10x Reaction Buffer
2.5 µl T7 Enzyme Mix
2.5 µl Biotin-NTP Mix
Reverse Transcription Master Mix (for a single 20 µl reaction)
Amount Component
1 µl T7 Oligo(dT) Primer
2 µl 10x First Strand Buffer
4 µl dNTP Mix
1 µl RNase Inhibitor
1 µl ArrayScript (reverse transcriptase)
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cRNA purification
Nuclease-free water (at least 200 µl/sample) was preheated to 55°C before starting with the purification. 
350 µl cRNA Binding Buffer were intermixed with each cRNA sample. Afterwards 250 µl 100 % (v/v) 
ethanol were mixed by pipetting (NOT vortexing!) with the samples until a homogenous, clear solution 
was achieved. Each probe was directly transferred to a cRNA Filter Cartridge within a cRNA Collection 
Tube and centrifuged for 1 min. Flow-through was discarded, filters replaced in their collection tubes 
and 650 µl Wash Buffer were applied to them. After two additional centrifugation steps for 1 min, 
filters were placed into a new collection tube. 200 µl of  preheated, nuclease-free water were applied to 
the center of  the filters, which were then incubated for 10 min at 55°C in a heat block. In the end, filters 
were centrifuged for 2 min to obtain the cRNA within 200 µl of  eluate. As for total RNA, quantity 
and quality of  cRNA was determined by measuring its absorbance at 260 nm with a nanophotometer 
(Nanodrop 2000, Thermo Fisher Scientific) and by capillary gel electrophoresis using the RNA 6000 
Nano Kit (Agilent Technologies) on an Agilent 2100 Bioanalyzer (Agilent Technologies) according 
to the manufacturer��s specifications. As only 1.5 µg cRNA in a maximum volume of  10 µl RNA-free 
water (AmbionR) can be loaded onto an Illumina array, cRNA sample volumes were if  necessary 
downsized by evaporation using a vacuum centrifuge (Eppendorf).
8.3.3 Micoarray-based gene expression profiling
Samples containing 1.5 µg labeled cRNA were hybridised onto the whole mouse genome gene 
expression microarray “Illumina MouseWG-6 v2.0 Expression BeadChip Kit”. These BeadChips 
consist of  oligonucleotides immobilised to beads held in microwells on the surface of  an array 
substrate. The labelled RNA strand is hybridised to these beads on the BeadChip containing the 
complementary gene-specific sequence. The following hybridisation, washing and signal detection steps 
were performed in cooperation with Dr. Peter Weber from the MPI of  Psychiatry and according to the 
Illumina “WGGEX Direct Hybridization Assay Guide 11322355A”. Utilised buffers and BeadChip-
specific devices were purchased from Illumina unless stated otherwise. Sample randomisation and 
alternate processing between the experimental groups was applied in order to avoid technical bias to 
be correlated with group comparisons.
Hybridisation
The hybridisation oven was set to 58°C. H�B and HCB buffers were heated to 58°C for 10 min in 
this oven, cooled down to RT and thoroughly mixed before use. BeadChips were removed from cold 
storage and equilibrated to RT for 10 min. 200 µl of  HCB buffer were pipetted into the humidifying 
buffer reservoirs of  the Hyb Chamber. Only reservoirs containing BeadChips later on were filled 
with buffer. cRNA probes were brought to a volume of  10 µl either by adding nuclease-free water 
or by vacuum centrifugation (see 8.3.2 cRNA purification). They were incubated for 5 min at 65°C, 
shortly vortexed, pulse centrifuged at 250 x g. and allowed to cool to RT. Subsequently 20 µl of  H�B 
buffer were added to the probes. BeadChips were unpacked and placed into the Hyb Chambers. 
cRNA probes (now 30 µl)  were carfully pipetted onto the center of  each inlet port of  the BeadChips 
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thereby avoiding air bubbles. The Hyb Chamber was then placed into the hybridisation oven (58°C 
with rocking platform inside) according to Illuminas instructions and incubated rocking slowly (speed 
5) at least 14 h but not more than 20 h. 500 ml 1x High-Temp Wash Buffer were added to a Hybex 
Waterbath insert sitting within a Hybex Heating Base and warmed to 55°C over night.
Washing steps
The next day, BeadChips were removed from the Hyb Chamber and submerged face up at the bottom 
of  a Pyrex No. 3140 beaker containing 1 liter of  Wash E1BC buffer. Within the buffer BeadChips 
were consecutively freed from their coverseals and transitionally placed into a slide rack within a glass 
jar containing 250 ml Wash E1BC buffer. Subsequently the slide rack containing all BeadChips was 
transferred into the preheated (55°C) Hybex Waterbath containing the 1x High-Temp Wash Buffer 
and incubated for 10 min. Afterwards BeadChips were thoroughly washed by plunging them 5 to 10 
times into fresh Wash E1BC buffer (250 ml) and shaking them for 5 min at RT on an orbital-shaker at 
medium speed. The rack was now plunged 5 to 10 times into 250 ml 100 % (v/v) ethanol and shaken 
for 10 min at RT on an orbital-shaker at medium speed. BeadChips were placed back into the glass jar 
with the Wash E1BC buffer and shaken for 2 min at RT again.
Blocking
BeadChip Wash Trays containing 4 ml Block E1 buffer were placed on a rocker mixer. BeadChips 
were transferred face up into the wash trays thereby ensuring that they are completely covered with 
buffer and rocked at medium speed for 10 min at RT.
Signal detection
Cy3-Streptavidin (1 mg/ml) was removed from cold storage and equilibrated to RT for 10 min. 2 ml 
of  Block E1 buffer containing Cy3-Streptavidin (dilution 1:1000) were prepared for each BeadChip 
and were poured into BeadChip Wash Trays. BeadChips were now transferred into the Block E1 
buffer with Cy3-Streptavidin ensuring that BeadChips are covered in it. Wash trays were covered with 
a lid and rocked at medium speed for 10 min at RT. BeadChips were then submerged in a rack placed 
in 250 ml Wash E1BC buffer and shaken for 5 min at RT on an orbital-shaker at medium speed. 
Afterwards the rack with the BeadChips was immediately centrifuged at 1.400 rpm for 4 min at RT. 
Once BeadChips were dry they were stored in darkness and scanned within one hour of  the final RT 
washing step.
BeadChip imaging (performed by Dr. Peter Weber, MPI of  Psychiatry)
Microrrays were scanned and intensity extractions were computed using a BeadArray Reader (Illumina) 
via the BeadScan Software (Version 3.7.9) with activated internal outlier detection and a scan factor of  1 
(PMT = 478; PMTFactor = 1). The extracted bead summary data provides gene expression levels 
from 45281 array features per sample. Quality control (QC) of  microarray data was based on visual 
inspection of  scan images, data distributions, internal Illumina controls, pairwise scatterplots and 
statistical outlier detection of  samples. 
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Microarray data processing and statistical analysis (in cooperation with Dr. Peter Weber, MPI of  
Psychiatry)
For the samples fulfilling QC criteria, bead summary scan data were filtered (background removal) for 
detected probes with p-detection < 0.05 in at least three samples in the whole data set. 20242 variables 
remained and were VSN (Variance Stabilising Normalisation) transformed and normalised using the 
bioconductor R package “beadarray” (The R Project for Statistical Computing, R version 2.15.1, 
(Dunning et al., 2007). Hierarchical clustering was also performed in R using the “stats” package. 
��olcano plots were also generated in R. Normalised and filtered data were imported into Qlucore 
Omics Explorer 2.3 (Qlucore) for exploration of  batch effects and for inference testing. Principal 
component analysis (PCA) was used to identify batch effects and artefacts according to correlations of  
the sample structure with putative confounders. PCA is a common multivariate technique for finding 
patterns in data sets comprising high dimensions. The central idea is to reduce the dimensionality of  
a data set consisting of  a large number of  interrelated variables (in our case genes), while retaining as 
much as possible of  the existing variation. This is achieved by transforming to a new set of  variables, 
the so called principal components, which are uncorrelated, and which are ordered so that the first 
few (in our case the first three principal components) retain most of  the variation present in all of  
the original variables (Jolliffe, 2002). So by this means most of  the information is extracted from 
the data set and represented by the principal components. In PCA graphs each point represents one 
sample and its distance to other points reflects its similarity or difference to the other samples (Abdi 
and Williams, 2010). For inference testing and the subsequent generation of  lists with differentially 
regulated genes, variables (individual microarray probes) were further filtered for variance (variance 
> 0.05). Subsequent, statistical tests of  microarray data are based on two group comparisons using 
ANO��A. A mild technical bias was removed by using bead chip-id amplification rounds as co-variate 
in ANOVA. For comparisons among CD19Cre+/- samples paired tests were applied, whereas for the 
other comparisons unpaired tests were performed. To control for false positive rates due to multiple 
testing the Benjamini-Hochberg procedure was used for correction of  the p-values, thereby obtaining 
the Benjamini-Hochberg based FDR-analogue q-values. Annotation of  microarray probes was done 
by using the manufacturer��s annotation file (MouseWG-6_��2_0_R2_11278593_A.bgx). 
Microarray data analysis - Functional Annotation
For functional annotation of  the differentially regulated genes the “Functional Annotation Clustering” 
tool of  the DAVID (Database for Annotation, Visualization and Integrated Discovery) Bioinformatics 
Resources 6.7 was used. Gene lists of  interests were submitted to DAVID by using the Illumina_ID 
as identifier and the “MouseWG-6_��2_0_R2_11278593_A” as backgound (provided by DA��ID 
software). Subsequently the “Functional Annotation Clustering” tool was selected and performed. 
Classification stringencies were set to “high” unless stated otherwise.
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8.4 Protein detection
8.4.1 Protein isolation & quantification
Following MACS purification, ex vivo isolated B cells were rested for one hour in 1 % BCM at 37°C 
before proteins were isolated. In vitro cultured B cells were directly subjected to the protein isolation 
procedure. Cells were washed twice with ice-cold PBS before protein extraction. To prepare whole-
cell extracts, 20 μl of  2x NP40 lysis buffer (100 mM Tris pH 7.4, 300 mM NaCl, 4 mM EDTA, 2 % 
(v/v) NP40) containing freshly added phosphatase inhibitors (Halt phosphatase inhibitor cocktail, 
Pierce) and protease inhibitors (Mini Complete, Roche Diagnostics) were added to a pellet of  5x106 B 
cells without resuspension and reaction tubes were mixed on a vortexer at 4°C for 20 min. Cell debris 
and DNA was separated from the protein supernatant by centrifugation at maximum speed for 15 min 
at 4°C. Protein samples were subsequently frozen at -80°C. Protein concentration of  protein samples 
was measured by using a Bradford reagent (DC protein assay; Bio-Rad) according to manufacturer’s 
instructions and a BSA in standard slope. 
8.4.2 SDS polyacrylamide gel electrophoresis (PAGE)
Protein mixtures were separated by discontinuous SDS PAGE (Laemmli, 1970). In discontinuous 
PAGE, the acrylamide gel is composed of  a stacking gel (5 % (v/v) acrylamide, 0.625 mM Tris pH 
6.8, 0.1 % (w/v) SDS, 0.1 % (w/v) APS, 0.006 % (w/v) TEMED), in which negatively charged 
proteins are focused at the separation line, and a resolving gel (10 to 12 % (v/v) acrylamide, 3.75 mM 
Tris pH 6.8, 0.1 % (w/v) SDS, 0.1 % (w/v) APS, 0.004 % (w/v) TEMED), in which proteins are 
separated according to molecular weight. 5x Laemmli buffer (300 mM Tris pH 6.8, 7.5 % (w/v) SDS, 
50 % (v/v) glycerin, 0.01 % (v/v) bromphenol blue, 1 % (v/v) �-mercaptoethanol) was added to the 
samples to a concentration of  1x before heating the samples at 70°C for 10 min and loading denatured 
proteins onto a SDS polyacrylamide gel together with a protein standard (BenchmarkTM, Invitrogen). 
Electrophoresis was accomplished in Laemmli running buffer (25 mM Tris base, 0.2 M glycine, 0.1 % 
(v/v) SDS) for at least 30 min at 30 V (stacking gel) and after that at up to 100 V (resolving gel), using 
a Bio-Rad electrophoresis chamber.
8.4.3 Western blotting
After having separated proteins by SDS PAGE, proteins were transferred onto a polyvinyliden-fluoride 
(PVDF) membrane by using electrical current (Western blotting, (Towbin et al., 1979). Proteins were 
blotted to the PVDF membrane (ImmobilonTM P membrane, Millipore) by wet transfer over night at 
80 mA per gel in transfer buffer (25 mM Tris base, 0.2 M glycine, 20 % (v/v) methanol), utilising a 
Bio-Rad mini tank blotting chamber on a magnetic stirrer in the cold room. To verify protein transfer 
and equal loading, the membrane was incubated for 5 min in Ponceau S solution (Sigma-Aldrich) to 
stain proteins non-specifically.
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8.4.4 Immunostaining
Non-specific binding sites were blocked by incubating membranes at RT in TBST (0.1 M Tris/HCl 
pH 7.5, 0.1 M NaCl, 0.02 % (v/v) Tween20), containing 5 % (w/v) BSA, for several hours with slight 
shaking. Incubation with the primary antibody was performed over night at 4°C in TBST, containing 
5 % (w/v) BSA, unless stated otherwise. The membrane was incubated with the secondary antibody, 
conjugated to HRP, diluted in TBST, containing 1 - 5 % (w/v) milk powder, for two hours at RT. 
Antibody incubation was always performed on a roller and the membranes were washed three times 
in between and afterwards with TBST for 7 min with vigorous shaking. Proteins were visualised using 
Enhanced Chemiluminescence ECLTM (GE Healthcare) according to manufacturer’s instructions. 
Signals were detected by the exposition of  photosensitive films (CEA RP new) using a Cawomat 2000 
IR processor (both ErnstChristiansen). For reprobing with further antibodies, bound antibodies were 
stripped from the membrane by incubating in stripping buffer (62.5 mM Tris/HCl pH 6.8, 2 % (w/v) 
SDS, 100 mM �-mercaptoethanol) at 56°C for 30 min slightly shaking.
8.4.5 Western blot quantification
Films (Agfa Healthcare) were scanned with an Epson Expression-1680Pro scanner. For Western blot 
quantification by densitometry, films were scanned in transmission mode with off-switched automatic 
gain control. A reference film was generated by creating an exposure series with the use of  defined 
light quantities. All films (including reference film) were scanned using identical scanning conditions. 
The reference film ensured that only Western blot bands within the dynamic range of  the film and 
scanner were quantified. Thus, this reference assured that only films on which signals of  the respective 
proteins were not overexposed were used for densitometry. Images were quantified with ImageJ 
1.43 (NIH) according to the tutorial on www.lukemiller.org “Analyzing gels and Western blots with 
ImageJ” using the “area under the curve” values. The ration between the “area” of  the analysed 
protein and the “area” of  the reference protein (in this work GSK-3) were generated and used for 
further calculations.
8.5 Statistics
Two-tailed Student t-test was calculated using GraphPad Prism 4 software and was applied to 
determine the significance of  splenic weight values, cell numbers, antibody titers, percentages and 
absolute numbers of  flow cytometrically analysed cell populations and ratios of  signal intensities from 
immunoblotting. 
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10. Appendix
Supplementary Data
Table S1: Top 100 regulated genes between wild type MZ B and Fo B cells.
Probe_ID Gene symbol Accession q-value Relat. expression Fold change
ILMN_2765759 Asb2 NM_023049.1 9.85E-05 28.3245 28.3245
ILMN_2747923 Slc40a1 NM_016917.2 1.15E-03 14.7752 14.7752
ILMN_1227577 Rap1gap NM_001081155.1 1.38E-04 12.7579 12.7579
ILMN_2756046 Ffar2 NM_146187.3 1.84E-04 12.7011 12.7011
ILMN_2878071 Lyz NM_013590.2 2.86E-04 12.3668 12.3668
ILMN_1246808 Serpine2 AK045954 2.86E-04 12.0890 12.0890
ILMN_2778655 Vcam1 NM_011693.2 1.31E-03 10.6918 10.6918
ILMN_1223416 Fer1l3 XM_001480162.1 2.86E-04 9.7781 9.7781
ILMN_2651715 Axl NM_009465.3 2.25E-03 8.7607 8.7607
ILMN_2699531 Rgs10 NM_026418.2 9.04E-05 7.3290 7.3290
ILMN_2975312 Fcer2a (CD23) NM_013517.1 3.02E-04 0.1368 -7.3074
ILMN_2650557 Ccbp2 NM_021609.3 3.41E-04 7.2927 7.2927
ILMN_1237406 Itgad (CD11d) NM_001029872.1 1.57E-03 7.2887 7.2887
ILMN_2718589 Fcna NM_007995.3 1.12E-03 6.8123 6.8123
ILMN_1214608 Plxnd1 NM_026376.3 2.33E-04 6.4647 6.4647
ILMN_2432550 Trib2 NM_144551.3 8.41E-04 0.1711 -5.8450
ILMN_3092056 Itgad (CD11d) NM_001029872.1 1.82E-03 5.6914 5.6914
ILMN_1256771 Adrbk2 NM_001035531.1 3.02E-04 5.3235 5.3235
ILMN_2722996 Sirpa NM_007547.2 1.60E-03 5.2973 5.2973
ILMN_2725414 Cd9 NM_007657.2 3.94E-04 5.2842 5.2842
ILMN_2652877 Fcer2a (CD23) NM_013517.3 4.32E-04 0.1899 -5.2667
ILMN_1256817 Slpi NM_011414.2 1.73E-03 5.2381 5.2381
ILMN_2652875 Fcer2a (CD23) NM_013517.1 6.55E-04 0.1911 -5.2328
ILMN_2641793 Dtx1 NM_008052.3 8.65E-04 5.0124 5.0124
ILMN_2925653 Ear2 NM_007895.2 9.80E-04 5.0116 5.0116
ILMN_2604029 Klf2 NM_008452.1 9.61E-04 0.2007 -4.9818
ILMN_3124528 Hvcn1 NM_001042489.1 9.05E-04 0.2031 -4.9232
ILMN_2631161 Fcgr4 NM_144559.1 9.80E-04 4.9071 4.9071
ILMN_1228942 Cd59a NM_007652.2 4.96E-04 4.8092 4.8092
ILMN_1252076 Lyz2 NM_017372.3 9.20E-04 4.7926 4.7926
ILMN_2635272 Igh-VJ558 XM_001472091.1 8.84E-03 4.7819 4.7819
ILMN_2939681 Lyzs NM_017372.2 9.04E-05 4.7193 4.7193
ILMN_2790357 Sema7a NM_011352.2 1.07E-03 4.6383 4.6383
ILMN_1235456 Icosl AK041320 4.99E-03 0.2185 -4.5773
ILMN_2734212 Cd1d1 NM_007639.2 1.90E-04 4.4784 4.4784
ILMN_1243451 Hvcn1 NM_001042489.1 9.13E-04 0.2237 -4.4705
ILMN_1252005 B230334I05Rik AK046024 5.30E-04 4.4704 4.4704
ILMN_1256142 Marcks NM_008538.2 3.17E-04 4.3772 4.3772
ILMN_2903945 Gadd45g NM_011817.1 8.66E-04 0.2290 -4.3675
ILMN_2678127 Rnf144a NM_080563.3 3.41E-04 0.2309 -4.3300
ILMN_1253387 Klf5 NM_009769.4 6.55E-04 4.2957 4.2957
ILMN_1224754 Ckb NM_021273.3 9.55E-04 4.2489 4.2489
ILMN_1214783 A530050E01Rik AK040949 2.72E-04 0.2361 -4.2362
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Probe_ID Gene symbol Accession q-value Relat. expression Fold change
ILMN_1258908 A630008H02Rik AK041423 6.42E-04 0.2399 -4.1680
ILMN_2731735 Ear2 NM_007895.2 1.23E-03 4.1603 4.1603
ILMN_2716622 Mapk11 NM_011161.4 5.90E-04 0.2417 -4.1374
ILMN_2644587 Bzw2 NM_025840.2 1.38E-04 4.0998 4.0998
ILMN_2485323 Trf NM_133977.2 1.47E-03 4.0838 4.0839
ILMN_1220975 Ptpn22 NM_008979.1 1.63E-03 4.0757 4.0757
ILMN_2813830 Nt5e NM_011851.2 3.56E-04 4.0480 4.0481
ILMN_2619620 C1qb NM_009777.2 1.94E-03 4.0340 4.0340
ILMN_2729252 5830431A10Rik XR_002313.1 8.24E-06 0.2487 -4.0209
ILMN_2819558 Bach2 NM_007521.2 1.66E-03 0.2487 -4.0205
ILMN_2595973 Grn NM_008175.3 1.07E-03 3.9967 3.9967
ILMN_2703329 AI324046 NM_198640.1 1.07E-03 3.9649 3.9649
ILMN_1231884 Tmem121 NM_153776.2 2.27E-03 3.9454 3.9454
ILMN_1229449 B930008G09Rik AK046968 1.31E-04 0.2548 -3.9253
ILMN_2982781 Kcnk5 NM_021542.2 5.52E-04 3.9241 3.9241
ILMN_1252514 C920016N10Rik AK083355 2.26E-04 3.9092 3.9092
ILMN_2658501 Ifitm3 NM_025378.2 1.09E-03 3.8847 3.8847
ILMN_2858200 Klk4 NM_019928.1 1.29E-03 3.8793 3.8793
ILMN_2593994 5033430I15Rik XM_001473131.1 7.00E-04 3.8783 3.8783
ILMN_2721198 Ggnbp1 NM_027544.1 3.18E-04 3.8592 3.8592
ILMN_3162075 Fcrl5 NM_183222.2 8.41E-04 3.8235 3.8235
ILMN_2819586 Gpr156 NM_153394.2 4.32E-04 3.8025 3.8025
ILMN_2523841 AI324046 NM_198640.1 1.01E-03 3.7954 3.7954
ILMN_1226073 Trps1 AK036590 4.96E-04 3.7904 3.7904
ILMN_1250135 A930005H10Rik 1.07E-03 3.7854 3.7854
ILMN_2988143 Plac8 NM_139198.1 3.34E-04 3.7721 3.7721
ILMN_2657828 Rhbdf1 NM_010117.1 1.16E-03 3.7299 3.7299
ILMN_2715840 C1qc NM_007574.2 1.79E-03 3.7179 3.7179
ILMN_1248714 Cd55 NM_010016.2 4.97E-04 0.2705 -3.6963
ILMN_1244272 Epb4.1l3 NM_013813.1 1.59E-03 3.6443 3.6443
ILMN_1248890 AW011738 XM_489070 3.27E-04 3.6175 3.6175
ILMN_2749364 LOC382646 XM_356604.1 2.33E-04 0.2768 -3.6124
ILMN_2749363 LOC382646 XM_356604.1 1.38E-04 0.2779 -3.5978
ILMN_2883164 Serpine2 NM_009255.2 2.44E-03 3.5904 3.5904
ILMN_2721439 Csrp2 NM_007792.3 6.44E-03 0.2798 -3.5746
ILMN_1250195 Ndrg1 NM_008681.2 1.09E-03 0.2798 -3.5735
ILMN_1234988 Gad1 NM_008077.4 3.09E-04 0.2817 -3.5494
ILMN_1217527 Ly108 AK089750 6.56E-04 0.2839 -3.5219
ILMN_2576568 D130062J21Rik AK051661 3.09E-04 0.2846 -3.5134
ILMN_1259764 1500005K14Rik XM_203453 9.80E-04 0.2855 -3.5024
ILMN_3112011 Dusp16 NM_130447.2 8.73E-04 3.4977 3.4977
ILMN_1239430 Mrc1 NM_008625.1 2.49E-03 3.4964 3.4964
ILMN_2692615 Tgm2 NM_009373.3 1.68E-03 3.4824 3.4824
ILMN_3005873 Sort1 NM_019972.2 1.98E-03 3.4797 3.4797
ILMN_2792485 Ube2e2 NM_144839.1 5.27E-04 3.4572 3.4572
ILMN_1254409 Atxn1 NM_009124.4 4.29E-04 3.4526 3.4526
ILMN_1258272 LOC382646 XM_356604.1 4.96E-04 0.2907 -3.4404
Table S1 continued:
Supplementary Data
122
Probe_ID Gene symbol Accession q-value Relat. expression Fold change
ILMN_2550095 6230425C21Rik AK012678 3.25E-04 3.4337 3.4337
ILMN_1237978 9930005O13Rik AK036773 1.07E-03 0.2915 -3.4303
ILMN_1228320 Cfp NM_008823.3 4.97E-04 3.4050 3.4050
ILMN_2710819 Csf1r NM_001037859.2 2.37E-03 3.3507 3.3507
ILMN_2619707 Slco2b1 NM_175316.3 3.75E-03 3.3233 3.3233
ILMN_2901626 Tnfrsf21 NM_178589.2 8.03E-04 3.3072 3.3072
ILMN_1253182 Hs3st1 NM_010474.1 1.54E-03 3.3009 3.3009
ILMN_2721571 Slamf1 NM_013730.4 3.41E-04 0.3078 -3.2491
ILMN_1234020 scl0002007.1_97 5.90E-04 3.2469 3.2469
ILMN_3091003 Ms4a7 NM_027836.5 6.10E-04 3.2372 3.2372
Final gene lists from the comparison wild type MZ B vs. Fo B cells were sorted by q-value and only genes with a 
q-value < 0.05 were chosen. Remaining genes were sorted according to their absolute fold change (regardless of 
up- or downregulation) and the top 100 most strongly regulated genes were chosen for this table. Genes upregu-
lated in MZ B have positive fold change values, genes upregulated in Fo B cells negative values. Illumina internal 
identifier (Probe_ID).
Table S2: Top 100 regulated genes between Notch2-deficient Fo B and Notch2IC-expressing MZ B cells.
Probe_ID Gene symbol    Accession q-value Relat. expression Fold change
ILMN_2765759 Asb2 NM_023049.1 8.04E-06 0.0328 -30.4901
ILMN_2756046 Ffar2 NM_146187.3 1.76E-05 0.0378 -26.4380
ILMN_2975312 Fcer2a (CD23) NM_013517.1 8.04E-06 25.7955 25.7955
ILMN_1214608 Plxnd1 NM_026376.3 7.50E-06 0.0456 -21.9239
ILMN_2699531 Rgs10 NM_026418.2 8.04E-06 0.0467 -21.3948
ILMN_1223416 Fer1l3 XM_001480162.1 1.61E-05 0.0483 -20.6941
ILMN_2792485 Ube2e2 NM_144839.1 8.04E-06 0.0514 -19.4489
ILMN_1227577 Rap1gap NM_001081155.1 2.98E-05 0.0552 -18.1162
ILMN_1256771 Adrbk2 NM_001035531.1 7.73E-05 0.0712 -14.0538
ILMN_2725414 Cd9 NM_007657.2 1.20E-05 0.0723 -13.8279
ILMN_2641793 Dtx1 NM_008052.3 7.50E-06 0.0737 -13.5603
ILMN_1243451 Hvcn1 NM_001042489.1 1.90E-05 12.8988 12.8988
ILMN_2604029 Klf2 NM_008452.1 2.78E-05 12.6686 12.6686
ILMN_2550095 6230425C21Rik AK012678 1.59E-05 0.0873 -11.4513
ILMN_3124528 Hvcn1 NM_001042489.1 2.26E-05 10.8238 10.8238
ILMN_2759207 Kcne1 NM_008424.2 3.53E-05 0.0926 -10.8045
ILMN_2790357 Sema7a NM_011352.2 3.99E-05 0.0936 -10.6794
ILMN_2652875 Fcer2a (CD23) NM_013517.1 2.35E-05 10.2966 10.2966
ILMN_2652877 Fcer2a (CD23) NM_013517.3 5.38E-05 9.5545 9.5545
ILMN_2716622 Mapk11 NM_011161.4 1.91E-05 8.2945 8.2945
ILMN_1253182 Hs3st1 NM_010474.1 6.92E-05 0.1207 -8.2869
ILMN_1227434 Itgb7 NM_013566.1 2.51E-05 8.2575 8.2575
ILMN_2692615 Tgm2 NM_009373.3 1.88E-05 0.1224 -8.1727
ILMN_2856926 Gpr114 NM_001033468.1 1.42E-05 0.1280 -7.8121
ILMN_2819586 Gpr156 NM_153394.2 1.92E-05 0.1310 -7.6320
ILMN_2467596 Dusp16 NM_001048054.1 1.59E-05 0.1356 -7.3756
ILMN_2988143 Plac8 NM_139198.1 2.51E-05 0.1365 -7.3269
ILMN_1259339 Cdk5r1 NM_009871.2 2.27E-05 0.1378 -7.2581
ILMN_2644587 Bzw2 NM_025840.2 2.51E-05 0.1442 -6.9355
ILMN_1248714 Cd55 NM_010016.2 3.65E-05 6.5238 6.5238
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Probe_ID Gene symbol    Accession q-value Relat. expression Fold change
ILMN_1252005 B230334I05Rik AK046024 2.79E-04 0.1605 -6.2310
ILMN_2749363 LOC382646 XM_356604.1 1.32E-04 6.2302 6.2302
ILMN_2724570 Mapk12 NM_013871.2 1.98E-05 6.2168 6.2168
ILMN_2749364 LOC382646 XM_356604.1 8.00E-05 6.1651 6.1651
ILMN_1258272 LOC382646 XM_356604.1 8.36E-05 6.1639 6.1639
ILMN_2903945 Gadd45g NM_011817.1 2.43E-05 6.1586 6.1586
ILMN_1220124 Gpr156 NM_153394.2 7.50E-06 0.1632 -6.1289
ILMN_2432550 Trib2 NM_144551.3 1.90E-04 6.0388 6.0388
ILMN_2645780 Osgin1 NM_027950.1 1.48E-05 0.1699 -5.8864
ILMN_1219878 9930022F21Rik AK036897 1.47E-05 0.1753 -5.7043
ILMN_1248890 AW011738 XM_489070 1.59E-05 0.1754 -5.7010
ILMN_2798086 Fchsd2 NM_199012.1 1.95E-05 5.6693 5.6693
ILMN_2683316 Ctsb NM_007798.2 1.84E-05 0.1767 -5.6586
ILMN_1228942 Cd59a NM_007652.2 3.17E-04 0.1787 -5.5963
ILMN_3112011 Dusp16 NM_130447.2 7.50E-06 0.1808 -5.5302
ILMN_1221819 Fcgrt NM_010189 6.04E-04 5.4677 5.4677
ILMN_3150811 Tsc22d3 NM_001077364.1 2.28E-03 5.4559 5.4559
ILMN_2650557 Ccbp2 NM_021609.3 8.04E-06 0.1834 -5.4530
ILMN_2958099 Adssl1 NM_007421.1 2.20E-05 0.1836 -5.4481
ILMN_2661340 Slco4a1 NM_148933.1 3.48E-05 0.1868 -5.3529
ILMN_1253414 Hes5 NM_010419.2 7.43E-05 0.1877 -5.3283
ILMN_1256142 Marcks NM_008538.2 7.50E-06 0.1888 -5.2970
ILMN_1229449 B930008G09Rik AK046968 9.86E-05 5.1300 5.1300
ILMN_2593994 5033430I15Rik XM_001473131.1 8.04E-06 0.1969 -5.0794
ILMN_2982781 Kcnk5 NM_021542.2 2.45E-04 0.1988 -5.0300
ILMN_2592486 Pglyrp1 NM_009402.1 9.87E-05 5.0035 5.0035
ILMN_1246808 Serpine2 AK045954 4.15E-04 0.2008 -4.9790
ILMN_2729252 5830431A10Rik XR_002313.1 1.84E-05 4.9626 4.9626
ILMN_2593787 Kcnk13 NM_146037.1 3.45E-05 0.2033 -4.9184
ILMN_2451022 Vim NM_011701.3 2.16E-04 4.9042 4.9042
ILMN_2595973 Grn NM_008175.3 4.42E-05 0.2047 -4.8863
ILMN_1252514 C920016N10Rik AK083355 2.43E-05 0.2069 -4.8333
ILMN_2819558 Bach2 NM_007521.2 7.37E-04 4.7991 4.7991
ILMN_2583351 D930042A21Rik AK086621 2.82E-05 0.2090 -4.7836
ILMN_1247691 Hes1 NM_008235.2 4.87E-05 0.2097 -4.7678
ILMN_2734212 Cd1d1 NM_007639.2 1.90E-04 0.2099 -4.7642
ILMN_2667994 Dnase1l3 NM_007870.2 2.43E-05 0.2107 -4.7472
ILMN_2733356 Endod1 NM_028013.2 6.14E-05 0.2121 -4.7149
ILMN_2984744 Emp3 NM_010129.1 1.07E-04 4.6659 4.6659
ILMN_1231851 Enpp1 NM_008813.3 7.50E-06 4.5977 4.5977
ILMN_1223317 Lgals3 NM_010705.2 3.35E-04 4.5963 4.5963
ILMN_2743902 Matk NM_010768.1 7.16E-05 0.2226 -4.4927
ILMN_2624153 Hes5 NM_010419.4 1.89E-04 0.2250 -4.4450
ILMN_2818246 Cpne4 NM_028719.1 1.04E-04 4.4216 4.4216
ILMN_1212982 Zfp318 NM_207671.2 1.99E-04 4.3960 4.3960
ILMN_1216368 B3gnt5 NM_054052.2 1.18E-04 4.3648 4.3648
ILMN_1247704 Hmgn3 NM_175074.1 3.35E-05 0.2298 -4.3523
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ILMN_2678127 Rnf144a NM_080563.3 8.39E-05 4.3147 4.3147
ILMN_2754148 Dusp16 NM_001048054.1 8.04E-06 0.2331 -4.2893
ILMN_2506039 A130090K04Rik 3.47E-04 0.2345 -4.2651
ILMN_2843782 Tpst2 NM_009419.2 1.20E-04 0.2374 -4.2129
ILMN_2914010 Dmwd NM_010058.1 1.60E-05 4.2018 4.2018
ILMN_2645208 Arhgef3 NM_027871.1 2.17E-05 4.1699 4.1699
ILMN_3128992 Cd27 NM_001033126.2 6.58E-05 0.2400 -4.1666
ILMN_2674367 Agrn NM_021604.2 3.09E-05 0.2411 -4.1480
ILMN_2675785 Myo18b XM_912851.3 2.45E-04 0.2413 -4.1443
ILMN_2508910 Tpst2 NM_009419 1.19E-04 0.2428 -4.1182
ILMN_2878071 Lyz NM_013590.2 9.68E-03 0.2436 -4.1059
ILMN_2644719 Hmgn3 NM_026122.3 1.71E-05 0.2444 -4.0918
ILMN_1248028 Emp3 NM_010129.1 1.20E-05 4.0509 4.0509
ILMN_2502471 BC023892 XM_994662.1 2.31E-05 4.0467 4.0467
ILMN_2782964 Enpp1 NM_008813.2 1.15E-04 4.0394 4.0394
ILMN_3091003 Ms4a7 NM_027836.5 1.32E-04 0.2479 -4.0339
ILMN_2917497 Fcgrt NM_010189.1 1.28E-04 4.0308 4.0308
ILMN_2767605 Lmo2 NM_008505.3 8.04E-06 4.0263 4.0263
ILMN_2458765 Ahnak NM_009643.1 1.24E-03 4.0209 4.0209
ILMN_2744846 Guca2b NM_008191.1 8.04E-06 0.2494 -4.0104
ILMN_2772582 Smad3 NM_016769 7.36E-05 0.2515 -3.9758
ILMN_2629191 Cpm XM_994613.1 2.07E-04 3.9512 3.9512
ILMN_1226766 B430320J11Rik AK046714 2.45E-04 0.2536 -3.9434
Final gene lists from the comparison Notch2-deficient Fo B vs. Notch2IC-expressing MZ B cells were sorted by q-
value and only genes with a q-value < 0.05 were chosen. Remaining genes were sorted according to their absolute 
fold change (regardless of up- or downregulation) and the top 100 most strongly regulated genes were chosen 
for this table. Genes upregulated in Notch2-deficient cells have positive fold change values, genes upregulated in 
Notch2IC-expressing cells negative values. Illumina internal identifier (Probe_ID).
Table S3: Top 100 regulated genes between wild type and Notch2IC-expressing MZ B cells.
Probe_ID Gene symbol Accession q-value Relat. expression Fold change
ILMN_2759207 Kcne1 NM_008424.2 8.11E-05 0.0844 -11.8446
ILMN_2792485 Ube2e2 NM_144839.1 4.31E-04 0.1410 -7.0915
ILMN_2467596 Dusp16 NM_001048054.1 1.51E-04 0.1711 -5.8452
ILMN_1253414 Hes5 NM_010419.2 1.51E-04 0.1874 -5.3363
ILMN_2661340 Slco4a1 NM_148933.1 2.81E-04 0.1930 -5.1818
ILMN_1377919 Tubb2b NM_023716.2 4.42E-04 0.2017 -4.9576
ILMN_2856926 Gpr114 NM_001033468.1 1.51E-04 0.2091 -4.7824
ILMN_1219878 9930022F21Rik AK036897 8.11E-05 0.2149 -4.6531
ILMN_2747923 Slc40a1 NM_016917.2 3.55E-02 4.4105 4.4105
ILMN_2624153 Hes5 NM_010419.4 3.29E-04 0.2307 -4.3345
ILMN_2778655 Vcam1 NM_011693.2 2.97E-02 4.2022 4.2022
ILMN_1214608 Plxnd1 NM_026376.3 1.40E-03 0.2420 -4.1327
ILMN_2550095 6230425C21Rik AK012678 1.65E-03 0.2492 -4.0127
ILMN_2645780 Osgin1 NM_027950.1 7.97E-04 0.2630 -3.8024
ILMN_2596979 Nrarp NM_025980.2 8.54E-04 0.2723 -3.6720
ILMN_2975312 Fcer2a (CD23) NM_013517.1 3.55E-03 3.6246 3.6246
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ILMN_1221819 Fcgrt NM_010189 2.43E-02 3.6220 3.6220
ILMN_1237406 Itgad (CD11d) NM_001029872.1 1.90E-02 3.5631 3.5631
ILMN_2651715 Axl NM_009465.3 3.79E-02 3.5387 3.5387
ILMN_2725414 Cd9 NM_007657.2 1.21E-03 0.2964 -3.3740
ILMN_2958099 Adssl1 NM_007421.1 3.69E-04 0.2990 -3.3446
ILMN_1243451 Hvcn1 NM_001042489.1 6.51E-03 3.3340 3.3340
ILMN_2780247 Lta NM_010735.1 3.80E-03 3.2637 3.2637
ILMN_1256817 Slpi NM_011414.2 2.30E-02 3.2626 3.2626
ILMN_1256771 Adrbk2 NM_001035531.1 4.26E-03 0.3143 -3.1814
ILMN_2740869 Rims2 NM_053271.1 3.66E-03 0.3147 -3.1778
ILMN_2604029 Klf2 NM_008452.1 3.84E-03 3.1291 3.1291
ILMN_1236799 Ttll2 NM_001098267.1 2.77E-04 0.3202 -3.1228
ILMN_2657980 Faah NM_010173.3 1.65E-03 3.0948 3.0948
ILMN_3092056 Itgad (CD11d) NM_001029872.1 2.24E-02 3.0924 3.0924
ILMN_2718589 Fcna NM_007995.3 2.75E-02 3.0922 3.0922
ILMN_2595918 Gimap7 NM_146167.3 8.51E-03 3.0058 3.0058
ILMN_2638509 LOC639715 XM_916269.3 1.39E-03 0.3416 -2.9271
ILMN_2657175 Anxa2 NM_007585.3 1.59E-02 2.9255 2.9255
ILMN_2790357 Sema7a NM_011352.2 4.59E-04 0.3426 -2.9186
ILMN_2699531 Rgs10 NM_026418.2 4.59E-04 0.3469 -2.8823
ILMN_3128992 Cd27 NM_001033126.2 5.27E-03 0.3480 -2.8733
ILMN_1245079 Adssl1 NM_007421.1 6.29E-04 0.3564 -2.8062
ILMN_3124528 Hvcn1 NM_001042489.1 1.84E-02 2.7792 2.7792
ILMN_1227434 Itgb7 NM_013566.1 7.60E-04 2.7397 2.7397
ILMN_2756046 Ffar2 NM_146187.3 8.26E-03 0.3663 -2.7304
ILMN_2917497 Fcgrt NM_010189.1 7.61E-03 2.6365 2.6365
ILMN_1252601 Bcl7a NM_029850.2 1.02E-03 0.3805 -2.6284
ILMN_2593787 Kcnk13 NM_146037.1 1.07E-03 0.3827 -2.6131
ILMN_2495896 IGKV1-88_AJ231206
Ig�variable1-88_289
8.31E-03 2.6004 2.6004
ILMN_2675785 Myo18b XM_912851.3 2.35E-03 0.3847 -2.5994
ILMN_2592486 Pglyrp1 NM_009402.1 2.77E-03 2.5918 2.5918
ILMN_2692615 Tgm2 NM_009373.3 1.47E-02 0.3868 -2.5854
ILMN_1213139 Heyl NM_013905.3 4.42E-04 0.3918 -2.5520
ILMN_2596932 Rapgef2 NM_001099624.1 8.32E-05 0.4069 -2.4579
ILMN_2919786 Erh NM_007951.1 3.62E-02 0.4077 -2.4528
ILMN_2715840 C1qc NM_007574.2 1.56E-02 2.4276 2.4276
ILMN_1220124 Gpr156 NM_153394.2 3.80E-03 0.4128 -2.4222
ILMN_2819586 Gpr156 NM_153394.2 8.42E-03 0.4165 -2.4012
ILMN_2619620 C1qb NM_009777.2 3.34E-02 2.3785 2.3785
ILMN_1217879 LOC100042777 XM_001478939.1 3.45E-02 0.4220 -2.3698
ILMN_2485323 Trf NM_133977.2 3.68E-02 2.3441 2.3441
ILMN_2458765 Ahnak NM_009643.1 2.79E-03 2.3150 2.3150
ILMN_2682162 Bcl2 NM_177410.2 3.55E-03 2.3137 2.3137
ILMN_1223317 Lgals3 NM_010705.2 1.16E-02 2.3002 2.3002
ILMN_2766930 Faah NM_010173.3 3.80E-03 2.2839 2.2839
ILMN_2619707 Slco2b1 NM_175316.3 4.05E-02 2.2666 2.2666
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ILMN_2440634 3526401B18Rik 4.42E-04 2.2616 2.2616
ILMN_2770119 Zbtb32 NM_021397.2 5.22E-02 2.2580 2.2580
ILMN_1231915 LOC633273 XM_919047.2 5.73E-03 0.4430 -2.2573
ILMN_1216880 Emr1 NM_010130.3 1.34E-02 2.2525 2.2525
ILMN_2742840 Gpr34 NM_011823.4 3.29E-04 2.2508 2.2508
ILMN_3005873 Sort1 NM_019972.2 3.26E-02 2.2253 2.2253
ILMN_1231884 Tmem121 NM_153776.2 5.05E-02 2.2198 2.2198
ILMN_2743902 Matk NM_010768.1 2.31E-04 0.4510 -2.2172
ILMN_2467151 Cyp11a1 NM_019779 3.46E-03 0.4513 -2.2157
ILMN_2925653 Ear2 NM_007895.2 5.02E-02 2.2150 2.2150
ILMN_1239430 Mrc1 NM_008625.1 3.89E-02 2.1936 2.1936
ILMN_2658501 Ifitm3 NM_025378.2 2.39E-02 2.1835 2.1835
ILMN_2716622 Mapk11 NM_011161.4 7.80E-03 2.1777 2.1777
ILMN_2742152 Gadd45a NM_007836.1 3.60E-03 0.4596 -2.1760
ILMN_1255207 LOC100047749 XM_001478817.1 1.65E-03 2.1474 2.1474
ILMN_3158919 Prkcz NM_001039079.1 1.77E-03 2.1360 2.1360
ILMN_1217032 D230048P18Rik AK052127 2.24E-02 0.4689 -2.1325
ILMN_1238725 C130086J11Rik AK081910 3.65E-02 2.1207 2.1207
ILMN_2697002 Tlr3 NM_126166.4 1.02E-03 0.4719 -2.1191
ILMN_1249975 Ighg XM_001001076.2 1.56E-02 0.4729 -2.1146
ILMN_1244272 Epb4.1l3 NM_013813.1 3.67E-02 2.1036 2.1036
ILMN_2903945 Gadd45g NM_011817.1 3.67E-02 2.0957 2.0957
ILMN_2826881 Mybl2 NM_008652.2 7.60E-04 0.4780 -2.0919
ILMN_1226607 Cort NM_007745.3 7.40E-03 2.0916 2.0916
ILMN_2522460 3010031K01Rik 5.23E-03 0.4811 -2.0784
ILMN_2657828 Rhbdf1 NM_010117.1 3.79E-03 2.0671 2.0671
ILMN_1236107 Ogfrl1 XM_973033.1 7.40E-03 0.4849 -2.0622
ILMN_2684205 4930431B09Rik XR_002338.2 5.46E-03 0.4873 -2.0522
ILMN_3112011 Dusp16 NM_130447.2 2.73E-02 0.4891 -2.0446
ILMN_1227836 Arpc1b NM_023142.1 1.67E-02 0.4901 -2.0402
ILMN_3162125 Grm6 NM_173372.1 2.24E-02 2.0377 2.0377
ILMN_2795791 Tmem38b NM_028053.1 3.60E-03 0.4911 -2.0362
ILMN_2744846 Guca2b NM_008191.1 8.11E-05 0.4912 -2.0360
ILMN_1233809 Cmtm7 NM_133978.1 7.79E-03 2.0324 2.0324
ILMN_2715042 Sdc3 NM_011520.3 4.45E-02 2.0316 2.0316
ILMN_1218799 Emb NM_010330.3 2.35E-03 2.0246 2.0246
ILMN_2960114 Cyp27a1 NM_024264.3 6.29E-04 0.4944 -2.0225
ILMN_2631143 Sox5 NM_011444.1 2.57E-03 2.0208 2.0208
Final gene lists from the comparison wild type MZ B vs. Notch2IC-expressing MZ B cells were sorted by q-value 
and only genes with a q-value < 0.05 were chosen. Remaining genes were sorted according to their absolute fold 
change (regardless of up- or downregulation) and the top 100 most strongly regulated genes were chosen for this 
table. Genes upregulated in wild type MZ B cells have positive fold change values, genes upregulated in Notch2IC-
expressing cells negative values. Illumina internal identifier (Probe_ID).
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Table S4: Top 100 regulated genes between wild type and Notch2-deficient Fo B cells.
Probe_ID Gene symbol Accession q-value Relat. expression Fold change
ILMN_1256699 Sfi1 NM_030207.2 1.17E-03 0.2882 -3.4696
ILMN_1260218 Sfi1 NM_030207.2 1.81E-04 0.2930 -3.4130
ILMN_2655015 Alad NM_008525.3 9.42E-04 2.4674 2.4674
ILMN_1259339 Cdk5r1 NM_009871.2 1.41E-03 2.4265 2.4265
ILMN_2944601 4933439C20Rik NM_001004146.1 1.41E-03 0.4442 -2.2512
ILMN_2762380 Enpp4 NM_199016.2 1.81E-04 0.4536 -2.2048
ILMN_2641793 Dtx1 NM_008052.3 3.74E-03 2.1099 2.1099
ILMN_1222071 C920004C08Rik 3.74E-03 0.4843 -2.0647
ILMN_1255287 Mela NM_008581 2.86E-02 0.5075 -1.9706
ILMN_1228919 St13 NM_133726.2 5.43E-02 1.8862 1.8862
ILMN_2988143 Plac8 NM_139198.1 1.41E-03 1.8375 1.8375
ILMN_1377919 Tubb2b NM_023716.2 1.45E-02 1.8324 1.8324
ILMN_1253182 Hs3st1 NM_010474.1 4.56E-02 1.7933 1.7933
ILMN_2645333 H60a NM_010400.2 3.74E-03 1.7921 1.7921
ILMN_2705578 Snx30 NM_172468.2 1.34E-02 1.7879 1.7879
ILMN_2732848 Tagln2 NM_178598.2 2.17E-02 0.5648 -1.7706
ILMN_2583351 D930042A21Rik AK086621 3.45E-03 1.7331 1.7331
ILMN_2672597 Gng10 NM_025277.3 3.38E-03 1.6775 1.6775
ILMN_2697615 Mapk12 NM_013871.2 3.97E-02 0.6006 -1.6651
ILMN_1214874 LOC386068 XM_359052.1 2.48E-02 0.6032 -1.6579
ILMN_1228093 Arhgap8 NM_028455.2 1.50E-03 0.6173 -1.6200
ILMN_2817714 Tspan17 NM_028841.1 1.25E-02 0.6221 -1.6075
ILMN_1247691 Hes1 NM_008235.2 5.01E-03 1.5835 1.5835
ILMN_2700166 Ccnd2 NM_009829.3 1.75E-02 1.5732 1.5732
ILMN_1228320 Cfp NM_008823.3 3.14E-02 1.5712 1.5712
ILMN_2967266 Fxyd5 NM_008761.2 5.42E-02 0.6379 -1.5677
ILMN_2733356 Endod1 NM_028013.2 2.71E-02 1.5645 1.5645
ILMN_2657980 Faah NM_010173.3 4.63E-03 0.6419 -1.5579
ILMN_2965669 Xlr4a NM_001081642.1 3.97E-02 1.5562 1.5562
ILMN_1252288 2010007H06Rik 2.56E-02 0.6527 -1.5322
ILMN_2421220 Brwd1 NM_145125.2 7.92E-03 1.5295 1.5295
ILMN_2700168 Ccnd2 NM_009829 4.79E-02 1.5203 1.5203
ILMN_1249378 Bhlhb2 NM_011498.4 8.82E-03 1.5200 1.5200
ILMN_2987062 Thyn1 NM_144543.1 4.98E-03 1.5131 1.5131
ILMN_1213448 LOC669658 XM_976371.1 8.82E-03 0.6629 -1.5086
ILMN_1258950 Slc16a6 NM_134038.2 4.99E-02 1.5078 1.5078
ILMN_1257126 9530055J05Rik AK020610 4.56E-02 1.5024 1.5024
ILMN_1237034 AU040320 NM_133886.2 4.81E-03 0.6661 -1.5013
ILMN_1252496 Wdr9 NM_145125 1.58E-02 1.4983 1.4983
ILMN_1256780 LOC381528 XM_355489.1 3.27E-02 0.6749 -1.4817
ILMN_2833652 Cr2 (CD21) NM_007758.2 4.43E-02 1.4797 1.4797
ILMN_2742928 Fxyd5 NM_008761.2 2.56E-02 0.6809 -1.4686
ILMN_2834573 Brwd1 NM_145125.1 1.22E-02 1.4611 1.4611
ILMN_2513837 Gng10 NM_025277.3 8.82E-03 1.4605 1.4605
ILMN_2619316 Prnp NM_011170.1 3.27E-02 0.6880 -1.4535
ILMN_3152380 Flot2 NM_001040403.1 8.82E-03 0.6898 -1.4498
ILMN_2699531 Rgs10 NM_026418.2 1.22E-02 1.4438 1.4438
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Probe_ID Gene symbol Accession q-value Relat. expression Fold change
ILMN_1234746 AI790298 XM_902445.3 3.38E-02 0.6946 -1.4397
ILMN_1245389 LOC236604 NR_003517.1 2.66E-02 0.6951 -1.4387
ILMN_1217068 Tusc1 NM_026954.1 4.60E-02 1.4367 1.4367
ILMN_2697174 Trrap NM_001081362.1 3.09E-02 1.4342 1.4342
ILMN_3006911 Cyp4f13 NM_130882.1 4.14E-02 0.7022 -1.4241
ILMN_2766930 Faah NM_010173.3 2.93E-02 0.7044 -1.4196
ILMN_2833936 Cryl1 NM_030004.2 1.45E-02 0.7049 -1.4186
ILMN_2562789 C730037N04Rik AK050331 4.24E-02 0.7089 -1.4106
ILMN_3035795 Mllt3 NM_027326.3 3.74E-03 1.4032 1.4032
ILMN_1247862 Rad23b AK084917 1.72E-02 1.4005 1.4005
ILMN_2747857 Slc27a3 XM_130954.3 4.14E-02 1.4001 1.4001
ILMN_2506039 A130090K04Rik 3.74E-03 1.3971 1.3971
ILMN_2710484 Rufy3 NM_027530.2 3.19E-02 1.3920 1.3920
ILMN_2683316 Ctsb NM_007798.2 3.27E-02 1.3919 1.3919
ILMN_2457752 Centd1 XM_001001363.1 2.96E-02 1.3916 1.3916
ILMN_2580536 D630016F07Rik AK085364 5.11E-03 0.7202 -1.3886
ILMN_2692554 9330186A19Rik NM_178781.2 3.89E-02 0.7211 -1.3867
ILMN_1221598 9330133O14Rik NM_176948 1.63E-02 1.3795 1.3795
ILMN_2936199 Trim32 NM_053084.1 3.38E-03 1.3750 1.3750
ILMN_2607786 Fads1 NM_146094.1 3.38E-03 1.3746 1.3746
ILMN_1232452 4921528G01Rik NM_023884 1.00E-02 1.3719 1.3719
ILMN_2762334 Cept1 NM_133869.3 3.97E-02 1.3666 1.3666
ILMN_1216689 Aplp2 NM_009691.2 4.43E-02 1.3650 1.3650
ILMN_1236601 Pole4 NM_025882.3 2.17E-02 1.3618 1.3618
ILMN_2627179 Ell3 NM_145973.2 1.11E-02 1.3578 1.3578
ILMN_2975312 Fcer2a (CD23) NM_013517.1 5.26E-02 0.7387 -1.3537
ILMN_1250687 EG627022 XM_891654.3 3.15E-02 0.7395 -1.3522
ILMN_2565243 B130018P07Rik AK045005 2.48E-02 1.3481 1.3481
ILMN_2623983 Egr2 NM_010118.1 4.62E-02 1.3459 1.3459
ILMN_1256142 Marcks NM_008538.2 2.29E-02 1.3458 1.3458
ILMN_1233293 Gbp1 NM_010259.2 2.93E-02 1.3440 1.3440
ILMN_1239507 Mrpl15 NM_025300.2 1.82E-02 1.3437 1.3437
ILMN_2730425 Ryr1 NM_009109.2 5.00E-02 0.7464 -1.3398
ILMN_1234618 D630004K10Rik 3.15E-02 0.7495 -1.3342
ILMN_1225994 Vav2 NM_009500.1 2.17E-02 1.3321 1.3321
ILMN_2737463 Ccdc88b NM_001081291.1 3.97E-02 1.3281 1.3281
ILMN_1249366 LOC100046608 XM_001476583.1 3.38E-02 0.7532 -1.3276
ILMN_1253993 A430083F12Rik AK040286 3.15E-02 0.7554 -1.3239
ILMN_1258094 4933403K19Rik AK030157 2.56E-02 1.3232 1.3232
ILMN_1235602 D0Kist3 1.33E-02 1.3214 1.3214
ILMN_2859847 Pygl NM_133198.1 3.27E-02 0.7569 -1.3211
ILMN_2880536 Uck2 NM_030724.1 5.36E-02 1.3207 1.3207
ILMN_1217454 Lamp2 NM_010685.3 1.82E-02 1.3190 1.3190
ILMN_2517041 Uhrf1 NM_010931.2 3.97E-02 1.3184 1.3184
ILMN_2538597 LOC386405 XM_359211.1 5.20E-02 1.3174 1.3174
ILMN_2758070 Rtn1 NM_153457.6 1.82E-02 0.7591 -1.3173
ILMN_2880052 Xlr4c NM_183094.1 1.85E-02 1.3157 1.3157
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Probe_ID Gene symbol Accession q-value Relat. expression Fold change
ILMN_2821736 Jmjd5 NM_029842.1 1.05E-02 0.7602 -1.3154
ILMN_2494455 Zfp219 NM_027248 5.42E-02 0.7618 -1.3126
ILMN_2747472 A230050P20Rik NM_175687.1 3.89E-02 0.7625 -1.3115
ILMN_2455089 LOC100046087 XM_001475552.1 2.17E-02 1.3100 1.3100
ILMN_1222069 Bbx NM_027444 3.87E-02 1.3076 1.3076
ILMN_2638558 Pes1 NM_022889.3 5.11E-03 1.3042 1.3042
Final gene lists from the comparison wild type Fo B vs. Notch2-deficient Fo B cells were sorted by q-value and only 
genes with a q-value < 0.05 were chosen. Remaining genes were sorted according to their absolute fold change 
(regardless of up- or downregulation) and the top 100 most strongly regulated genes were chosen for this table. 
Genes upregulated in wild type Fo B cells have positive fold change values, genes upregulated in Notch2-deficient 
cells negative values. Illumina internal identifier (Probe_ID).
Table S5: Some of the most significant functional annotation clusters comparing gene expression profiles 
of Notch2IC-expressing MZ B and Notch2-deficient Fo B cells. 
Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
1 12.87
Ribosome 70 2.41 6.10E-15
2 9.94
Lymphocyte activation 61 2.1 9.12E-10
3 9.42
Intracellular organelle lumen 234 8.06 3.52E-10
4 8.99
ATP-binding 260 8.96 4.18E-08
5 8.69
Phosphorylation 156 5.38 1.69E-07
6 6.68
Lysosome 54 1.86 5.45E-08
7 6.12
Immune system development 77 2.65 1.70E-07
8 5.12
Apoptosis 106 3.65 2.84E-06
9 5.04
Positive regulation of  lymphocyte activation 32 1.1 1.85E-06
Positive regulation of  T cell activation 24 0.83 2.46E-05
10 4.95
Positive regulation of  transcription factor activity 16 0.55 5.06E-05
11 4.33
Protein amino acid phosphorylation 133 4.58 2.04E-05
Protein serine/threonine kinase activity 90 3.1 1.97E-04
15 3.68
GTP binding 81 2.79 5.61E-05
17 3.55
Positive regulation of  lymphocyte proliferation 18 0.62 2.33E-04
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Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
18 3.51
Antigen receptor-mediated signalling pathway 15 0.52 1.51E-04
T cell receptor signalling pathway 11 0.38 4.38E-04
20 3.34
Lymphocyte mediated immunity 21 0.72 3.48E-03
21 3.32
Mitochondrial inner membrane 63 2.17 6.21E-04
23 3.10
Positive regulation of  T cell differentiation 14 0.48 4.32E-04
Positive regulation of  lymphocyte differentiation 14 0.48 8.59E-04
24 3.02
Positive regulation of  alpha-beta T cell differentiation 10 0.34 8.94E-04
Positive regulation of  alpha-beta T cell activation 11 0.38 2.28E-03
25 3.00
Regulation of  JNK cascade 17 0.59 3.23E-04
Regulation of  MAPKKK cascade 22 0.76 2.59E-02
29 2.44
Cytoplasmic membrane-bounded vesicle 81 2.79 2.87E-03
30 2.39
Mitotic cell cycle 56 1.93 1.16E-03
34 2.23
Ras GTPase 31 1.07 6.26E-03
36 2.15
Pattern recognition receptor signalling pathway 7 0.24 1.45E-03
Activation of  innate immune response 8 0.28 2.32E-03
38 2.12
ATP biosynthetic process 19 0.65 4.11E-02
39 2.09
Protein transport 118 4.07 1.23E-02
40 2.04
B cell mediated immunity 17 0.59 1.46E-02
42 2.00
T cell selection 9 0.31 6.23E-03
43 1.88
Regulation of  ARF GTPase activity 9 0.31 8.75E-03
46 1.77
Protein tyrosine phosphatase activity 26 0.9 7.51E-03
51 1.66
Histone deacetylase activity 8 0.28 5.83E-03
Chromatin remodeling complex 7 0.24 7.12E-01
52 1.66
Transcription regulation 265 9.13 6.18E-03
55 1.63
Regulation of  protein kinase activity 37 1.27 4.58E-02
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Highly enriched biological terms found among differentially regulated genes between Notch2IC-expressing MZ B 
cells and Notch2-deficient Fo B cells (q-value ≤ 0.0149). Terms are clustered in groups of similar meaning. Clusters 
were obtained by using the Functional Annotation Clustering Tool of the DAVID Bioinformatics Resources.
Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
57 1.61
Antigen processing & presentation of  peptide or polysaccha-
ride antigen via MHC class II
8 0.28 1.24E-02
Antigen processing & presentation of  exogenous peptide anti-
gen via MHC class II
7 0.24 2.45E-02
58 1.61
Guanine-nucleotide dissociation stimulator CDC25 10 0.34 1.63E-02
Ras guanine nucleotide exchange factor 10 0.34 3.16E-02
59 1.60
Class II histocompatibility antigen 5 0.17 3.33E-02
70 1.33
Ly-6 antigen / uPA receptor -like 9 0.31 2.99E-02
CD59 antigen 9 0.31 9.03E-02
86 1.00
Ras GTPase-activating protein 5 0.17 1.14E-01
96 0.95
Regulation of  IFN-beta production 5 0.17 1.50E-01
112 0.80
Positive regulation of  humoral immune response 3 0.1 1.11E-01
116 0.77
PKC-like, phorbol ester/diacylglycerol binding 14 0.48 1.44E-01
117 0.77
Rel-related protein 3 0.1 6.01E-02
NF-kB/Rel/dorsal 4 0.14 1.75E-01
118 0.77
TNFR-associated factor TRAF 4 0.14 4.58E-02
121 0.75
Positive regulation of  PI3-kinase activity 3 0.1 2.27E-01
128 0.73
Negative regulation of  T-helper cell differentiation 3 0.1 1.67E-01
Negative regulation of  alpha-beta T cell differentiation 3 0.1 2.27E-01
129 0.72
Positive regulation of  ERK1 and ERK2 cascade 3 0.1 3.47E-01
130 0.72
Regulation of  actin polymerization / depolymerization 12 0.41 1.25E-01
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Table S6: Some of the most significant functional annotation clusters comparing gene expression profiles 
of wild type MZ B and Fo B cells. 
Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
1 7.64
Phosphorylation 133 5.33 2.35E-06
2 Purine ribonucleotide binding 309 12.39 1.24E-09
ATP binding 241 9.66 1.44E-06
Adenyl nucleotide binding 249 9.98 8.96E-06
3 5.87
Lymphocyte activation 44 1.76 4.66E-05
6 5.67
Lysosome 46 1.84 4.78E-07
7 5.02
Cell death 101 4.05 4.65E-06
9 4.19
Protein kinase, C-terminal 15 0.60 2.48E-04
10 4.19
Positive regulation of  adaptive immune response 15 0.601 6.80E-06
11 4.15
Transcription regulation 252 10.10 1.73E-05
12 4.09
Protein amino acid phosphorylation 125 5.01 3.61E-07
Protein serine/threonine kinase activity 76 3.05 1.01E-03
16 3.60
GTP binding 71 2.85 8.78E-05
18 3.38
Endocytosis 42 1.68 2.38E-04
20 2.88
B cell mediated immunity 17 0.68 3.27E-03
21 2.80
Regulation of  ARF GTPase activity 10 0.40 6.84E-04
23 2.69
Immune system development 55 2.205 1.89E-03
27 2.33
Histone core 13 0.52 1.46E-03
Nucleosome organization 18 0.72 6.94E-03
28 2.32
Positive regulation of  lymphocyte proliferation 15 0.60 1.50E-03
29 2.29
Positive regulation of  T cell activation 17 0.68 5.50E-03
36 2.05
Immune response-activating signal transduction 13 0.52 1.02E-02
Immune response-activating cell surface receptor
signalling pathway
11 0.44 2.00E-02
Antigen receptor-mediated signalling pathway 10 0.40 2.13E-02
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Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
39 1.87
Positive regulation of  transferase activity 27 1.08 1.52E-02
Positive regulation of  protein kinase activity 25 1.00 1.73E-02
43 1.80
Positive regulation of  lymphocyte mediated immunity 11 0.44 1.11E-02
44 1.79
Positive regulation of  phagocytosis 9 0.36 3.33E-03
48 1.74
Ribosome 35 1.40 7.11E-03
49 1.73
Protein tyrosine/serine/threonine phosphatase activity 11 0.44 1.96E-02
65 1.38
Positive regulation of  alpha-beta T cell differentiation 7 0.28 2.85E-02
72 1.26
Positive regulation of  T cell mediated cytotoxicity 5 0.20 2.06E-02
73 1.23
Small GTPase binding 14 0.56 3.56E-02
80 1.13
Chemokine receptor activity 6 0.24 1.45E-01
Chemokine binding 6 0.24 1.67E-01
81 1.13
Regulation of  IFN-beta production 5 0.20 9.69E-02
Regulation of  type I IFN production 5 0.20 1.19E-01
82 1.12
T cell proliferation 8 0.32 6.16E-02
90 1.03
Ly-6 antigen / uPA receptor -like 8 0.32 3.89E-02
101 0.92
Regulation of  actin polymerization / depolymerization 12 0.48 5.21E-02
104 0.90
Phosphatidylinositol 3- and 4-kinase, conserved site 5 0.20 1.12E-01
108 0.87
TNF receptor-associated factor TRAF 4 0.16 3.03E-02
111 0.84
Plexin 8 0.32 6.61E-02
113 0.82
Positive regulation of  NF-�B transcription factor activity 7 0.28 9.51E-02
Highly enriched biological terms found among differentially regulated genes between wild type MZ B and Fo B 
cells (q-value ≤ 0.0149). Terms are clustered in groups of similar meaning. Clusters were obtained by using the 
Functional Annotation Clustering Tool of the DAVID Bioinformatics Resources.
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Cluster
number Enrichment score / Annotation term
Genes
(Counts)
Genes
(%) p-value
1 5.04
Cell death 52 5.31 4.81E-06
2 3.91
Positive regulation of  apoptosis 29 2.96 1.08E-04
3 3.82
Ribosomal protein 23 2.35 7.72E-05
6 3.16
B cell mediated immunity 11 1.12 1.25E-03
7 3.06
Endocytosis 22 2.24 7.85E-04
8 2.93
Positive regulation of  transcription factor activity 8 0.82 1.90E-03
11 2.5
Positive regulation of  lymphocyte activation 13 1.33 2.32E-03
13 2.46
Lysosome 20 2.04 1.24E-03
14 2.42
Translation initiation factor activity 11 1.12 1.13E-03
15 2.4
Cytoplasmic membrane-bounded vesicle 36 3.67 1.52E-03
17 2.18
Phosphorylation 55 5.61 4.00E-03
19 2
ATP binding 95 9.69 6.98E-03
21 1.83
Positive regulation of  lymphocyte proliferation 8 0.82 1.08E-02
22 1.81
Positive regulation of  JNK cascade 6 0.61 1.18E-03
Positive regulation of  IL-6 production 5 0.51 1.13E-02
Regulation of  MAPKKK cascade 10 1.02 5.25E-02
23 1.76
Apoptosis regulator Bcl-2 5 0.51 2.40E-02
25 1.72
Protein serine/threonine kinase activity 31 3.16 3.89E-02
26 1.69
Regulator of  G protein signalling 6 0.61 1.72E-02
27 1.67
Ras guanine nucleotide exchange factor 6 0.61 1.96E-02
28 1.66
Hemopoiesis 20 2.04 6.11E-02
30 1.51
GTP binding 28 2.86 2.60E-02
Table S7: Some of the most significant functional annotation clusters comparing gene expression profiles 
of wild type and Notch2IC-expressing MZ B cells. 
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Cluster
number Enrichment score / Annotation term
Genes
(Counts)
Genes
(%) p-value
31 1.48
Ras GTPase binding 7 0.71 7.57E-02
36 1.28
Regulation of  calcium ion transport 6 0.61 3.39E-02
37 1.27
Protein tyrosine kinase activity 14 1.43 8.15E-02
38 1.26
Mitochondrial inner membrane 23 2.35 3.16E-02
39 1.18
RhoGAP 8 0.82 4.48E-02
40 1.17
Myelination 6 0.61 4.21E-02
Regulation of  action potential 6 0.61 1.55E-01
44 1.12
CARD domain 5 0.51 1.90E-02
46 1.11
Positive regulation of  peptidase/caspase activity 6 0.61 4.21E-02
Positive regulation of  hydrolase activity 8 0.82 1.45E-01
47 1.1
TNFR binding 4 0.41 1.05E-01
59 0.84
Mitochondrial large ribosomal subunit 4 0.41 8.54E-02
61 0.83
PKC-like, phorbol ester/diacylglycerol binding 7 0.71 1.09E-01
62 0.83
Positive regulation of  tyrosine phosphorylation of  STAT 3 0.31 8.09E-02
Positive regulation of  JAK-STAT cascade 3 0.31 1.15E-01
63 0.81
Regulation of  ion transmembrane transporter activity 3 0.31 1.52E-01
65 0.79
Thymic T cell selection 3 0.31 1.92E-01
69 0.78
Nucleosome/Chromatin assembly 6 0.61 2.92E-01
72 0.75
LPS-mediated signalling pathway 4 0.41 2.37E-02
TLR signalling pathway 3 0.31 5.07E-02
Activation of  innate immune response 3 0.31 1.72E-01
74 0.73
Cellular calcium ion homeostasis 8 0.82 2.18E-01
75 0.72
Plexin 5 0.51 5.89E-02
Semaphorin/CD100 antigen 4 0.41 1.97E-01
80 0.69
Ly-6 antigen / uPA receptor -like 4 0.41 1.46E-01
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Table S8: Some of the most significant functional annotation clusters comparing gene expression profiles 
of wild type and Notch2-deficient Fo B cells. 
Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
1 2.32
Heat shock chaperonin-binding 3 0.90 9.44E-03
2 2.29
Intracellular organelle lumen 31 9.28 5.25E-03
3 1.79
Transcription regulation 40 11.98 5.65E-03
4 1.78
Cation binding 84 25.15 1.27E-02
6 1.65
Cellular ion homeostasis 11 3.29 1.25E-02
Cluster
number Enrichment score / Annotation term
Genes
(Counts)
Genes
(%) p-value
CD59 antigen 4 0.41 2.25E-01
89 0.61
Intracellular organelle lumen 62 6.33 2.38E-01
90 0.61
Clathrin adaptor, alpha/beta/gamma-adaptin 3 0.31 7.44E-02
Clathrin coat 4 0.41 2.28E-01
91 0.59
Positive regulation of  T cell differentiation 4 0.41 2.46E-01
95 0.58
Regulation of  immunoglobulin production 4 0.41 1.49E-01
Regulation of  isotype switching 3 0.31 1.72E-01
98 0.55
Regulation of  protein transport 6 0.61 2.40E-01
Regulation of  protein localization 7 0.71 3.17E-01
100 0.54
Cation binding 204 20.82 2.56E-01
102 0.51
IgG/MHC, conserved site 6 0.61 2.99E-01
105 0.49
T cell activation during immune response 3 0.31 1.72E-01
107 0.48
Chemokine receptor activity 3 0.31 3.20E-01
111 0.45
Antigen processing & presentation 4 0.41 2.76E-01
119 0.41
Toll/Interleukin receptor (TIR) 3 0.31 3.51E-01
Highly enriched biological terms found among differentially regulated genes btween wild type and Notch2IC-ex-
pressing MZ B cells (q-value ≤ 0.0549). Terms are clustered in groups of similar meaning. Clusters were obtained by 
using the Functional Annotation Clustering Tool of the DAVID Bioinformatics Resources.
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Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
7 1.58
PKC-like, phorbol ester/diacylglycerol binding 5 1.50 2.29E-02
8 1.57
Lymphocyte activation 9 2.69 1.36E-02
9 1.53
Regulation of  phosphorylation 11 3.29 2.48E-02
10 1.51
Response to DNA damage stimulus 10 2.99 5.84E-02
12 1.35
Intracellular protein transport 9 2.69 9.35E-02
13 1.30
Proteolysis involved in cellular protein catabolic process 16 4.79 3.89E-02
16 1.17
Lysosome 7 2.10 3.49E-02
18 1.12
Chromatin modification 9 2.69 5.13E-02
Chromosome organization 12 3.59 8.34E-02
20 1.03
Positive regulation of  immune response 6 1.80 7.19E-02
21 0.97
Rho / Ras guanyl-nucleotide exchange factor activity 4 1.20 1.23E-01
22 0.97
GTPase activator activity 7 2.10 1.17E-01
27 0.91
Negative regulation of  apoptosis 8 2.40 1.17E-01
29 0.88
Membrane fraction 13 3.89 1.32E-01
33 0.81
Ras-associating domain 3 0.90 1.26E-01
34 0.79
Lymphocyte proliferation 3 0.90 1.59E-01
35 0.78
Myofibril 4 1.20 1.85E-01
36 0.77
Mitochondrial envelope 10 2.99 1.77E-01
41 0.68
Positive regulation of  lymphocyte mediated immunity 3 0.90 1.23E-01
42 0.67
Protein localization 17 5.09 2.10E-01
Protein transport 15 4.49 2.15E-01
44 0.60
GTP-binding 9 2.69 1.51E-01
46 0.56
T cell activation 5 1.50 1.36E-01
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Table S9: Some of the most significant functional annotation clusters obtained with genes upregulated in 
wild type MZB in comparison to Fo B cells. 
Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
1 5.01
Lysosome 26 2.04 5.93E-06
2 4.58
Ribosome 25 1.96 1.84E-08
3 3.81
Positive regulation of  adaptive immune response 11 0.86 1.30E-05
4 3.17
Histone core 11 0.86 7.73E-05
Nucleosome assembly 13 1.02 1.28E-03
Highly enriched biological terms found among differentially regulated genes between wild type and Notch2-de-
ficient Fo B cells (q-value ≤ 0.0549). Terms are clustered in groups of similar meaning. Clusters were obtained by 
using the Functional Annotation Clustering Tool of the DAVID Bioinformatics Resources.
Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
T cell differentiation 4 1.20 1.37E-01
B cell differentiation 3 0.90 1.59E-01
Hemopoietic or lymphoid organ development 5 1.50 6.90E-01
47 0.55
Ribosome 6 1.80 1.92E-01
48 0.55
Microtubule motor activity 3 0.90 3.39E-01
49 0.54
ATP binding 29 8.68 3.13E-01
50 0.54
Sarcoplasmic reticulum 3 0.90 1.04E-01
Calcium ion transport 3 0.90 6.15E-01
51 0.54
Negative regulation of  protein kinase activity 3 0.90 2.15E-01
53 0.53
Cell growth 3 0.90 1.34E-01
61 0.45
Cation channel activity 7 2.10 2.64E-01
62 0.45
Positive regulation of  protein modification process 4 1.20 1.37E-01
65 0.39
Regulation of  locomotion 3 0.90 5.51E-01
66 0.38
Dual-specific/protein-tyrosine phosphatase, conserved region 3 0.90 4.04E-01
70 0.34
Mitosis 5 1.50 4.19E-01
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Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
5 2.87
Programmed cell death 46 3.61 4.72E-03
6 2.72
Plexin/semaphorin/integrin 10 0.78 1.88E-03
7 2.67
ATP binding 117 9.17 2.31E-03
Nucleoside binding 123 9.64 4.27E-03
9 2.55
“Complement activation, classical pathway” 8 0.63 1.83E-03
Humoral immune response 10 0.78 4.87E-03
10 2.51
Ly-6 antigen / uPA receptor -like 8 0.63 9.55E-04
12 2.38
Positive regulation of  lymphocyte mediated immunity 9 0.71 1.64E-03
13 2.37
Adaptive immune response 13 1.02 5.31E-03
B cell mediated immunity 11 0.86 5.43E-03
17 2.26
Mitotic cell cycle 30 2.35 1.36E-03
20 2.13
Positive regulation of  phagocytosis 7 0.55 1.85E-03
Positive regulation of  endocytosis 7 0.55 1.43E-02
21 2.09
Regulation of  phosphorylation 30 2.35 1.10E-02
22 1.99
Positive regulation of  interferon-beta biosynthetic process 4 0.31 8.16E-03
Regulation of  type I interferon production 5 0.39 1.42E-02
26 1.78
Protein tyrosine kinase activity 18 1.41 3.02E-02
31 1.57
GTP binding 33 2.59 2.44E-02
32 1.56
Glycosylation 12 0.94 3.15E-02
33 1.51
Positive regulation of  T cell mediated immunity 5 0.39 6.04E-03
Positive regulation of  T cell mediated cytotoxicity 4 0.31 1.77E-02
38 1.43
Positive regulation of  lymphocyte proliferation 9 0.71 9.57E-03
Positive regulation of  lymphocyte activation 12 0.94 2.72E-02
41 1.41
Positive regulation of  JNK cascade 5 0.39 1.80E-02
Positive regulation of  MAPKKK cascade 6 0.47 1.84E-01
45 1.32
Regulation of  ARF GTPase activity 5 0.39 4.56E-02
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Table S10: Some of the most significant functional annotation clusters obtained with genes upregulated in 
Notch2IC-expressing MZ B cells in comparison to wild type MZ B cells. 
Cluster
number Enrichment score / Annotation term
Genes
(Count)
Genes
(%) p-value
52 1.21
Immune response-activating signal transduction 7 0.55 7.31E-02
54 1.17
Positive regulation of  alpha-beta T cell activation 6 0.47 2.16E-02
58 1.12
Positive regulation of  chemokine biosynthetic process 3 0.24 3.79E-02
63 1.05
Positive regulation of  inflammatory response 5 0.39 3.89E-02
Positive regulation of  type IIa hypersensitivity 3 0.24 5.44E-02
Positive regulation of  B cell mediated immunity 3 0.24 1.61E-01
74 0.89
Positive regulation of  I-kappaB kinase/NF-kappaB cascade 6 0.47 5.62E-02
77 0.84
MHC class I protein complex 6 0.47 7.05E-02
80 0.83
Rho guanyl-nucleotide exchange factor activity 9 0.71 6.78E-02
Ras guanyl-nucleotide exchange factor activity 9 0.71 1.39E-01
82 0.82
Negative regulation of  gene-specific transcription 5 0.39 5.29E-02
121 0.51
Rho GTPase binding 5 0.39 6.37E-02
	 	
Table S9 continued:
Highly enriched biological terms found among genes upregulated in wild type MZ B cells versus wild type Fo B 
cells (q-value ≤ 0.0549). Terms are clustered in groups of similar meaning. Clusters were obtained by using the 
Functional Annotation Clustering Tool of the DAVID Bioinformatics Resources.
Cluster
number
Enrichment score / Annotation term
Genes
(count)
Genes
(%)
p-value
1 6.88
Ribosomal protein 22 4.53 2.35E-09
2 4.26
Translation initiation factor activity 10 2.06 2.53E-05
3 3.43
Mitochondrial inner membrane 21 4.32 2.56E-05
4 3.12
Intracellular organelle lumen 45 9.26 8.76E-04
5 2.59
Positive regulation of  apoptosis 16 3.29 2.38E-03
6 2.49
Cholesterol binding 4 0.82 1.30E-03
Steroid binding 5 1.03 1.95E-02
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Cluster
number
Enrichment score / Annotation term
Genes
(count)
Genes
(%)
p-value
7 2.11
Purine ribonucleotide binding 64 13.17 4.19E-03
ATP binding 52 10.70 8.50E-03
11 1.62
Mitochondrial large ribosomal subunit 4 0.82 1.39E-02
12 1.6
Positive regulation of  caspase/peptidase activity 5 1.03 1.55E-02
13 1.46
Myelination 5 1.03 1.55E-02
Regulation of  action potential in neuron 5 1.03 3.02E-02
15 1.36
„RNA helicase, ATP-dependent, DEAD-box, conserved site“ 5 1.03 6.91E-03
ATP-dependent helicase activity 7 1.44 2.30E-02
16 1.36
Positive regulation of  B cell proliferation/activation 4 0.82 1.36E-02
17 1.35
Ly-6 antigen / uPA receptor -like 4 0.82 2.58E-02
18 1.3
Positive regulation of  transcription factor activity 4 0.82 6.27E-02
19 1.18
Phosphorylation 27 5.56 5.63E-02
21 1.11
GTP binding 15 3.09 7.02E-02
23 1.05
Neuron projection 6 1.23 6.99E-01
25 0.98
Cellular amino acid catabolic process 5 1.03 5.10E-02
Carboxylic acid catabolic process 5 1.03 1.64E-01
26 0.9
Positive regulation of  JNK cascade 3 0.62 6.77E-02
Positive regulation of  stress-activated protein kinase signaling 
pathway
3 0.62 6.77E-02
Positive regulation of  cytokine biosynthetic process 4 0.82 9.77E-02
Positive regulation of  MAPKKK cascade 3 0.62 3.53E-01
29 0.87
„Serine/threonine protein kinase, active site“ 14 2.88 9.90E-02
32 0.8
Gut morphogenesis 3 0.62 1.17E-01
33 0.77
Regulator of  G protein signalling 3 0.62 1.70E-01
34 0.75
Lysosome 8 1.65 1.38E-01
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Cluster
number
Enrichment score / Annotation term
Genes
(count)
Genes
(%)
p-value
35 0.75
NADP metabolic process 3 0.62 5.32E-02
Pyridine nucleotide metabolic process 3 0.62 1.74E-01
36 0.74
Purine nucleotide biosynthetic process 7 1.44 1.46E-01
Nucleotide & nucleic acid biosynthetic process 8 1.65 1.86E-01
39 0.69
Glycolysis 3 0.62 3.03E-01
40 0.66
Negative regulation of  protein kinase activity 4 0.82 1.51E-01
41 0.66
hydrogen ion transmembrane transporter activity 5 1.03 1.40E-01
ATP synthesis coupled proton transport 3 0.62 2.43E-01
purine ribonucleotide biosynthetic process 5 1.03 3.01E-01
44 0.62
Neural tube development 4 0.82 3.66E-01
45 0.61
Glutathione transferase activity 3 0.62 1.28E-01
49 0.49
Endoplasmic reticulum membrane 6 1.23 3.05E-01
61 0.42
Positive regulation of  T cell activation 4 0.82 2.41E-01
64 0.39
„IgG/MHC, conserved site“ 3 0.62 5.29E-01
65 0.39
Protein transport 14 2.88 3.62E-01
69 0.37
Glycerophospholipid biosynthetic process 3 0.62 3.23E-01
Phosphoinositide metabolic process 3 0.62 4.83E-01
70 0.37
Links between Pyk2 and Map Kinases 3 0.62 2.90E-01
Angiotensin II med. activation of  JNK via Pyk2 dependent 
signaling
3 0.62 3.05E-01
71 0.37
Rho guanyl-nucleotide exchange factor activity 4 0.82 2.59E-01
77 0.31
Regulation of  actin polymerization or depolymerization 3 0.62 3.92E-01
Regulation of  actin cytoskeleton organization 3 0.62 4.83E-01
79 0.26
Ras GTPase binding 3 0.62 4.38E-01
Small GTPase binding 3 0.62 4.55E-01
Highly enriched biological terms found among genes upregulated in Notch2IC-expressing MZ B versus wild type 
MZ B cells (q-value ≤ 0.0549). Terms are clustered in groups of similar meaning. Clusters were obtained by using 
the Functional Annotation Clustering Tool of the DAVID Bioinformatics Resources.
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